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1.1 History of DNA research
During the winter of 1868-1869 Friedrich Miescher, a Swiss physician, performed experiments 
at Germany’s University of Tübingen on the composition of leukocytes, which eventually led 
to the discovery of DNA. Miescher noticed an unknown substance in the precipitates derived 
from the leukocytes. Further characterization showed that the substance was neither lipid 
nor protein. Because the nuclei were the source of isolation he named the novel substance 
Nuclein [1]. In 1919 the base, sugar and phosphate were identified by Phoebus Levene to be 
the building blocks of DNA [2]. It took more than 30 years thereafter before Watson and 
Crick revealed the 3D-structure of DNA in 1953 [3]. 
Since these basic discoveries, tremendous scientific progress has been made in the fields of 
genetics and biotechnology. These developments have led to a new era in science and 
medicine, accelerated by the development of DNA sequencing [4] and the Polymerase Chain 
Reaction (PCR) [5]. 
Determining the sequence of a specific DNA stretch of interest was made possible by the 
introduction of DNA sequencing. Subsequently, the PCR technique made it possible to 
amplify small amounts of DNA and the variations therein, further enhancing the potential of 
DNA sequencing by combining both techniques. This allowed scientists to study specific DNA 
regions of interest. These developments resulted in the identification of variations in 
oncogenes and tumor suppressor genes (TSGs). 
A very important initiative was the Human Genome Project (HGP), which started in 1990. The 
completion of this project revealed the human genome sequence [6-8]. The results of the HGP 
have led to an extremely detailed dataset with regard to the similarities in and differences between 
human genomes. The human genome was estimated to consist of about 98.5% non-coding 
sequences and only 1.5% coding sequences and to contain approximately 30,000 genes.
1.2 Impact of molecular diagnostics in pathology
Molecular diagnostics, referring to the field of detection and analysis of nucleic acids, is 
currently the most rapidly expanding discipline within the field of pathology. 
Advances in molecular biology led to the discovery of numerous types of DNA variations 
amongst individuals and DNA alterations in cancer, some of which confer a selective growth 
advantage to the affected (tumor) cell. These include mutations that lead to changes in DNA 
copy numbers such as gains and losses of a chromosomal locus [9]. 
The applications of molecular diagnostics in pathology therefore range from tissue 
identification to various purposes in oncology. The applications in oncology include disease 
diagnosis and prognosis of disease susceptibility, prognosis of clinical outcome and therapy 
selection and prediction of therapy efficacy.
1
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Further technological developments subsequently led to a wide variety of molecular methods 
to detect (somatic) DNA alterations implicated in clinical oncology, such as gains or losses of 
cancer-critical genes, and to use germline DNA variations amongst individuals for tissue 
identification purposes. Nowadays, diagnostic strategies for these applications, such as the 
characterization of repetitive genomic elements to determine the loss of a particular stretch 
of DNA or tissue identity, exist. Implementation in routine molecular laboratories however, is 
often hampered by several issues such as: the need for expensive equipment, poor DNA 
quality of the investigated tissues, increased contamination risk due to the necessity of 
post-PCR processing and the difficulty of data interpretation. 
To overcome part of these issues, the feasibility of a universal method utilizing real time PCR 
to characterize a panel of carefully selected Single Nucleotide Polymorphisms (SNPs) with 
regard to tissue identification as well as the detection of DNA copy number changes in 
oncology was explored in this thesis.
1.3 DNA variations
Several different DNA variations occur in the human genome. Some of these are found in 
highly polymorphic regions and consist of variations in the number of nucleotide repeats, 
which are tandemly organized. Variable number of tandem repeats (VNTRs) and short 
tandem repeats (STRs), also known as mini- and microsatellites (respectively), are such short 
repetitive nucleotide sequences and range from around 10-60 bp (VNTRs) and 2-7 bp (STRs) 
[10, 11]. Some diseases have been associated with alterations within these repetitive 
sequences, for example fragile X syndrome, spinal and bulbar muscular atrophy and 
Huntington’s disease with intragenic expansion of trinucleotide repeats [12]. 
Other variations are e.g. deletion, duplication and multiplication of a certain chromosomal 
locus resulting in copy number variation (CNV) of the gene(s) involved. An example of a locus 
regularly affected in such a way is 22q13.1, resulting in CNV of the gene encoding cytochrome 
P450 2D6 (CYP2D6). CYP2D6 plays a pivotal role in the metabolism of many drugs including 
β-blockers, antiarrhythmics and a number of antidepressant and antipsychotic agents [13]. 
Deletion, duplication and multiplication of CYP2D6 affects enzymatic activity, which may 
result in failure or toxicity of the administered treatment [13]. 
Other genetic variations that are found in the human genome involve polymorphisms of a 
single nucleotide.
1.3.1. Single nucleotide polymorphisms 
SNPs are the most common sequence variations found in the human genome [14, 15]. SNPs 
are frequently defined as a single base difference between members of a biological species 
or paired chromosomes, occurring at a particular position in the genome and at a certain 
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frequency within a healthy population (a minimal frequency of occurrence within a population 
of 1% is often described in the literature) [16]. Additionally, SNPs are regularly considered to 
be non-disease conferring by definition. Single base variants that occur at a frequency of 
<1% in a certain population or cause disease are therefore often considered to be mutations 
rather than polymorphisms. However, these restrictions both pose a dilemma. Firstly, a SNP 
in one population, should theoretically be considered a mutation in the other due to 
population dependent occurrence of >1% vs. <1%. Secondly, a mutation of a single 
nucleotide that causes disease in one individual could hypothetically cause no illness in 
another individual making the variation a SNP. To overcome these issues the term SNP will be 
used throughout this thesis as a single base variation on a certain genomic position regardless 
of occurrence and disease causing potential, that persists in a population. Moreover, SNPs are 
not considered to include insertion or deletion polymorphisms (indels) [16]. A minor allele 
frequency (MAF) of a particular SNP is the frequency at which this less common allele occurs 
within a given population [17]. SNP frequencies may vary greatly between populations 
[14-16]. The vast majority of SNPs are biallelic of nature, although tri- and even tetra-allelic 
SNPs are found [8]. In principle, four different (bi-allelic) SNPs can be classified as possible 
variants: CóT on one DNA strand and their base pairing nucleotides on the complementary 
strand (GóA), CóA (GóT), CóG (GóC) and TóA (AóT), with the first SNP being a 
nucleotide transition (purineópurine or pyrimidineópyrimidine) and the latter three being 
nucleotide transversions (purineópyrimidine). About two-third of SNPs in the human 
genome are CóT (GóA) variants, the remaining one-third is comprised of a more or less 
evenly distributed amount of the other 3 variants [16].
SNPs occur approximately once in every 100-1000 base pairs (bp) throughout the genome 
and it is estimated that about 90% of sequence variation can be attributed to SNPs [16-18]. 
The occurrence of SNPs however is not evenly distributed across the genome, SNP frequencies 
can vary as much as several hundred-fold between two regions. Generally, SNPs are found 
more frequently in non-coding regions compared to coding regions (SNP frequencies are 
about fourfold lower within exons). SNPs in coding sequences are more likely to cause 
functional differences with regard to the encoded protein, although SNPs in non-coding 
regions may also affect gene expression and function [19, 20]. More “favorable” SNPs in a 
coding region are therefore fixed in a population due to natural selection.
1.3.2. SNP associated traits and disorders
Taking the frequency of SNP occurrence and the total amount of basepairs (3 billion) in 
account, the human genome contains millions of SNPs. These small sequence variations 
therefore make up for a large part of the nucleotide variations in the human genome. Each 
individual has a unique set of SNPs, this SNP genotype can therefore be considered as a 
unique genetic fingerprint. In general, variations in SNPs do attribute largely to human 
1
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phenotypic diversity. A well know example is the presence of SNPs in genes encoding 
erythrocyte membrane molecules. These SNPs determine a large part of the blood group 
antigen diversity and in this way largely define ones blood group [21]. Additionally, SNPs have 
a certain level of effect on eye-, hair and skin color [22] and are for example (in part) 
responsible for the variation in medicine efficacy and diverse responses of individuals to 
identical medicinal doses. During the last decade many association studies have been 
performed, which have identified a large group of traits and diseases linked with certain 
SNPs, some of which are denoted in table 1.
SNPs in coding regions may introduce a premature stopcodon, be synonymous (not 
influencing the encoded amino acids) or non-synonymous (altering the encoded amino acids) 
[16, 23, 24]. SNPs may also yield functional effects in a combined manner with other SNPs to 
manifest a disease condition like in for example osteoporosis [25]. 
Although SNPs in non-coding regions do not alter encoded proteins, they may influence 
gene expression when present in regulatory sites –such as promoter sequences and 
transcription binding sites-, or when present in sequences of splicing relevance (which in fact 
can also influence the encoded protein), which may induce profound functional alterations in 
the affected gene products. This type of SNP is referred to as an eSNP (expression SNP) and 
may be located up- or downstream of the gene involved [26, 27]. Additionally, SNPs in 
microRNA genes and their corresponding binding sites are known to be able to alter gene 
expression and can therefore yield a functional effect [28]. Because of their genome wide 
Table 1   Some traits and disorders associated with SNPs, the genes involved – including 
genomic location- and reference [30-48].
Involved  
gene
Genomic  
location
Associated disorder / trait Reference
c-REL 2p13 Rheumatoid arthritis 30
FV 1q23 thrombosis 31
FII 11p1 thrombosis 32
HFE 6p21 Hereditary hemochromatosis 33-36
DPYD 1p22 Increased toxicity of 5-fluorouracil (chemotherapeutic agent) 37
JAK2 9p24 JAK2V617F conferring susceptibility haplotype 38-40
FTO 16q12 Increased body mass index (BMI) 41, 42
DRD1 5q35 Susceptibility to nicotine addiction 43
AR Xq11-12 Alopecia 44
OCA2 15q11 Eye color 45-47
HBB 11p15 Malaria resistance 48
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distribution and possible impact on gene function, SNPs are thought to be putative key 
enablers in realizing the concept of personalized medicine [29].
Currently, approximately 9-10 million SNPs are reported in several public databases [14, 15]. 
Some of these databases, such as dbSNP and HapMap [49, 50], include SNPs from the entire 
genome. Others specialize in disease entities such as SNPs in cancer related genes –the 
SNP500Cancer database [51]- or in SNPs in genes involved in drug metabolism (PharmGKB 
database [52]), certain genes such as the Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee [13] or gene groups such as Cytokine Gene Polymorphisms [53].
Even when SNPs may not be responsible for a specific disease or trait, their sheer number and 
omnipresence throughout the genome makes them excellent markers for e.g. loss or gain of 
particular parts of the genome. Additionally, the highly frequent occurrence of SNPs and 
relatively easy molecular detection techniques like real time PCR make a detailed view of a 
specific locus under investigation feasible. 
1.4 Somatic mutations and cancer
Oncogenesis relies on a complex mix of biological capabilities acquired by a tumor cell during 
the multi-step development of cancer. The development of malignancies may be characterized 
by eight “hallmark capabilities”, as was proposed by Hanahan and Weinberg [54]: a malignant 
tumor is able to sustain proliferative signaling, evade growth suppressors, activate invasion 
and metastasis, enable replicative immortality, induce angiogenesis, resist cell death, avoid 
immune destruction and deregulate cellular energetics. 
Among the key steps in the development of malignant neoplasms, constitutive activation of 
cell signaling pathways plays an important role [54-56]. A largely simplified view of such a 
signaling pathway (EGFR-RAS-MAPK signaling) is shown in figure 1. Sustained activation of 
signal transduction may occur in all pathway steps by alterations in the genes encoding each 
of the involved molecules. Such alterations for example include the introduction of activating 
point mutations in proto-oncogenes, the emergence of fusion genes and their subsequent 
highly active gene products, loss of TSGs and amplification of proto-oncogenes. Well-known 
examples of these somatically acquired genetic aberrations are BCR/ABL fusion in chronic 
myeloid leukemia [57-59], amplification of HER2 in breast cancer [60, 61], loss of chromosome 
18q –containing several TSGs- in colorectal cancer [62] and point mutations in EGFR and 
KRAS in lung cancer [63, 64]. 
1.4.1. Loss of heterozygosity 
One of the mechanisms that results from chromosomal instability and that contributes to the 
accumulation of genetic alterations during carcinogenesis is loss of heterozygosity (LOH) 
[67-69]. LOH is a common genetic incident where heterozygosity at a chromosomal locus 
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within an organism’s germline DNA is lost in a somatically altered ((pre)cancer) cell. When 
LOH profi les of primary tumors and their distant metastases are compared, the number of 
chromosomes altered by LOH is signifi cantly higher in the metastases, suggesting that LOH 
–along with other genetic aberrations- accumulates during tumor progression [70-76]. 
Figure 1  Schematic model of EGF (Epidermal Growth Factor) mediated RAS-MAPK (rat sarcoma- 
mitogen-activated protein kinase) signaling. The pathway is activated by binding of an extracellular 
signal molecule to an EGFR (EGF receptor). Upon EGFR activation, GRB2 (growth factor receptor-bound 
protein 2) is recruited. This in turn results in RAS phosphorylation mediated by SOS (son of sevenless). 
Activated RAS binds and phosphorylates RAF (Rapidly Accelerated Fibrosarcoma), which subsequently 
results in phosphorylation of MEK (mitogen-activated protein kinase kinase) and ERK (extracellular sig-
nal-regulated kinase). Phorphorylated ERK then translocates to the nucleus where it acts as an activator 
of various transcription factors such as ELK1 (Ets-like Gene 1), C-Myc (v-Myc Myelocytomatosis Viral 
Oncogene Homolog) and TFIIIB (RNA polymerase (pol) III-specifi c transcription factor) [65, 66].
EG
FR
EG
FR
Genetranscription
Transcription factor activation:
- ELK1
- C-myc
- TFIIIB
- Etc.
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With the occurrence of LOH, chromosomal regions containing tumor suppressor genes (TSG) 
may be affected. If one of the alleles contains a TSG that is inactivated by mutation, loss of 
the other functional allele may occur through LOH, as was proposed in the two-mutational-
events model leading to TSG inactivation by Knudson in the early 1970’s [69]. In this model a 
TSG is inactivated by a loss-of-function mutation on one allele as a primary event. The second 
allele contains a normally functioning TSG. However, when LOH at this particular locus occurs 
as a secondary event this can result in hemi- or homozygosity of the inactivated TSG, which 
results in complete loss-of-function of the involved TSG. 
Major mechanisms of LOH include whole chromosome loss and several processes that lead 
to partial chromosome loss, such as terminal and interstitial deletions. These LOH causing 
chromosomal alterations are frequently observed in human cancers, e.g. in retinoblastoma 
and colorectal cancer [69, 77]. However, during tumor development LOH may also occur 
through mitotic recombination (fi gure 2A), leading to uniparental disomy (UPD) [77-81]. 
Double stranded breaks (DSB) may occur during mitosis, which are followed by DSB repair 
(DSBR). During this process strand invasion may occur assisted by base pairing of the 
homologous regions between affected chromosomal loci. Single stranded parts of the DNA 
Figure 2  Schematic model of mitotic recombination. A. During mitosis paternal and maternal 
chromosomes are recombined. The resulting 2 daughter cells both harbor UPD resulting in homozygosity 
for the Guanine (G)-SNP or Adenine (A)-SNP (adapted from [78]). B. Double stranded breaks (DSB) occur 
in both chromosomes, followed by strand invasion assisted by base pairing and followed by ligation, 
resulting in recombinant chromosomes (adapted from [80, 81]).
Double stranded break 
Base pairing assisted 
strand invasion 
Ligation 
A B
Maternal chromosome 
Paternal chromosome 
Recombinant 
chromosomes 
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are repaired through ligation ultimately resulting in recombined chromosomes (figure 2B) 
[80, 81].
UPD is defined by the inheritance of two copies of (part of) a chromosome from the same 
parent –paternal or maternal- and no copies from the second parent [82]. Because UPD 
through LOH is acquired somatically it is defined as acquired UPD (aUPD) [83, 84]. 
In addition to TSG loss, an oncogene activating mutation may also be followed by aUPD, by 
which the activated oncogene becomes homozygously present. Homozygosity through 
aUPD of the oncogenic allele could then further potentiate the effect of the mutation [78]. A 
point mutation is a well-known example of such an activating mutation and may be defined 
as a somatically introduced alteration in a DNA sequence caused by a single nucleotide base 
variation, deletion or insertion. Although SNPs and point mutations are much alike and the 
terms are loosely used in the literature, SNPs are generally more common and do have a more 
persistent presence throughout a population. 
1.4.2. Oncogene amplification 
A common genetic event in solid tumors is gene amplification, which can be defined as a 
copy number increase of a restricted region (containing the amplified gene) of a chromosome 
arm [85]. A likely initiator of gene amplification is the occurrence of chromosomal instability 
resulting in DNA double strand breaks during DNA replication in cells not able to induce cell 
cycle arrest [86-88]. The amplified genomic fragment may encompass a few kilobases to tens 
of megabases [55]. 
With the amplification of a particular chromosomal region, oncogene amplification may 
occur. Amplification of such an oncogene can lead to overexpression of the gene involved, 
for example resulting in constitutive activation of the pathway or oversensitivity to extracellular 
signaling and thereby conferring a selective growth advantage. This abnormal protein activity 
can be attributed to the simple fact that the involved tumor cells contain as many as 100 gene 
copies per cell, instead of the 2 copies present in normal cells [9]. Oncogene amplification 
often is a late event in the development of tumor cells and clinically correlates to more 
aggressive tumors [89-92]. Amplification of specific oncogene containing stretches of DNA 
can have implications for both prognosis as well as targeted therapies. 
1.5 Application of SNP detection in molecular diagnostics
1.5.1. SNP genotyping methods 
Many SNP genotyping techniques are available. These methods include a wide variety of 
sequencing strategies, such as Sanger sequencing [93] and pyrosequencing [94] and different 
next generation sequencing (NGS) approaches. Some of these NGS strategies are e.g. single 
molecule real time sequencing (Pacific Biosciences), Ion semiconductor sequencing (Ion 
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torrent) and sequencing by synthesis (Illumina) [95]. These platforms yield large amounts of 
data and are mainly employed for determining the sequences of (extremely) large stretches 
of DNA, potentially incorporating many SNPs and other DNA variations and mutations. Often, 
these technologies are relatively costly to employ and require expensive equipment [95]. 
Another high throughput SNP genotyping technology employs oligonucleotide microarrays 
(Affymetrix) to assess DNA copy number variations [96]. Additionally, many SNP specific 
detection methods (often suitable to multiplex) are employed, such as single base primer 
extension (minisequencing, SNaPshot) [97], oligonucleotide ligation (SNPlex) [98], allelic-spe-
cific cleavage by flap endonucleases (the Invader assay) [99, 100] and Taqman based real time 
PCR [101]. These methods are mainly employed for specific disease conferring SNPs and the 
detection of hot spot point mutations. 
1.5.2. Tissue identification
Although specimen identification in clinical laboratories is a carefully controlled process, 
errors do occur. Unfortunately these errors can have very serious consequences for the 
patient(s) involved. Mislabeling of formalin-fixed paraffin-embedded (FFPE) tissues, the most 
widely used patient material in surgical pathology, occurs in approximately 0.08-1.2% of 
samples [102-107]. In the case of serum, a second widely used patient material for diagnostic 
and treatment-related purposes, the estimated mislabeling percentage is around 0.1% 
[108-111]. DNA based tissue identification in cases of suspected sample mix-ups is therefore 
of great value with regard to reliable laboratory results and patient safety.
Several methods have been used for tissue identification, mostly in forensic science. The 
primary method of choice was restriction fragment length polymorphisms (RFLP) analysis of 
VNTRs [10]. Although highly specific “DNA fingerprints” could be obtained by RFLP of VNTRs, 
this technique also suffered from difficulties such as the need for large quantities of input 
DNA [112] and the inability to analyze degraded DNA samples. These issues were partly 
overcome by the introduction of PCR to accumulate specific stretches of DNA incorporating 
the VNTRs under investigation [113]. At present however, the methodology of choice for 
specimen identification is often based on characterization of a (multiplexed) panel of STRs by 
PCR and subsequent capillary electrophoresis [11]. An alternative target for tissue identification 
is for example the highly polymorphic human leukocyte antigen (HLA) locus [114]. 
The discriminatory power using these methods is extremely high and may exceed a probability 
of identity of 1011 [115-117]. Therefore, such technologies may provide valuable information in 
courtroom proceedings. To solve potential cases of clinical sample mix-ups however, this 
extraordinary high discriminatory power is not necessary. In addition, these methods remain 
relatively time consuming and/or require expensive equipment.
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1.5.3. Cancer diagnostics
1.5.3.A. LOH of the JAK2 locus in myeloproliferative disease
The (somatic) introduction of a mutation within a TSG or proto-oncogene may lead to TSG 
inactivation or oncogene activation and thereby constitutive activation of the pathway 
involved [54]. A well-studied example of oncogene activation is the G-to-T missense mutation 
in the gene encoding the janus kinase 2 (JAK2) tyrosine kinase, which results in a valine-to-
phenylalanine (V-F) amino acid substitution at codon 617 (JAK2V617F) [78, 84, 118, 119]. 
JAK2 is a non-receptor tyrosine kinase involved in the JAK/STAT signaling pathway [120]. The 
mutation is thought to alter the autoinhibitory pseudokinase JH2 domain in such a way that 
the JAK/STAT signaling pathway is constitutively activated, resulting in growth factor 
independent cell proliferation [121]. JAK/STAT signaling has been determined to play a 
mediating role in many cytokine-signaling events and therefore has a large impact on 
haematopoiesis. Some cytokines that are associated with downstream JAK2 signaling are 
erythropoietin (EPO), thrombopoietin (TPO), granulocyte-macrophage colony stimulating 
factor (GM-CSF), multiple interleukines (ILs), etc [122]. The JAK2V617F mutation is commonly 
found in several myeloproliferative neoplasms: in 65-97% of polycythemia vera (PV) cases, in 
23-57% of the essential thrombocythemia (ET) cases, and in 35-57% of primary myelofibrosis 
(PMF) cases [123, 124]. These myeoloproliferative diseases (MPD) are closely related and 
represent clonal disorders of multipotent hematopoietic progenitors. Essential components 
for PV and ET are erythrocytosis and thrombocytosis, respectively (although excess 
proliferation of erythrocytes, thrombocytes and leukocytes is often observed in both 
phenotypes). Clinical manifestations are for example (but not limited to) headaches, enlarged 
spleen size, thrombohemorrhagic complications and pruritis (infrequent in ET). PMF is 
characterized by fibrosis of the bone marrow and has similar clinical manifestations as 
observed in PV and ET. The diagnostic value of JAK2 mutational analysis in MPD has been 
endorsed in the WHO classification of haematological malignancies [125]. 
A correlation between JAK2V617F mutant allele burden and severity of disease has been 
postulated on several occasions. With regard to PV and ET lower platelet counts, higher 
incidence of splenomegaly in combination with larger spleen size, cytoreductive therapy 
needed in a greater number of patients and higher white blood cell counts have been found 
to be correlated to the burden of JAK2V617F allele [126-128]. A higher incidence of thrombotic 
events is also observed in PV and ET, particularly with mutant allele burdens greater than 
50% [128-130]. Significantly higher chances of fibrotic transformation have been observed in 
both PV and ET [126]. Pruritis was found more frequently in PV with higher mutant allele 
burdens [126, 131-133]. On the contrary, low mutant allele burdens in PMF seem to correlate 
to shortened progression time to anemia and leukopenia [134] and poorer survival, which 
was found to be due to leukemic transformation and systemic infections, [134, 135]. The 
mechanism(s) behind this correlation are yet to be established [136].
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Investigation of LOH of chromosome 9p, with a focus on the JAK2 containing region, has 
initially been performed using microsatellite mapping [78, 137]. These studies showed that 
9pLOH was a frequent chromosomal event occurring in approximately one-third of PV 
patients and one-fifth of MPD patients. During subsequent studies on this issue, the 
methodology of choice was high resolution Single Nucleotide Polymorphism-array mapping, 
because it is capable of generating detailed chromosomal maps pinpointing lesions 
throughout the entire genome. Size of chromosomal regions lost ranged from 4.8-42.0 
million base pairs and were found in three-fourths of MPD cases [138-141].
When LOH leads to aUPD, conventional cytogenetic analysis –such as fluorescence in situ 
hybridization (FISH) and array comparative genomic hybridization (aCGH)- is not able to 
detect these abnormalities because the resulting karyotype appears ‘normal’ [142]. High-
resolution analysis of (part of) the genome by Short Tandem Repeat (STR)- or SNP-based 
techniques provide the information necessary at the level of the individual allele [142]. In 
particular, SNP oligonucleotide genomic microarrays are able to generate genome-wide data 
with regard to copy-number and copy-number-neutral (such as aUPD) changes throughout 
the whole genome [143, 144].
1.5.3.B. HER2/TOP2A locus in breast cancer
A well-documented example of oncogene amplification is that of the human epidermal 
growth factor receptor 2 (HER2; also known as erbB-2 and neu) in breast cancer. The 
transmembrane tyrosine kinase receptor HER2 is encoded by the HER2 gene, a member of 
the HER (1-4) receptor family [145-147] that is expressed in various cell and tissue types [148]. 
HER family members form homo- and heterodimers when binding to their corresponding 
ligand (a specific HER2 ligand has yet to be elucidated), upon which signal transduction is 
subsequently activated [149]. Amplification and subsequent overexpression of HER2 occurs 
frequently in human cancers of different origin [148] and leads to an increase of intracellular 
signaling [150]. The role of HER2 amplification is particularly evident in breast cancer, where 
it is found in 25-30% of the cases [151] and is associated with more aggressive tumor behavior 
and poor clinical outcome [90, 92, 152]. Tumors can become ‘addicted’ to the enhanced 
expression resulting from oncogene amplification. This tumor specific oncogene dependence 
results in a differential sensitivity for tumor cell specific therapy targeting the product of the 
oncogene [153]. This oncogene addiction in combination with the availability of an 
extracellular domain of the HER2 protein makes it well suited for therapeutic targeting. 
Trastuzamab (Herceptin), a monoclonal antibody (MAb) against HER2, is only active against 
HER2 amplified tumors [154, 155]. This MAb is thought to abolish the function of (dimerized) 
HER2, thereby removing HER2 mediated signaling leaving only the part of the HER signaling 
network that sends relatively weak growth signals [156]. Therefore, the determination of the 
amplification status of oncogene encompassing stretches of DNA plays a pivotal role in 
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cancer prognosis and prediction of therapy efficacy. Additionally, several studies have shown 
an improved response rate for adjuvant anthracycline (AC)-based chemotherapy in HER2 
amplified breast tumors [157]. There is however no known AC induced HER2 inhibiting 
mechanism. It is therefore suggested that coamplification of the HER2 juxtaposed TOP2A 
gene, which occurs in approximately 30-45% of HER2 amplified breast tumors [158-160], is 
the biological rationale behind these observations [160]. The TOP2A gene, which encodes for 
the DNA topoisomerase 2-alpha, is adjacent (700 kb telomeric) to the HER2 gene locus [161]. 
The 170 kDa TOP2A enzyme plays a pivotal role in DNA replication, cell-cycle progression and 
chromosome segregation by catalyzing the topological DNA changes required during these 
processes [161, 162]. ACs are chemotherapeutic agents known to have, among other 
mechanisms of action, TOP2A inhibiting properties. These inhibiting properties are established 
during the topological DNA changes catalyzed by TOP2A by intercalating of the AC molecules 
in the intermediate complex where TOP2A tyrosine residues are covalently linked to the 
5’phosphoryl ends of the cut DNA. This results in stabilization of the intermediate complex 
and trapping it in this state, which prevents DNA resealing and further cell cycle progress. 
This ultimately leads to programmed cell death [161, 163, 164]. TOP2A amplification is 
associated with an improved response to adjuvant AC-based chemotherapy [159]. Patients 
with TOP2A amplified breast tumors show a trend towards a better disease free survival 
when compared to patients with tumors lacking this amplification [159]. Additionally, TOP2A 
amplification is an independent predictor of a significantly higher pathological complete 
response rate in these patients [159]. TOP2A deletion on the contrary, occurring in 15-40% 
of HER2 amplified breast cancers, has been associated with AC resistance [158-160]. 
Additionally, copy number alterations across the 17q12-q22 genomic region, incorporating 
the HER2 and TOP2A genes, have been proposed to be a marker for the degree of 
chromosomal imbalance in breast cancer [165, 166]. The high degree of chromosomal 
imbalance has been associated with improved response to AC-based therapy. Extensive 
chromosomal instability was found to be correlated to a decreased risk of death and showed 
a trend towards a decreased risk of relapse when compared to a low degree of chromosomal 
instability [165-167].
Other well known examples of proteins that are often excessively present in breast tumors 
and play a critical role in breast cancer diagnostics and choice of therapy, are the estrogen 
and progesterone receptors (ER and PR). Available targeted therapies in these breast cancer 
cases are e.g. Tamoxifen and aromatase inhibitors [168-170]. Breast tumors lacking the 
excessive presence of HER2, ER and PR are defined as “triple negative”. Triple negative tumors 
are associated with poor clinical outcome and lack of available targeted therapy [167, 
171-178]. These different breast cancer entities have been subcategorized based on distinct 
profiles of gene-expression or genetic alterations, using high resolution array based systems, 
targeting SNPs or utilizing Comparative Genomic Hybridization [167, 173-177]. ER and PR 
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positive tumors with no HER2 amplification showed minor and less frequent chromosomal 
instability whereas HER2 amplified breast tumors and triple negative breast tumors were 
shown to harbor more frequent and extensive chromosomal instability [167, 173-178].
1.6 Outline of this thesis
The omnipresence of SNPs throughout the human genome, in combination with the relative 
ease of real time PCR based detection of SNPs, makes them a valuable –and almost infinite 
in number- source of biomarkers. Utilizing these key SNP features for the development of 
various diagnostic applications may result in easy implementable and clinically significant 
assays for routine molecular laboratories. Human tissue identification with regard to sample 
mix-ups, loss of heterozygosity analysis and testing of allelic instability were determined as 
applications of interest in this thesis. Although techniques exist for these various applications, 
most of them –such as short tandem repeat (STR) analysis [82, 137] and SNP based arrays 
[138-141]- require expensive equipment, in contrast to real time PCR equipment, which is 
currently widely available in diagnostic laboratories. Secondly, real time PCR based SNP 
profiling only needs short stretches of DNA (± 80 bp), whereas e.g. STR-based assays require 
up to 360-bp fragments. Therefore real time SNP PCR is expected to be an excellent diagnostic 
tool in combination with the fragmented DNA present in FFPE tissues. A third advantage of 
SNP profiling is that, in contrast to other methods, processing after PCR is not required in  real 
time PCR analysis. This substantially reduces the risk of contamination with PCR products 
while keeping high specificity. 
The aim of this thesis was to develop real time PCR based SNP assays for human identity 
testing, LOH testing and allelic imbalance testing, predominantly utilizing DNA extracts from 
(archival) FFPE tissues. In chapter 2 the most suitable DNA extraction method for FFPE tissues 
was determined by an inter-assay comparative analysis. In chapter 3 and 4, a real time PCR 
based SNP profiling assay able to confirm the identity of human FFPE tissues and serum 
samples was developed and validated. The suitability of SNP profiling using real time PCR for 
LOH detection was investigated, with LOH of the JAK2 region in patients suspected of my-
eloproliferative disease as a proof of principle, and described in Chapter 5 (JAK2V617F 
detection), and Chapter 6 (LOH analysis). Finally, the allelic (im)balance at the HER2/TOP2A 
locus in patients with different entities of primary breast cancer was determined using a 
panel of real time SNP PCR assays in Chapter 7.
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Abstract
Background: A large portion of tissues stored worldwide for diagnostic purposes is 
formalin-fixed and paraffin-embedded (FFPE). These FFPE-archived tissues are an extremely 
valuable source for retrospective (genetic) studies. These include mutation screening in can-
cer-critical genes as well as pathogen detection. In this study we evaluated the impact of 
several widely used DNA extraction methods on the quality of molecular diagnostics on FFPE 
tissues.
Findings: We compared 4 DNA extraction methods from 4 identically processed FFPE 
mammary-, prostate-, colon- and lung tissues with regard to PCR inhibition, real time SNP 
detection and amplifiable fragment size. The extraction methods, with and without proteinase 
K pre-treatment, tested were: 1) heat-treatment, 2) QIAamp DNA-blood-mini-kit, 3) EasyMAG 
NucliSens and 4) Gentra Capture-Column-kit. Amplifiable DNA fragment size was assessed 
by multiplexed 200-400-600 bp PCR and appeared highly influenced by the extraction 
method used. Proteinase K pre-treatment was a prerequisite for proper purification of DNA 
from FFPE tissue. Extractions with QIAamp, EasyMAG and heat-treatment were found 
suitable for amplification of fragments up to 400 bp from all tissues, 600 bp amplification 
was marginally successful (best was QIAamp). QIAamp and EasyMAG extracts were found 
suitable for downstream real time SNP detection. Gentra extraction was unsuitable. Hands-on 
time was lowest for heat-treatment, followed by EasyMAG.
Conclusions: We conclude that the extraction method plays an important role with regard 
to performance in downstream molecular applications.
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Findings
Due to the tremendous progress in molecular pathology during the last decade, molecular 
techniques are moving rapidly from research to routine use in diagnostic pathology. At present, 
routine tests include for example the detection of bacteria and viruses [1-7], neoplasm- 
associated mutations [8-10], microsatellite instability [11,12] and up- and down-regulation of 
mRNAs [13]. Archives of formalin-fixed paraffin-embedded (FFPE) tissues -that are often 
maintained over decades- represent an extraordinary source of morphologically well defined 
tissues that now allow retrospective studies to correlate molecular findings with therapy and 
clinical outcome [14]. However, the application of molecular DNA-based techniques to FFPE 
tissues suffers from challenges. Formalin-fixation, the most widely used fixative in histopathology, 
has many advantages such as the ease of tissue handling, the possibility of long-term storage, 
an optimal histological quality and its availability in large quantities at low price [15,16]. 
Unfortunately formalin-fixation induces DNA-tissue protein cross-links, which can prevent 
amplification. In addition, nucleic acid fragmentation may occur in formalin-fixed tissue due to 
aging of the specimen or the pH of the fixative [17]. Previous studies have shown that DNA 
extraction and subsequent downstream processes such as PCR from FFPE tissues is difficult, 
especially when longer stretches of DNA templates  are targeted  [18]. It has been reported that 
DNA fragments of up to only 100-300 bp are obtained from FFPE tissues [19].
To recover nucleic acids from non-fixed tissues we routinely combine proteinase K (prot. K) 
digestion with commercial extraction methods. The aim of this study was to test whether DNA 
isolation techniques routinely available in molecular diagnostic laboratories can be applied to 
FFPE tissues. In addition, we think it is handy to employ DNA extraction kits that are suitable for 
the extraction of DNA from a wide variety of patient materials, e.g. blood, buccal swabs and 
FFPE tissues. We therefore compared four different extraction protocols with and without prot. K 
digestion, and evaluated the impact of these DNA isolation methods on downstream molecular 
techniques. The extractions tested were: 1) heat-treatment, 2) QIAamp DNA-blood-mini-kit 
extraction, 3) EasyMAG NucliSens extraction and 4) Gentra Capture-Column-kit extraction.
Experiments were carried out regarding i) the inhibition of PCR by monitoring amplification 
of an internal control DNA virus, ii) the performance of the isolated DNA in SNP analysis by 
real time PCR and iii) performance in a conventional multiplex PCR amplifying 200, 400 and 
600 bp human DNA fragments. Studies comparing the suitability of different DNA extraction 
methods such as (modified) phenol-chloroform extraction, boiling, microwave and QIAamp 
DNA-blood-mini-kit extraction have been published [20-24]. However these studies did not 
include a comparison of the in this study described commercial methods, which are routinely 
used by hospital laboratories when performing molecular diagnostics.
The data presented here indicate that proteinase K digestion is required for obtaining DNA of 
sufficient quality by all 4 extraction methods. The size of the amplifiable DNA fragments 
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highly depended on the extraction method. QIAamp extraction and heat-treatment in 
combination with proteinase K digestion resulted in amplification of the longest DNA 
fragments- up to 600 bp. Amplification inhibitors were found in all Gentra extracts and in 
one colon tissue extract after prot. K digestion and heat-treatment. EasyMAG NucliSens 
extraction and the QIAamp method seemed to be equally effective in extracting 200 bp 
fragments, and therefore suitable for real time SNP detection. An advantage of heat-treatment 
and the EasyMAG NucliSens extraction was their lower hands-on time.
Methods
Experimental set-up
The workflow of the presented study is described in figure 1. Four tissues (A-D) were subjected 
to proteinase K digestion and no proteinase K digestion. Subsequently, 4 different extraction 
methods were performed: 1) heat-treatment, 2) QIAamp DNA-blood-mini-kit extraction, 3) 
EasyMAG NucliSens extraction and 4) Gentra Capture-Column-kit extraction. All extracts 
were tested regarding: i) cumulative effect of PCR inhibition and extraction efficiency, ii) 
performance in real time SNP detection and iii) performance in conventional multiplex PCR 
amplifying 200, 400 and 600 bp human genomic DNA fragments.
Tissue processing
Four randomly chosen biopsies, taken for diverse clinical purposes, from different patients 
and organs were used for this study: A. mammary, B. colon, C. prostate and D. lung. The 
tissues were rendered anonymous before use in this study and were formalin-fixed and 
 paraffin-embedded 1-4 weeks ago. Tissues were fixed in 0.01 mol/L buffered (0.005 mol/L 
disodium hydrogen phosphate anhydrous and 0.005 mol/L sodium dihydrogen phosphate 
dihydrate, pH 7.0) 10% formalin, and processed for paraffin-embedding using a Tissue-Tek 
VIP 5 (Sakura, Torrance, USA). The dehydration program consisted of 14 steps of 1 hour 
under continuous agitation, pressure, vacuum, and heating. At 40°C, two 10% formalin 
steps were followed by one 70% (v/v) ethanol step, two 96% ethanol steps, three 100% 
ethanol steps, and two 100% xylene steps. Paraffin-embedding was done at 60°C in four 
100% paraffin steps.
DNA extractions
The four DNA isolation procedures were: heat-treatment, QIAamp DNA-blood-mini-kit 
extraction (silica membrane-based column extraction; Qiagen, Hilden, Germany), EasyMAG 
NucliSens extraction (magnetic silica beads-based extraction; Biomerieux, Boxtel, The 
Netherlands) and Gentra Capture-Column-kit extraction (silica membrane-based column 
extraction; Gentra Systems Inc, Minneapolis, USA).
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Paraffi n-embedded tissues were trimmed of paraffi n excess and cut into 3-μM-thick sections. 
Approximately 1 to 1.5 cm2  of sectioned tissue (a single section or short ribbons depending 
on the surface per section) was put in 250 μL of digestion solution (digestion solution with 
proteinase K was prepared by adding 100 μL of proteinase K solution (20 mg/mL; Roche 
Diagnostics GmbH, Mannheim, Germany) and 10 μL of Tween 20 (Merck BV, Amsterdam, 
The Netherlands) to 2 mL of TE buffer (1 mmol/L ethylenediaminetetraacetic acid, and 10 
mmol/L Tris-HCl buffer, pH 8.0)) and incubated overnight at 45°C. Proteinase K was inactivated 
the next day by incubation at 100°C for 15-30 minutes. Afterwards, samples were centrifuged 
for 2 minutes at 14,000 rpm.
From each material eight paraffi n sections were cut, 4 were digested in digestion solution 
with proteinase K (according to the method described above) and 4 were submerged in 
digestion solution without proteinase K. All 32 samples were further processed as described 
Figure 1  Study design. Schematic representation of study-design.
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above. To assure an equal quantity of DNA in each procedure, the supernatants -located 
beneath the paraffin cap- from the 4 proteinase K digested samples as well as the 4 
non-digested samples were pooled for each material. These pools were homogenized and 
processed as detailed below.
Heat treatment
Two-hundred μL of pool was mixed with 10 μL of Phocine herpes virus (PhHV, seal herpes 
virus, kindly provided by the Erasmus Medical Centre in Rotterdam, The Netherlands), which 
served as an internal extraction control, and was used directly in the downstream applications.
QIAamp DNA-blood-mini-kit extraction
Two-hundred μL pool and 10 μL of PhHV were added to 200 μL AL buffer, homogenized and 
incubated for 10 min. at room temperature. Two-hundred μL of 96% ethanol (Merck KgaG, 
Darmstadt, Germany) was added. The mixture was transferred to a QIAamp column and 
centrifuged for 1 min. at 8,000 rcf. The column was put in a new collection tube, 500 μL 
AW1 buffer was added and centrifuged for 1 min. at 8,000 rcf. This procedure was repeated 
with 500 μL AW2 buffer and the column was centrifuged for 1 min. at 14,000 rcf. To remove 
all ethanol from the column it was put in a new collection tube and then subjected to a dry 
spin for 1 min. at 14,000 rcf. Elution was performed by adding 200 μL EL buffer, incubating 
for 5 min. at room temperature followed by centrifugation for 1 min. at 8,000 rcf. 
EasyMAG NucliSens extraction
Two-hundred μL pool and 10 μL of PhHV were added to 2 mL NucliSens lysis buffer, 
homogenized and incubated for 10 min. at room temperature. The mixture was then added 
to the EasyMAG vessel and 100 μL of diluted magnetic silica (50 μL silica + 50 μL ultrapure 
water) was subsequently added. The DNA was extracted on the EasyMAG machine using the 
“Generic 2.0.1” program. Elution was performed in 200 μL NucliSens Extraction buffer 3.
Gentra Capture-Column-kit extraction
Two-hundred μL pool and 10 μL of PhHV were directly added to the column and incubated 
for 5 min. at room temperature. Four-hundred μL of Purification Solution 1 was added 
followed by 5 min. incubation at room temperature and a 15 sec. centrifugation step at 
8,000 rcf. This step was performed twice. Subsequently 200 μL of Elution Solution 2 was 
added followed by a 15 sec. centrifugation step at 8,000 rcf. To elute the purified DNA, 200 
μL of Elution Solution 2 was added to the column and incubated for 10 min. at 100°C. 
Collection of the DNA was performed by centrifugation for 25 sec. at 8,000 rcf.
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Internal control amplification
A PhHV specific real time PCR was performed. Twenty-five μL of PCR, using a homebrew 
“JBZ” 4× mastermix, contained 20 mmol/L Tris-HCl, pH 8.4, 50 mmol/L KCl, 3 mmol/L MgCl2 
(prepared from 10× PCR buffer and 50 mmol/L MgCl2 solution delivered with Platinum Taq 
polymerase), 0.75 U of Platinum Taq polymerase (Invitrogen BV, Breda, The Netherlands), 4% 
glycerol (molecular biology grade; Calbiochem, VWR International BV, Amsterdam, The 
Netherlands), 200 μmol/L of each dNTP (Invitrogen BV), 0.5 μL of Rox reference dye (Invitrogen 
BV), 300 nM of PhHV forward primer 5'-GGG CGA ATC ACA GAT TGA ATC-3', 300 nM of 
PhHV reverse primer 5'-GCG GTT CCA AAC GTA CCA A-3', 100 nM PhHV TaqMan probe 
5'-FAM-TTT TTA  TGT  GTC  CGC  CAC  CAT  CTG  GAT  C- TAMRA-3' and 10 μL extracted 
DNA [25]. Real time PCR was performed in an ABI Prism 7000 SDS (Applied Biosystems (ABI), 
Foster City CA, USA) for 2 minutes at 50°C, 10 minutes at 95°C, followed by 45 cycles of 15 
seconds at 95°C and 1 minute at 60°C.
SNP analysis using real time PCR
Predesigned TaqMan Assays-on-Demand SNP genotyping products rs2043731 and 
rs1350138 (ABI) were used according to the manufacturer’s instructions. Two mastermixes 
were tested: the homebrew JBZ 4× mastermix and the commercial ABI 2× TaqMan Universal 
PCR mastermix. Twenty-five μL of PCR, using the JBZ 4× mastermix contained, 20 mmol/L 
Tris-HCl, pH 8.4, 50 mmol/L KCl, 3 mmol/L MgCl2 (prepared from 10× PCR buffer and 50 
mmol/L MgCl2 solution delivered with Platinum Taq polymerase), 0.75 U of Platinum Taq 
polymerase (Invitrogen BV, Breda, The Netherlands), 4% glycerol (molecular biology grade; 
Calbiochem, VWR International BV, Amsterdam, The Netherlands), 200 μmol/L of each dNTP 
(Invitrogen BV), 0.5 μL of Rox reference dye (Invitrogen BV), 1.25 μL of predeveloped assay 
reagent from the Assays-on-Demand SNP genotyping products (ABI) containing two primers 
and two MGB TaqMan probes (5' VIC for allele 1, 5' FAM for allele 2 and a 3' black hole 
quencher for both alleles), and 11.25 μL of target DNA. Twenty-five μL of PCR, using the 
commercial mastermix, contained 12.5 μL of 2× TaqMan Universal PCR Mastermix (ABI), 1.25 
μL of predeveloped assay reagent from the Assays-on-Demand SNP genotyping products 
and 11.25 μL of target DNA. Real time PCR was performed in an ABI Prism 7000 SDS (ABI) 
for 2 minutes at 50°C, 10 minutes at 95°C, followed by 45 cycles of 15 seconds at 95°C and 
1 minute at 60°C.
Assessment of maximum amplicon length
Five μL of eluate was added to 12.5 μL of 2× Qiagen Multiplex Mastermix® (Qiagen), 2.5 μL 
of primer pool (containing 2 μM of each primer) and 5 μL of ultrapure water (Gibco BRL 
division of Invitrogen, Gaithersburg, USA). Amplification was performed in a Veriti (ABI): 5 
min. at 95°C, 35 cycles of 30 sec. at 94°C, 1:30 min. at 57°C and 1:30 min. at 72°C, followed 
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by 10 min. at 72°C, and fi nally ∞ at 10°C. Separation on gel, visualization and quantifi cation 
of the PCR products was performed in a 2100 BioAnalyzer (Agilent Technologies, Santa Clara 
CA, USA) using the DNA 1000 series II kit according to the manufacturer’s protocol.
Results
Internal control amplification
To monitor the presence of inhibiting substances in the PCR, 10 μL of seal herpes virus (PhHV) 
was added to each material before DNA isolation and a PhHV specifi c real time PCR was 
performed after DNA isolation. The fi xed quantity  of PhHV added  to each extraction method 
in this study is exactly in accordance with the quantity used in our routine diagnostics. Based 
on 340 measurements of DNA isolations for diagnostic purposes, the expected Ct value is the 
mean Ct value = 25.8; coeffi cient of variation, 2.5% (data not shown); the threshold for 
inhibition was set at Ct 27.7 being the mean + 3 standard deviations. DNA isolates with PhHV 
values that exceed 27.7 are considered to be inhibited. 
Figure 2 shows the mean PhHV PCR Ct values of the 4 tissues (A, B, C and D) for the different 
extraction methods. PhHV amplifi cation after Gentra extraction from all four tissues (with 
and without prot. K pre-treatment; Ct 33.1 ± 0.4 and Ct 34.0 ± 1.2, respectively) and prot. K 
plus heat-treatment for colon tissue B (Ct 30.0) generated Ct values > 27.7 indicating PCR 
inhibition. PhHV amplifi cation of DNA-extracts obtained using all other methods showed no 
inhibition (Ct values < 27.7). 
Figure 2  Internal control amplifi cation. Mean Ct value of PhHV PCR of the 4 materials (A, B, C and 
D) for the different extraction methods. The +/ and -/ indicate the use of proteinase K digestion or no 
digestion, respectively. The different extraction methods are indicated by: heat-treatment =/-, QIAamp 
DNA extraction =/Q, EasyMAG DNA extraction =/EM, Gentra DNA extraction =/G.
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SNP analysis using real time PCR
To determine the suitability of the different DNA extracts for SNP analysis, real time 
amplifi cation using Assays-On-Demand SNP genotyping products was performed. Different 
PCR buffer systems and/or different Taq polymerases may yield different real time PCR results 
[26,27]. We therefore evaluated 2 different mastermixes.
Figure 3A shows a representative example (colon tissue) of real time amplifi cation component 
plots using SNP assay rs1350138 in JBZ 4× (home-made) mastermix and ABI 2× mastermix. 
Figure 3B shows the mean Ct values for the different DNA extraction procedures after real 
time amplifi cation using SNP Assays-On-Demand Genotyping products rs2043731 and 
rs1350138 in JBZ 4× mastermix and ABI 2× mastermix. Use of the JBZ 4× mastermix resulted 
in slightly higher fl uorescence and lower mean Ct values than the ABI 2× mastermix. Mean 
Ct’s were lowest after prot. K digestion followed by QIAamp and EasyMAG extraction (mean 
Ct value in JBZ mix = 26.5 and 26.6, respectively).
Assessment of maximum amplicon length
A multiplex PCR was performed to assess the ability of 200, 400 and 600 bp human DNA 
fragments to be amplifi ed using the DNA yielded by the different extraction methods. 
Visualization of the PCR products on gel of representative tissue B (colon) is shown in fi gure 4. 
The mean yields of the multiplexed 200 bp, 400 bp and 600 bp PCR products of 4 different 
Figure 3  SNP analysis using real time PCR. A. Two representative component plots generated after 
proteinase K treatment followed by EasyMAG extraction from colon tissue B and real time amplifi cation 
using SNP assay rs1350138. The light grey line indicates allele 1 (VIC label), the dark grey line indicates 
allele 2 (FAM label). B. Mean Ct value of SNP rs2043731 and rs1350138 of the 4 materials (A, B, C and 
D) in JBZ 4× mastermix or ABI 2× mastermix for the different extraction methods. The +/ and -/ indicate 
the use of proteinase K digestion or no digestion, respectively. The different extraction methods are 
indicated by: heat-treatment =/-, QIAamp DNA extraction =/Q, EasyMAG DNA extraction =/EM, Gentra 
DNA extraction =/G.
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tissues (A, B, C and D) for the different extraction methods are shown in fi gure 5. To compare 
the methods’ yields the QIAamp DNA extraction in combination with proteinase K digestion 
was set at 100%. The multiplex amplifi cation of DNA extracted by prot. K digestion in 
combination with QIAamp, EasyMAG or heat-treatment extracts was successful for fragments 
up to 400 bp from all tissues (400 bp amplicon yields of 11.0 ± 1.2 ng/μL, 8.2 ± 5.8 ng/μL 
Figure 4  Assessment of maximum amplicon length: visualisation on gel. Gel image of 200-400- 
600 bp multiplex PCR-products of representative tissue B. The +/ and -/ indicate the use of proteinase K 
digestion or no digestion, respectively. The different extraction methods are indicated by: heat-treatment 
=/-, QIAamp DNA extraction =/Q, EasyMAG DNA extraction =/EM, Gentra DNA extraction =/G. Neg = 
ultrapure water in PCR, Pos = QIAamp extracted DNA from EDTA-blood.
Figure 5  Assessment of maximum amplicon length: PCR product yield. Mean relative yield (%) 
of 200, 400 and 600 bp PCR products of 4 materials (A, B, C and D). The prot. K + QIAamp extraction’s 
yield was set at 100%. The +/ and -/ indicate the use of proteinase K digestion or no digestion, 
respectively. The different extraction methods are indicated by: heat-treatment =/-, QIAamp DNA 
extraction =/Q, EasyMAG DNA extraction =/EM, Gentra DNA extraction =/G.
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and 9.02 ± 4.56 ng/μL, respectively), 600 bp amplification  was marginally  successful  in 3/4 
tissues  for QIAamp and EasyMAG and in 4/4 tissues for heat-treatment with low yields (6.5 
± 8.2 ng/μL, 3.5 ± 4.6 ng/μL and 3.42 ± 4.96 ng/μL, respectively).
Discussion
Currently routine molecular techniques are increasingly used on FFPE tissues. An important 
basic requirement is optimal DNA preparation. We tested human DNA extracts from 4 
commonly used DNA extraction methods for the presence of inhibiting substances, and in two 
downstream applications: real time SNP amplification and multiplexed 200-400-600 bp PCR.
It has to be taken into account that this study was performed with relatively fresh specimens 
-common practice when the sample is investigated for diagnostic related purposes- and that 
the formalin-fixative was buffered. Both age of tissue blocks and buffering capacity of forma-
lin-fixative are known to be important factors that influence nucleic acid fragmentation [17]. 
In addition, the DNA extraction methods were studied using a limited number of samples. 
However the consistency of results justify several conclusions.
Gentra DNA extraction can be successfully employed on blood samples [28-32]. However, the 
reduced amplification of PhHV, the internal control virus, after Gentra extraction showed that 
the Gentra method was not able to sufficiently remove the inhibitory substances (figure 2). In 
addition, Ct values < 27.7 generated by amplifying PhHV DNA extracted by the other methods 
imply that proteinase K digestion is not necessary for the removal of possibly present 
inhibitory substances.
QIAamp as well as EasyMAG are both methods that are currently widely used in routine 
molecular diagnostics regarding the detection of pathogens, e.g. HPV detection [33,34], and 
mutation screening in cancer-critical genes, e.g. K-ras mutation detection [10]. With regard 
to real time SNP detection both methods performed well after proteinase K digestion. In line 
with previous findings (e.g. [35,36]) we observed that proteinase K digestion is required for 
optimal purification of paraffin-embedded DNA. The homebrew JBZ 4× mastermix yielded 
better results than the commercial ABI 2× mastermix: fluorescent signals were slightly higher 
and Ct values lower, suggesting a better real time PCR environment for SNP amplification 
(figure 3A and 3B). The absence and presence of > 200 bp PCR products after multiplex PCR 
(figure 4 and 5) of non-digested and digested samples (resp.) indicate that proteinase K 
treatment plays an important role in proper purification of fragments > 200 bp. Also for RNA 
it has been shown that small molecules are recovered more easily from FFPE tissues than 
larger RNA molecules [27,37]. The relatively high 200 bp PCR product yield for the extraction 
methods without proteinase K digestion is probably due to the lack of competition for PCR 
ingredients by the absence of amplification of the higher molecular DNA targets, which are 
known to be extracted better when proteinase K digestion is used in contrast to no digestion 
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[35,36]. This observation is important with regard to applications that target stretches of 
DNA > 200 bp, e.g. STR testing, P53 sequencing and APO-E genotyping [38-40]. Overall 
multiplex PCR results after Gentra extraction were very poor.
During the processes of paraffin-embedding, sectioning and further analysis by (real time) 
PCR, small traces of foreign DNA, e.g. introduced by floater tissue or a contaminated 
microtome blade, may contaminate the material under investigation thereby possibly 
influencing interpretation of results [41,42]. Thus, caution is advised when using FFPE tissues 
in combination with molecular techniques. In addition, we routinely process paraffin blocks 
without tissue, which we use as negative controls. DNA extracts from these blocks may 
generate real time PCR signals above Ct 35. To be sure that the signal under investigation is 
not due to background, we set the cut-off Ct value at 33 when using a SNP-profiling assay 
for identity confirmation [43], implicating that test results with Ct values > 33 were rejected, 
whereas test results with Ct values < 33 were accepted.
In summary, the Gentra extraction appeared not suitable to purify DNA from FFPE tissues. We 
speculate that this is possibly due to the methods’ inability to remove DNA-tissue protein 
cross-links, resulting in loss of DNA during  the  washing  steps  of the  DNA extraction method. 
In addition, column shredding, by which Gentra samples are lysed, could be less successful than 
guanidinium thiocyanaat lysis used by both the QIAamp and EasyMAG extraction methods. 
The other three methods were suitable for purifying DNA from paraffin-embedded tissues, but 
all of them required proteinase K digestion. For real time SNP detection, both QIAamp and 
EasyMAG DNA extraction performed best. For amplification of longer DNA fragments -up to 
600 bp-, the QIAamp DNA-blood-mini-kit extraction was most suitable, followed by 
heat-treatment and EasyMAG extraction. An advantage of the heat-treatment and EasyMAG 
was the reduced hands-on time (when extracting 24 samples: approximately 60 min. for 
QIAamp versus 5 min. for heat-treatment and 25 min. for EasyMAG).
Conclusions
We conclude that the extraction method significantly influences downstream molecular 
analysis, which is in line with the findings of previous studies [17,20-24]. The Gentra Capture-
Column-kit is not suitable for DNA recovery from FFPE tissues. Of the four methods tested 
QIAamp DNA-blood-mini-kit extraction and EasyMAG NucliSens extraction performed best 
for real time SNP detection. Amplification of 400-600 bp fragments appeared most successful 
after QIAamp isolation followed by the heat-treatment and EasyMAG.
Thus the method used for DNA isolation from FFPE tissues should be matched with the 
intended application.
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Abstract 
To identify issues of sample mix-ups, various molecular techniques are currently used. These 
techniques, however, are time consuming and require experience and/or DNA sequencing 
equipment or have a relatively high risk of errors because of contamination. Therefore, a 
quick and straightforward single nucleotide polymorphism (SNP) profiling assay was 
developed to link human tissues to a source. SNPs are common sequence variations in the 
human genome, and each individual has a unique combination of these nucleotide variations. 
Using potentially mislabeled paraffin-embedded tissues, DNA was extracted and SNP profiles 
were determined by real-time polymerase chain reaction analysis of the purified DNA using a 
selection of 10 commercially available SNP amplification assays. These profiles were compared 
with profiles of the supposed owners. All issues (34 in total) of potential sample mix-ups 
during the last 3 years were adequately solved, with six cases described here. The SNP 
profiling assay provides a quick (within 24 hours), easy, and reliable way to link human 
samples to a source, without polymerase chain reaction postprocessing. The chance for two 
randomly chosen individuals to have an identical profile is 1 in 18,000. Solving potential 
sample mix-ups will secure downstream evaluations and critical decisions concerning the 
patients involved.
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Introduction 
The clinically significant diagnostic error rate in surgical pathology reported in the literature 
varies from 0.08 to 1.2% [1–6]. One of the factors contributing to these errors is misidentification 
of paraffin-embedded tissue, the most commonly used material for diagnostic purposes. 
Although specimen identification is a carefully controlled factor in clinical laboratories, 
mislabeling still occurs. Unfortunately, sample mix-ups can have extremely serious 
consequences for the patients involved. Various methods to detect specimen mix-ups have 
been described. Most methods rely on characterization of DNA repeats [7–9], human leukocyte 
antigen system (HLA) [10–15], or other polymorphic genetic loci [14]. In addition, commercial 
identification kits are available [16–18]. Because these methods are time consuming and/or 
require DNA sequencing equipment, which is not available in many laboratories, we 
developed an easy, quick, and reliable method to link human tissues to a source. The method 
relies on the analysis of carefully selected SNPs by means of real-time polymerase chain 
reaction (PCR). Single nucleotide polymorphisms (SNPs) are the most frequent sequence 
variations in the human genome, occurring approximately once every 100 to 300 bp [19]. Apart 
from identical twins, each individual has a unique combination of nucleotides at these 
positions. Thus, a SNP profile provides a kind of fingerprint. SNP amplification assays have 
been commercially developed using DNA probes with conjugated minor groove binding 
(MGB) groups [20]. These probes form extremely stable duplexes with single-stranded DNA 
targets, thus allowing short probes to be used for hybridization-based assays. In this article, 
we describe a SNP profiling test for human tissues using 10 SNP assays that were selected on 
the basis of allele frequency and chromosomal location. By comparison, of the SNP profiles 
obtained from relevant samples, the test can reliably confirm the identity of human materials. 
The test can be used to detect sample mix-ups and to evaluate quality surveillance of sample 
handling and storage.
Materials and Methods
Tissue Processing
Tissues were fixed in 0.01 mol/L buffered (0.005 mol/L disodium hydrogen phosphate 
anhydrous and 0.005 mol/L sodium dihydrogen phosphate dihydrate, pH 7.0) 10% formalin, 
and processed for paraffin embedding using a Tissue-Tek VIP 5 (Sakura, Torrance, CA). The 
program consisted of 14 steps of 1 hour under continuous agitation, pressure, vacuum, and 
heating. At 40°C, two 10% formalin steps were followed by one 70% (v/v) ethanol step, two 
96% ethanol steps, three 100% ethanol steps, and two 100% xylene steps. Paraffin 
embedding was done at 60°C in four 100% paraffin steps.
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DNA Isolation
Blood
DNA was extracted from 200 µl of blood with the QIAamp DNA blood mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions and eluted in 150 µl of buffer AE (Qiagen).
Paraffin Sections
Paraffin-embedded tissues were trimmed of paraffin excess and cut into 3-µm-thick sections. 
As a control, a paraffin block without tissue, which had undergone the same treatment as 
the tissue containing blocks, was sectioned. Digestion solution was made by adding 100 µl 
of proteinase K (20 mg/ml; Roche Diagnostics GmbH, Mannheim, Germany) and 10 µl of 
Tween 20 (Merck BV, Amsterdam, The Netherlands) to 2 ml of TE buffer (1 mmol/L ethylene-
diaminetetraacetic acid, and 10 mmol/L Tris-HCl buffer, pH 8.0). Approximately 1 to 1.5 cm2 
of sectioned tissue (a single section or short ribbons depending on the surface per section) 
was put in 250 µl of digestion solution and incubated overnight at 45°C. Proteinase K was 
inactivated by incubation at 100°C for 15 minutes. Samples were centrifuged for 2 minutes 
at 14,000 rpm. DNA was extracted from the supernatants with QIAamp DNA blood mini kit 
(Qiagen), according to the manufacturer’s instructions (Qiagen protease digestion was not 
performed), and eluted in 150 µl of buffer AE.
TaqMan Assays-on-Demand SNP Genotyping Products
TaqMan Assays-on-Demand SNP genotyping products were purchased from Applied 
Biosystems (Foster City, CA). These assays are predesigned and validated by analyzing DNA 
samples from 180 individuals of four ethnic origins. The assays are supplied in single tube 
format and contain two unlabeled primers, a VIC dye-labeled TaqMan MGB probe with the 
sequence of allele 1 and a FAM dye-labeled TaqMan MGB probe with the sequence of allele 2.
Real-Time PCR
SNP amplification assays were used according to the manufacturer’s instructions. Twenty-five 
µl of PCR contained 20 mmol/L Tris-HCl, pH 8.4, 50 mmol/L KCl, 3 mmol/L MgCl2 (prepared 
from 10x PCR buffer and 50 mmol/L MgCl2 solution delivered with Platinum Taq polymerase), 
0.75 U of Platinum Taq polymerase (Invitrogen BV, Breda, The Netherlands), 4% glycerol 
(molecular biology grade; Calbiochem, VWR International BV, Amsterdam, The Netherlands), 
200 µmol/L of each dNTP (Invitrogen BV), 0.5 µl of Rox reference dye (Invitrogen BV), 1.25 µl 
of predeveloped assay reagent from the Assays-on-Demand SNP genotyping products 
(Applied Biosystems) containing two primers and two MGB TaqMan probes (5’ VIC for allele 
1, 5’ FAM for allele 2, a 3’ black hole quencher), and 11.25 µl of target DNA. Real-time PCR 
was performed in an ABI Prism 7000 SDS (Applied Biosystems) for 2 minutes at 50°C, 10 
minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.
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Results
Selection of SNP Assays
From an internet database containing more than 150,000 human TaqMan Assays-on-De-
mand SNP genotyping products (Applied Biosystems), we selected 17 SNP assays (Table 1). 
The principle of the assays is explained in Figure 1. An important criterion of selection was 
that minor (and major) allele frequency of the SNP should be ≈0.5. TaqMan Assays-on-De-
mand SNP genotyping products (Applied Biosystems) are validated by analyzing DNA samples 
from 180 individuals of four ethnic origins. Because the Dutch population is mainly of 
Caucasian origin, we used the Applied Biosystems indicated allele frequencies for Caucasians 
for the selection of SNP assays. Assuming the genotype frequencies to be in Hardy-Weinberg 
equilibrium, the chance to have identical outcome of two events (allele 1 versus allele 2) is = 
p2 + (1-p)2 [21,22]. To minimize this chance, the derivative of this equation equals 0. Thus, 
2p – 2 + 2p = 0 and p = 0.5. Another criterion of selection was that all SNPs should be 
situated on different chromosomes (c.q. autosomes). In addition, the SNPs should not reside 
within a coding region or the regulatory sequence of a gene. From the 17 SNP assays, the 
most suitable were selected for a panel of 10 SNP assays that we recommend to be used for 
the SNP profiling assay (Table 1). Beside the SNP assays, for identity confirmation we included 
the detection of one sequence specific to the human Y chromosome [23] to resolve male/
female sample mix-ups.
SNP Profiling
Because blood is an easy source of high-quality DNA, we tested the assays by analyzing four 
blood samples from four different patients. Figure 2 shows the fluorescent signals of three 
representative SNP assays; cycle thresholds (Ct values) were ≈23. The presence or absence of 
alleles 1 and 2 could easily be deduced from the signals (Table 2). All four individuals could 
easily be distinguished based on their SNP profiles.
Validation of the SNP Assays on Paraffin Tissues
To validate the SNP assays on paraffin materials, 35 paraffin-embedded tissues were analyzed 
in a total of 266 SNP assays. For the 35 tissues, the mean Ct value for fluorescent signals that 
were considered positive was 27.8 ± 4.2 (mean ± SD). A Ct value of 27.8 is approximately 
comparable with 104 cells in one PCR. During the processing of paraffin embedding, 
sectioning, and further analysis by real-time PCR, small traces of foreign DNA may contaminate 
the tissue under investigation. We therefore included a paraffin block in which no tissue was 
embedded in all analysis as a negative control. This paraffin block was processed identically 
to tissue containing blocks. The negative controls generated Ct values of 38.6 (FAM) and 41.9 
(VIC) in 1 of 122 SNP assays. Based on the above findings, we defined the cutoff level for 
3
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reliable Ct values at 33. Thus, Ct values higher than 33 were rejected, whereas Ct values 
lower than 33 were accepted. If Ct values exceeded 33, a larger surface of new sections was 
cut and analyzed.
Allele Frequencies of the SNP Assays
To test statistically whether the observed allele frequencies in the SNP assays differed from 
the frequencies indicated by Applied Biosystems for the Caucasian population, we used the 
χ2 test. For each SNP, materials from a minimum of 10 individuals (maximum 62 individuals) 
were analyzed. With a probability of exceeding the critical value of 0.05, the observed 
frequencies for SNP4, 10, and 12 differed signifi cantly from the expected frequencies (data 
not shown). We therefore excluded these SNP assays from the recommended panel of SNP 
assays (Table 1).
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Figure 1  SNP detection with MGB probes. A: Principle of SNP detection using hydrolysis probes. 
When the probe is intact, the quencher quenches the fl uorescent signal from the reporter. A/C SNP: in 
the presence of A, the VIC probe, complementary to A, is hydrolyzed during the PCR by the Taq 
polymerase. The VIC reporter is no longer quenched by the close proximity of the quencher and can be 
measured. In the presence of C, the VIC probe is removed from the DNA strand without being 
hydrolyzed. The FAM probe is complementary to C and, according to the same principle, generates a 
fl uorescent signal only in the presence of C. B: Fluorescent signals accompanying the different genotypes 
(SNP10; genotype is indicated in top left corner).
VIC FAM FAM 
FAM 
VIC 
VIC 
I
I
I
A 
B 
PCR Cycle  
Fl
uo
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sc
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te
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ity
 A/A  A/C  C/C  
(A)                                     (C) 
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SNP Assays and Loss of Heterozygosity (LOH)
LOH may lead to allelic loss and may therefore complicate the analyses of tumor tissues. 
During the development of the SNP profi ling assay, we encountered fl uorescent signals 
indicative of LOH in one lung tumor tissue (case 2, described below). We therefore investigated 
in silico whether the SNP assays were located in regions implicated in LOH by using the 
chromosomal region together with LOH as search terms in PubMed (Table 1). 3p25, 11p15, 
13q12, and 17p13 yielded between 59 and 218 hits, rendering them less suitable for analysis 
of tumor tissues. The number of hits for the 10 recommended SNPs varied from 1 to 21.
SNP Profiling to Resolve Potential Sample Mix-Ups
Within the last 3 years, we processed 182,695 specimens. We had 34 potential sample 
mix-ups in which 111 patient materials were involved. Thus, the potential error percentage 
was 0.06%. To solve these issues, a total of 29 archived tissue blocks were analyzed. Complete 
SNP profi les (10 SNPs) were analyzed for 21 tissue-pairs. In eight of those cases, the SNP 
profi les showed 100% match, and common origin of the tissues was concluded. In the 
discordant SNP profi les of the other 13 mix-ups, the number of differing SNPs between the 
two tissues was 3 (n = 3), 4 (n = 1), 5 (n = 3), or >6 (n = 6). All issues of possible mix-up were 
Figure 2  Fluorescent signals (light gray line, VIC; black line, FAM) of three SNP assays performed on DNA 
isolated from blood of four patients.
Blood 1                         Blood 2                       Blood 3                        Blood 4  
SNP 3 
A/C                                     
SNP 3 
A/A                                    
SNP 3 
A/C                                    
SNP 3 
C/C                                    
SNP 8 
A/C SNP 8 C/C                                    SNP 8 A/C                                    SNP 8 A/C                                    
SNP 15 
A/G SNP 15 A/A                                    SNP 15 G/G                                    SNP 15 G/G                                    
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Table 2   SNP Profiles: Presence (+) or Absence (-) of Allele 1 (V) and Allele 2 (F).
Case
pathology  
number
tissue
SNP 
1  
SNP 
3  
SNP 
5  
SNP 
8  
SNP 
11  
SNP 
13  
SNP 
14  
SNP 
15  
SNP 
16  
SNP 
17  
V F V F V F V F V F V F V F V F V F V F
rus Blood 1 - + + + + - + + + + + - + + + + - + + -
Patient 2 Blood 2 - + + - - + + - + + - + + - + - + + + -
Patient 3 Blood 3 - + + + + - + + + + + - + + - + + + + +
Patient 4 Blood 4 + - - + - + + + + - + + + - - + - + + -
1 1-A-I mammary tissue - + + - - + + + - + + - + - + + + - + -
1-A-II mammary tissue - + + + + + + + + + - + + + + - + + + -
1-B cervical polyp - + + - - + + + - + + - + - + + + - + -
1-C Infiltr.carcinoma - + + - - + + + - + + - + - + + + - + -
1-D mammary tissue
- + + + + + + + + + - + + + + - + + + -
1-E mammary tissue - + + + + + + + + + - + + + + - + + + -
2 2-A floater + + - + + - + - + - + + + + + + + + - +
2-B mediastinoscopy + + - + + - + - + - + + + + + + + + - +
3 3-A skin - + + + + + + - + - - + - + + - + - + +
3-B skin - + + + + - + + + + + - + + + + + + + +
3-C skin + - + + - + + - + + + + + - + - - + + +
 3-D skin + + - + + + + - + + + - - + + + + + + -
3-E vocal cord - + + + + - + + + + + - + + + + + + + +
3-F skin + + - + + + + - + + + - - + + + + + + -
3-G curettage + - + + - + + - + + + + + - + - - + + +
4 4-A skin + - - + + + - + + + + - + - + - + - + +
4-B skin + - - + + + - + + + + - + - + - + - + +
5 5-1-1 prostate - + + + + - + + + + - + + + - + + + + -
5-2-1 prostate + - + + + + + - + + - + + - + + + + - +
5-A prostate - + + + + - + + + + - + + + - + + + + -
15 specimens prostate - + + -
14 specimens prostate + - + +
5-1-12 prostate ? ? ? ?
5-1-13 prostate + - ? ?
5-1-16 prostate - +     ? ?        
6 6-A mammary biopsy + - + - - + + + + + - + + + + + + + - +
6-B mammary tissue + - + - - + + + + + - + + + + + + + - +
6-C mammary tissue + - + - - + + + + + - + + + + + + + - +
?, result not conclusive.
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adequately solved by SNP profi ling. The elucidation of six representative cases of sample 
mix-ups is described below.
Case 1. Mislabeling of Two Mammary Tissues
Two mammary needle biopsies were taken from patients 1 and 2, respectively, and processed 
on the same day. Both tissue blocks were numbered 1-A. Histological analyses revealed that 
one of them, assigned 1-A-I, showed the presence of an infi ltrative ductal carcinoma (Figure 3A), 
whereas the other, assigned 1-A-II, was benign (Figure 3B). The archive of paraffi n- embedded 
specimens contained a cervical polyp biopsy (1-B) derived from patient 1. Figure 4 and Table 2 
show that 1-A-I and 1-B have an identical SNP profi le that differed from 1-A-II. Thus 1-A-I 
was assigned to patient 1 and 1-A-II was assigned to patient 2. Sixteen days after the needle 
biopsies were taken, patient 1 underwent a mastectomy (1C). A tumor of 28 mm was found 
and diagnosed as an infi ltrative adenocarcinoma (Figure 3C). The SNP profi le of this tumor 
(1C) was identical to the profi le of 1-A-I and 1-B of patient 1 (Table 2). One and a half years 
Figure 3  Paraffi n-embedded mammary tissue. A: Tissue assigned 1-A-I, an infi ltrative ductal carcinoma. 
B: Tissue assigned 1-A-II, a benign, apocrine metaplasia. C: Infi ltrative adenocarcinoma. H&E stain. 
Original magnifi cations, x 100.
A B 
C 
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after the needle biopsies, two other histological needle biopsies were taken from patient 2. 
Both were diagnosed as benign lesions. The SNP profi les of both tissues were identical to 
1-A-II’s profi le (Table 2, 1-D and 1-E).
Case 2. Floater in a Lymph Node
The pathologist noticed a fl oater (2-A) of lung tumor tissue in a lymph node biopsy obtained 
by mediastinoscopy (2-B) from patient 3. Microscopically the fl oater was isolated from the 
surrounding nodal tissue. The question arose whether the fl oater and the lymph node were 
from the same individual. SNP analysis revealed a similar SNP profi le of the two tissues (Table 2). 
Theoretically, the chance to have such a profi le is lower than 1 in 30,000 assuming P = 0.5 
for the analyzed SNPs: 1/(0.255 x 0.55). In line with this, a keratin PAN immune peroxidase 
staining of another gland from patient 3 showed the presence of cells resembling the tumor 
cells in specimen 2-B (data not shown). The VIC signal of SNP14, although clearly present, 
was lower in the fl oater compared with the lymph node (Figure 5). SNP14 is located on 
15q21, a region for which, to date, no LOH in lung tumor tissue has been reported.
Figure 4  Fluorescent signals (light gray line, VIC; black line, FAM) of three SNP assays performed on DNA 
isolated from two mammary tissues (1-A-I and 1-A-II) from patients 1 and 2 and a cervical polyp from 
patient 1 (1-B).
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Case 3. Mix-Up of Four Skin Biopsies
Because of a technical failure of the dissection table, four skin biopsies (3-A, 3-B, 3-C, and 
3-D) derived from four patients (4, 5, 6, and 7) lost their identifi cation. For three of these 
patients, archived material was available: a vocal cord of patient 4 (3-E), a skin biopsy of 
patient 5 (3-F), and curettage of patient 6 (3-G). Table 2 shows that three of the four SNP 
profi les from the unlabeled skin biopsies matched SNP profi les from the archived tissues. 
Thus, similar SNP profi les were observed for 3-B and 3-E (patient 4), 3-C and 3-G (patient 6), 
and 3-D and 3-F (patient 5). The remaining skin biopsy (3-A) was assigned to patient 7.
Case 4. Postmortem Identification
Dutch parents received information that their son had died in a foreign country. A high 
degree of degradation complicated the identifi cation of the corpse. The parents asked the 
Jeroen Bosch Hospital to analyze whether a skin biopsy taken postmortem could be their 
son’s. The SNP profi le of the postmortem skin biopsy (4-A) was identical to the SNP profi le of 
an archived sample (4-B) of the son. Theoretically, the chance for the observed SNP profi le 
Figure 5  Diminished fl uorescent signal of SNP14 probably attributable to LOH. Fluorescent 
signal (light gray line, VIC; black line, FAM) of the SNP assays performed on DNA isolated from the lymph 
node biopsy (2-B), the fl oater of lung tumor tissue (2-A), and a skin sample from another patient (for 
SNP14 homozygous, genotype T/T). The near absence of the VIC signal for SNP14 in the homozygous 
individuals demonstrates that the VIC signals in the fl oater are not because of cross-reaction of the VIC 
probe with the other allele. Thus, the diminished VIC signal for SNP14 in the fl oater is likely attributable 
to LOH. The fl uorescent signals of SNP13 show no indication of LOH.
SNP 14 
C/T SNP 14 C/T SNP 14 T/T 
 2-B                              2-A (floater)                        Skin 3-B 
SNP 13 
A/C SNP 13 A/C 
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was ≈1 in 130,000. Another laboratory in The Netherlands later analyzed 10 tetranucleotide 
STR loci and Amelogenin using the AmpFLSTR SGM Plus PCR amplification kit (Applied 
Biosystems) of muscle and bone tissue of the deceased and mouth epithelial cells of the 
supposed mother. The DNA profiles very strongly suggested a mother-child relationship 
between the two individuals involved.
Case 5. Mislabeling of Prostate Gland Biopsies
Two prostate glands (5-1 from patient 8 and 5-2 from patient 9) were processed sequentially. 
According to our routine protocol, from each prostate, 17 biopsies were sectioned and labeled. 
The first sections from both prostates were labeled correctly (5-1-1 and 5-2-1), whereas all of 
the other sections were assigned to prostate gland 5-1 (two series labeled 5-1-2 to 5-1-17). 
From patient 8, archived material (5A) was present. An SNP profile was generated from 5-1-1 and 
5-2-1 and 5A to determine which SNPs were discriminatory (Table 2). SNP1 and SNP5 (CC and 
AA for patient 8, AA and AC for patient 9, respectively) were selected to analyze the 
remaining 32 samples. One section (5-1-12) yielded no results. Because the other section 
labeled 5-1-12 showed SNP1 and SNP5 alleles of patient 8, this section was assigned to 
patient 9. Thus, 16 sections could be assigned to patient 8 and 16 sections to patient 9 (Table 2).
Case 6. Tracing of Mammary Tumor
A mammary biopsy, 6-A, was sent in for analysis and found to be malignant. Mammary tissue 
was removed by mastectomy and analyzed (6-B and 6-C), but no tumor cells were found. The 
identical SNP profile of the biopsy and two other tissues (Table 2) rendered the possibility of 
sample mix-up extremely unlikely (1 in 30,000), which led us to further analyze 6-B and 6-C. 
Subsequent thorough analysis of the removed mammary tissue revealed a 6-mm medium 
differentiated malignant tumor in 6-C, thus confirming the exclusion of a sample mix-up.
Discussion
SNP profiling provides a quick, easy, and reliable way to confirm the source of human tissues. 
The SNP assays to be used to generate an SNP profile were carefully selected to meet certain 
criteria. We chose a symmetrical distribution of allele frequency (SNPs with minor, and major, 
allele frequency of ≈0.5) to maximize the chance that individuals can be distinguished on 
their SNP profile while analyzing a limited number of SNPs. To minimize the chance of linkage, 
the 10 SNPs were chosen on 10 different chromosomes. If an SNP consists of two variants (ie, 
A and C) an individual has three possibilities (AA, AC, and CC). Thus, for 10 SNPs, 310 (59,049) 
different profiles exist. Assuming the genotype frequencies to be in Hardy-Weinberg 
equilibrium, when 10 independent SNPs with P = 0.5 are analyzed, the chance for two 
randomly selected individuals to have the same genotype for one SNP is 0.252 + 0.52 + 0.252 
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= 0.375. For 10 SNPs, this chance is 0.37510 = 1 in 18,000. If the minor allele frequency is 0.4, 
this chance is 0.3856510 = 1 in 14,000, with minor allele frequency of 0.2 this chance is 1 in 
900. Thus, the resolution of the test is acceptable in the range of 0.4 < P < 0.5 but diminishes 
with more asymmetrical allele frequencies. Three SNP assays (SNP4, SNP10, and SNP12) with 
observed allele frequencies that differed significantly (χ2 test; P value of 0.05) from 0.5 were 
excluded from the recommended SNP panel.
For the Hardy-Weinberg equilibrium, the following assumptions are made: 1) individuals from 
the population are diploid and reproduce sexually; 2) the population size is infinite; 3) there 
is no movement from one population to the other; 4) there is no mutation (no biochemical 
changes in DNA that produce new alleles); 5) mating is random (this means that individuals 
do not select mates based on the genotype of the SNPs); and 6) the different genotypes of 
the SNPs have equal fitness. The 10 selected SNPs were located on 10 autosomes, ensuring 
that two copies of each selected locus are present (diploid) in each individual.
Because most people in The Netherlands are of Caucasian origin, a population that is 
reasonably assumed to be infinite, we selected SNPs with P values of ≈0.5 within the 
Caucasian population. Because allele frequencies differ from one population to the other, the 
resolution of the test within a non-Caucasian population is lower because of more 
asymmetrical distribution of alleles. Assuming allele frequencies indicated by Applied 
Biosystems, for African Americans the discriminatory power of the test using the 10 
recommended SNP assays is in the order of 4 x 103, for Chinese and Japanese even lower, 103. 
Thus for an SNP profiling test, it is important to select SNPs on the basis of allele frequencies 
within the population studied. With a limited number of people from other populations 
present in a Caucasian population, however, the test as presented here will maintain its 
resolution. Mutation rate in mammalian germ cells is low, estimated to be in the order of 1 x 
105  per locus per generation [24,25]. By choosing SNPs not crucial for gene function and 
expression, we have reduced the risk of analyzing SNPs related to health issues. When 
analyzing genetically related individuals, the Hardy-Weinberg equilibrium cannot be assumed, 
and the resolution of the SNP profiling test is reduced. The resolution of the test is also 
reduced when individuals from small isolated populations are analyzed.
Another criterion for selection of SNPs for SNP profiling was a low probability of LOH of the 
region where the SNP is located. In 1 of the 111 tissues analyzed (case 2, a floater of lung 
tumor tissue in a lymph node), we noticed decreased signals in one of the two alleles in the 
SNP14 assay (Figure 5). LOH is a common occurrence in cancer tissues [26 –32]. For rs690054 
(SNP14) located at 15q21, however, no LOH in lung tumor tissue has been described. Only 
few reports on LOH of this locus in other tumor tissue exist [33–37]. Circumstantial evidence 
that the floater indeed belonged to patient 3 was that 1) adjacent to the floater tumor cells 
were present in the lymph node, 2) another lymph node of the same patient contained tumor 
cells, and 3) the other SNPs (total of 12) were identical. This leaves LOH as the most likely 
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explanation for the diminished fluorescent signal. The remaining signal, probably attributable 
to the presence of normal infiltrating cells in the tumor tissue, rendered the SNP profile 
suitable for interpretation.
With regard to the quality of the assays, the fluorescent signals from some assays were easier 
to interpret than others. Ideally, the MGB probe complementary to one allele is not hydrolyzed 
in the presence of the other allele and vice versa. However, hydrolysis of the probes was not 
always 100% specific, and some cross-reaction occurred. In the SNP10 assay, for instance, 
the VIC (A) probe cross-reacted slightly with the C allele (Figure 1B, C/C genotype). In the 
SNP3, SNP8, and SNP15 assays, the FAM probe cross-reacted slightly with the allele recognized 
by the VIC probe and in the SNP1 assay, the VIC probe showed some cross-reaction (Figures 
2 and 4). Because SNP assays 6 and 9 did not perform adequately (data not shown), they 
were excluded from the panel of SNP assays that we recommend to be used for the SNP 
profiling assay. The SNP test could successfully be applied to paraffin-embedded human 
tissues, blood, swabs, and serum samples (data not shown). As expected, the Ct values for 
paraffin-embedded  tissues were higher than for blood samples (≈28 versus 23, respectively), 
because of the presence of lower quantities of DNA.
In the identity test as presented here, SNP profiles from recent tissues are compared with SNP 
profiles from archived samples. As an alternative for archived tissues, blood, or buccal swab 
can be obtained from the patients involved. We prefer to solve potential error issues, if 
available, with archived materials. The main reason for this is that the patient needs to be 
informed of the potential mix-up to obtain a new DNA sample. This may raise doubt with 
regard to clinical diagnosis and cause the patient unnecessary stress. We realize that when 
using archived materials, correct labeling of the archived tissue(s) is assumed. The potential 
mix-up percentage was 0.06% in our laboratory throughout the last 3 years. Although some 
errors may have remained unnoticed, the actual error rate is supposedly less and in range 
with error rates reported to be normal (0.08 to 1.2%) [1– 6].
Other methods currently used to exclude sample labeling errors include characterization of 
DNA repeats, ie, short tandem repeats (STRs)[7–9], HLA [10–15], and other polymorphic 
genetic loci[14]. In addition, commercial identification kits allow identification by use of DNA 
sequencing equipment[16–18,38–40]. With STR analysis, when using a combination of many 
STR systems, the power of discrimination may exceed 1011 [41–43]. With the AmpFlSTR SGM 
Plus PCR amplification kit up to 5 x 1012 average probability of identity can be obtained. 
Clearly, such strong evidence can have a powerful effect in courtroom proceedings. However, 
to solve potential issues of sample errors, the accuracy of our method (18 x 103 average 
probability of identity) seemed sufficient. Of course, analysis of more SNPs will increase 
discriminatory power of the SNP profiling test.
Because the size of DNA fragments is limited in paraffin-embedded tissues, the SNP profiling 
assay has the significant advantage of requiring the presence of very small DNA fragments 
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(up to 80 bp), whereas STR-based kits require up to 360-bp fragments. In addition, the SNP 
profiling assay can be performed in any real-time PCR machine and does not require DNA 
sequencing equipment. A third advantage of the SNP profiling test is that, in contrast to all 
other methods described so far, processing after PCR is not required in real-time PCR analysis. 
This substantially reduces the risk of contamination with PCR products. Each SNP profile, as 
described here, costs approximately €40 (US $50) per sample. Purchasing large-scale assays 
and reducing reaction volumes (5-µl reactions in 384-well plates) can reduce the costs to 
approximately one fifth. Thus, the costs of SNP profiling are relatively low as compared with 
the costs of biopsy needles or other assays.
We conclude that we have developed a simple, quick, and reliable SNP profiling test that can 
be used to confirm the identity of paraffin-embedded tissues to detect potential sample 
mix-ups. Besides this direct application, the assay can be used to survey the quality of tissue 
block handling and storage in medical laboratories.
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Abstract
Background and Objectives Sample mix-ups are a threat to the validity of clinical laboratory 
test results. To detect serum sample mix-ups we developed a single nucleotide polymorphism 
(SNP) profiling test. SNPs are frequent sequence variations in the human genome. Each 
individual has a unique combination of these nucleotide variations.
Materials and Methods Predeveloped SNP amplification assays are commercially available. 
We recently discovered that these SNP assays could be applied to serological samples, which 
is not self-evident because a key step in serum preparation is removal of white blood cells, 
the major source of DNA, from blood. DNA was extracted from serum samples. Real-time 
polymerase chain reaction (PCR) analysis of the purified DNA using a selection of 10 SNP 
assays provided SNP profiles.
Results The applicability of the SNP profiling test was demonstrated by means of a case 
where hepatitis E virus serological determinations of four serum samples of one patient 
seemed inconsistent. SNP profiling of the samples demonstrated that this was due to the 
enzyme-linked immunosorbent assay test instead of sample mix-up.
Conclusion We have developed an SNP profiling assay that provides a way to link human 
serum samples to a source, without post-PCR processing. The chance for two randomly 
chosen individuals to have an identical profile is 1 in 18,000. Solving potential serum sample 
mix-ups will secure downstream evaluations and critical decisions concerning the patients 
involved.
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Introduction
Serum is a widely used patient material for diagnostic and treatment-related purposes. Although 
serum identification is a carefully controlled factor in clinical laboratories, mislabelling still 
occurs. In general, the percentage of mislabelling is estimated to be around 0.1% [1–4]. Such 
misidentification can have extremely serious consequences for the patients involved. To be 
able to detect serum sample errors we set out to develop a method to identify serum samples 
based on single nucleotide polymorphisms (SNP) profiling.
Single nucleotide polymorphisms are the most common sequence variations in the human 
genome that occur approximately once every 100–300 base pairs [5]. Apart from identical 
twins, each individual has a unique combination of nucleotides at these positions. Single 
nucleotide polymorphism amplification assays employing DNA probes with conjugated minor 
groove binder (MGB) groups [6] are commercially available. These probes form extremely 
stable duplexes with single-stranded DNA targets, thus allowing short probes to be used for 
hybridization-based assays.
In this paper, we describe an SNP profiling test for serum employing 10 SNP assays that were 
selected on the basis of allele frequency and chromosomal location. By comparison of the 
SNP profiles obtained from relevant samples, the test can, with certain sureness, confirm the 
identity of human materials.
Materials and methods
DNA isolation
DNA was extracted from 200 µl of blood with QIAamp DNA blood mini kit (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions, and eluted in 150 µl buffer AE. DNA was 
extracted from 2 ml of serum using the NucliSens® MiniMAG extraction system (Biomerieux, 
Boxtel, The Netherlands). In duplicate, 1 ml of serum was added to 2 ml NucliSens® Lysis 
buffer and incubated for 10 min at room temperature. After a short spin the two lysates were 
pooled and 50 µl of magnetic silica particles was added. The samples were further processed 
according to the manufacturer’s instructions and eluted in 130 µl of elution buffer.
TaqMan® Assays-on-Demand™ SNP genotyping products
TaqMan® Assays-on-Demand™  were purchased (Applied Biosystems, Foster City, CA, USA). 
They are predesigned assays and validated on DNA from 180 individuals from four populations.
Real-time polymerase chain reaction
Single nucleotide polymorphism amplification assays were used according to the manufacturer’s 
instructions. In short, 11.25 µl of DNA was added to a reaction mixture containing 12.5 µl 2x 
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TaqMan® Universal PCR Master Mix (Applied Biosystems) and 1.25 µl of predeveloped assay 
reagent from the Assays-on-Demand™ SNP genotyping products (Applied Biosystems) 
containing two primers and two MGB-TaqMan probes. Real-time PCR was performed in an 
ABI Prism 7000 SDS (Applied Biosystems) for 2 min at 50 °C, 10 min at 95 °C followed by 40 
cycles of 15 min at 92 °C and 60 min at 60 °C.
Hepatitis antibody detection
For the detection of antibodies against hepatitis A virus (HAV) Ig total, IgM and hepatitis B virus 
(HBV) HBs-ag, antiHBc the VIDAS® Hepatitis A and B tests were used (BioMérieux, Marcy-
l’Etoile, France). Hepatitis C virus (HCV) Ig-total antibodies were detected in the Microplate – 
Ortho HCV 3.0 ELISA test system (Biorad, Marnes la Coquette, France). Antibodies against HEV 
were detected by means of HEV-IgG and HEV-IgM ELISA assays (Murex Diagnostics, Dartford, 
England). A single tube of serum sample was used for the simultaneous testing for IgG and IgM 
antibodies. The recomBlot HEV IgG/ IgM from Mikrogen (Molecularbiologische Entwieckulungs- 
GmbH, München, Germany) was used to detect HEV antibodies by Western blot.
Sample collection and storage
After collection of blood in BD Vacutainer® Z tubes, within 24 h samples were centrifuged for 
10 min at 3300 g. The serum was collected and stored at 4 °C. After a maximum period of 5 
days at 4 °C, the ELISA tests were performed. Serum samples were further routinely stored 
at -20 °C until repeat testing.
Results
Selection of SNP assays
From an internet database containing over 146,000 human TaqMan® Assays-on-Demand™ 
SNP genotyping products, we selected 10 SNP assays (Table 1). The principle of the assays is 
explained in Fig. 1a,b. The most discriminatory genetic marker is one with an equal distribution 
of alleles in a population. Thus, minor (and major) allele frequency of the SNP should be 
approximately 0.5. Other criteria of selection were: all SNPs should be situated on different 
chromosomes (c.q. autosomes); and the SNP should not be crucial for gene function and 
expression. To resolve male/female sample mix-ups, in addition to the SNP assays we used a 
real-time PCR assay to detect the presence of the SRY gene [7] which is located on the human 
Y chromosome.
SNP profile
To test the assays we analysed four blood samples from four different patients. Figure 1c 
shows the fluorescent signals of two representative SNP assays, cycle threshold values were 
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around 23. The presence or absence of allele 1 and 2 could easily be deduced from the 
signals. All four individuals could easily be distinguished based on their SNP profiles (Table 2).
Serum-identity testing
To test if serum could be used as a source of DNA we isolated DNA from 2 ml of serum using 
the NucliSens® MiniMAG extraction system as described in Materials and methods. Figure 1d 
shows fluorescent signals of two representative SNP assays of two different patients, cycle 
threshold values were around 28. The SNP profiles deduced from the signals are in Table 2. 
Extraction of DNA from 0.2 ml of serum with QIAamp DNA Blood Mini Kit also yielded 
interpretable results (data not shown).
Hepatitis E virus case
A patient with B cell chronic lymphocytic leukaemia (B-CLL) developed hepatitis with elevated 
levels of liver enzymes. The patient tested negative for antibodies against HBV and HCV, and 
positive for HAV IgG antibodies by ELISA. With regard to antibodies against HEV, two serum 
samples taken with a 3-day interval tested positive for the presence of IgG and IgM anti-HEV 
antibodies (Table 3A). However, two samples taken from the same patient 3.5 and 4.5 
months later tested negative in the ELISA for anti-HEV IgG antibodies. Because the discrepancy 
in the HEV ELISA results persisted after simultaneous testing of the four samples, the question 
raised whether a sample mix-up could have occurred.
Analysis of the four serum samples in the SNP profiling test indicated no differences in the 
SNP profiles of the four samples (A–D; Table 3B). A test for detection of SRY, a gene located 
Table 1   Single nucleotide polymorphism (SNP) assays selected from Applied Biosystems.
SNP Pre-developed 
assay reagent ID
SNP
ID Chromosome
SNP Location (gene) Genotype
VIC/FAM
Minor 
Allele 
frequency
1 C___2474321_1_ rs2283839 22 Intron (TPST2) A/C 0.5
2 C__11445512_10 rs1860300 17 Intergenic/Unknown A/C 0.5
3 C__15792496_10 rs2400077 5 Intron(CTNND2) A/C 0.5
4 C___1098888_10 rs663528 13 Intergenic/Unknown G/T 0.5
5 C___1315434_1_ rs2239508 18 Intron (RAB31) A/C 0.5
6 C___1523697_10 rs2658509 4 Intron (LDB2) A/C 0.49
7 C___1967983_10 rs1610180 3 Intron (SLC6A11) C/A 0.5
8 C___2511899_10 rs1202295 6 Intergenic/Unknown A/C 0.5
9 C___3142524_10 rs1150964 12 Intergenic/Unknown G/T 0.49
10 C___2574166_1_ rs2237958 11 Intron (USH1C) A/C 0.49
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Figure 1  Single nucleotide polymorphism (SNP) detection with minor groove binder (MGB) 
probes. (a) Principle of SNP detection using hydrolysis probes. When the probe is intact, the quencher 
quenches the fl uorescent signal from the reporter. A/C SNP: in the presence of A the VIC probe, 
complementary to A, is hydrolysed during the polymerase chain reaction (PCR) by the Taq-polymerase. 
The VIC reporter is no longer quenched by the close proximity of the quencher and can be measured; 
in the presence of C, the VIC probe is removed from the DNA strand without being hydrolysed. The FAM 
probe is complementary to C, and, according to the same principle, generates a fl uorescent signal only 
in the presence of C. (b) Fluorescent signals accompanying the different genotypes (SNP 10; genotypes 
are indicated in upper left corner). (c) Fluorescent signals [light grey, VIC; dark grey, FAM] of two SNP 
assays of blood samples from four patients; pt, patient. (d) Fluorescent signals [light grey, VIC; dark grey, 
FAM] of two SNP assays of serum samples from two patients.
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Table 2   Single nucleotide polymorphism (SNP) profi les: presence (+) or absence (–) of 
allele 1 (V:VIC) and allele 2 (F:FAM) in six patients (1–6).
Pa
ti
en
t
Sp
ec
im
en SN
P 
1
SN
P 
2
SN
P 
3
SN
P 
4
SN
P 
5
SN
P 
6
SN
P 
7
SN
P 
8
SN
P 
9
SN
P 
10
V F V F V F V F V F V F V F V F V F V F
1 blood - + + + + + + + + - + - + - + + + + + -
2 blood - + + + + - + + - + + - + - + - - + + +
3 blood - + + + + + + - + - - + + + + + + + - +
4 blood + - - + - + + + - + + + + + + + - + + +
5 serum - + + + - + + + + + + + + - + + + + - +
6 serum - + + + + + + + + + - + + - + - + + + -
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on the Y chromosome, showed the presence of this gene in all four serum samples (data not 
shown). This suggested one source of the four serum samples, and made it very unlikely that 
one of the four serum samples was obtained from another man. According to the Hardy–
Weinberg distribution of alleles this chance equals 0.58 (for seven heterozygous SNPs plus 
one positive SRY test) x 0.253 (for three homozygous SNPs) = 6.1 x 10-5 which equals to 1 in 
16,000.
The samples were subsequently sent to a reference laboratory where the four serum samples 
were analysed by Western blot for the presence of antibodies against HEV. The blot showed 
the presence of anti-HEV IgG and the absence of anti-HEV IgM in all four samples (Table 3A).
Table 3   (A) Four samples from a B cell chronic lymphocytic leukaemia (B-CLL) patient 
(A–D) were tested by enzyme-linked immunosorbant assay (ELISA) and Western 
blot for antibodies against hepatitis E virus (HEV) (B) SNP profiles of samples A–D: 
presence (+) or absence (–) of allele 1 (V) and allele 2 (F).
A) 
Hepatitis E virus
ELISA BLOT
Date of serum sampling sample IgM IgG IgM IgG
1st September, 2003 A Postive Postive Negative Postive
4th September, 2003 B Postive Postive Negative Postive
16th December, 2003 C n.d. Negative Negative Postive
16th January, 2004 D n.d. Negative Negative Postive
n.d., not done.
B) 
Sa
m
p
le
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ec
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en SN
P 
1
SN
P 
2
SN
P 
3
SN
P 
4
SN
P 
5
SN
P 
6
SN
P 
7
SN
P 
8
SN
P 
9
SN
P 
10
V F V F V F V F V F V F V F V F V F V F
A serum + + + + + + + + + - + + + + + + - + - +
B serum + + + + + + + + + - + + + + + + - + - +
C serum + + + + + + + + + - + + + + + + - + - +
D serum + + + + + + + + + - + + + + + + - + - +
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Discussion
The SNP profiling test described in this paper provides a way to confirm the identity of serum 
samples.
The SNP assays were selected to meet certain criteria. We chose a symmetrical distribution of 
allele frequency (SNPs with minor and major allele frequency of approximately 0.5) to 
maximize the chance that individuals can be distinguished on their SNP profile while analysing 
a limited number of SNPs. To minimize the possibility of linkage, the 10 SNPs were chosen on 
10 different chromosomes. Assuming the genotype frequencies to be in Hardy–Weinberg 
equilibrium, when 10 independent SNPs with P = 0.5 are analysed, the chance for two 
randomly selected individuals to have the same genotype for one SNP is 0.252 + 0.52 + 0.252 
= 0.375. For 10 SNPs this chance is 0.37510 = 1 in 18,000.
Because most people in The Netherlands are of Caucasian origin, we selected SNPs with P 
values of 0.5 within the Caucasian population. This implies that the resolution of the test 
within a non-Caucasian population will be lower due to asymetrical distribution of genotypes 
of the selected SNPs. If an SNP profiling test was to be developed for other ethnic groups, 
Applied Biosystems supplies the allele frequencies for African American, Japanese and 
Chinese population in addition to Caucasian, and the SNP profiling test can be adapted 
according to the population studied. With a limited number of people from other populations 
present in the Caucasian population the test will maintain its resolution. By choosing SNPs 
not crucial for gene function and expression we have reduced the risk of analysing SNPs 
related to health issues.
The SNP test could be applied to serum samples. Apparently, serum, although essentially cell 
free, contains enough DNA to generate fluorescent signals. As expected, the cycle threshold 
values for serum samples were higher than for blood samples (around 28 vs. 23), because of 
the presence of lower quantities of DNA.
In blood from pregnant women fetal DNA might be present in concentrations that range 
from 0.4 to 12% of total plasma DNA [7]. Thus paternal alleles can be present in quantities of 
up to 6%. Although the percentage of fetal DNA in serum has not been investigated, it is 
likely to resemble the plasma percentage. Such a low quantity of DNA ‘contamination’ may 
slightly alter the fluorescence curves, but probably not the allele calling. In contrast SNP 
profiles from serum from people that underwent bone marrow or solid organ transplanta-
tion, or recent blood transfusions should be considered with utmost care.
With regard to the quality of the assays, the fluorescent signals from some assays were easier 
to interpret than others. Ideally the MGB probe complementary to allele 1 is not hydrolysed 
in the presence of allele 2 and vice versa. However, hydrolysis of the probes was not always 
100% specific, and some cross-reaction occurred. In the SNP 5 assay the allele 2 probe (FAM) 
cross-reacted with allele 1 (Fig. 1c, patients 1 and 3), in the SNP 6 and 10 assays the VIC 
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probe cross-reacted with allele 2 (Fig. 1d, patient 6; Fig. 1b, C/C genotype; Fig. 1c, patient 3; 
Fig. 1d, patient 5). In the SNP 9 assay, cross-reaction of the allele 1 probe (VIC) with allele 2 
was considerable (data not shown).
The applicability of the test was demonstrated by the analysis of four samples from a single 
patient with apparently conflicting HEV ELISA results. The linking of the four samples to one 
source and the subsequent analysis of the four samples by means of immunoblotting 
indicated that the ELISA assays used for the detection of IgG and IgM antibodies against HEV 
exhibited a different sensitivity when compared with the immunoblot assay.
Both plasma and serum identity tests have been described that are based on detection of 
short tandem repeat (STR) DNA typing [8,9]. With STR analysis, when using a combination of 
many STR systems, the power of discrimination may exceed 1011 [10–12]. With the AmpFlSTR® 
SGM Plus® PCR Amplification Kit up to 5 x 1012 average probability of identity can be 
obtained. Clearly, such strong evidence can have a powerful effect in courtroom proceedings. 
However, to solve potential issues of sample errors, the accuracy of our method (18 x 103 
average probability of identity) suffices. Our SNP profiling assay has some advantages in 
comparison with STR DNA typing. The SNP test relies on the presence of shorter DNA 
fragments (around 80 bp for the SNP tests vs. 200 bp for the STR tests), has a slightly shorter 
turnaround time – 4 h, and does not require post-PCR processing. Besides, SNPs with two 
variants (i.e. C or T) provide binary data that are less subjective of interpretation than STR 
data. In addition, DNA sequence equipment, required for the STR assay, is less standard 
equipment in medical laboratories than a real-time PCR machine, required for the SNP assay.
We conclude that we have developed an SNP profiling assay that can be used to link human 
serum samples to a source.
In theory, each serum sample can be identified by a personal identification SNP code of its 
owner. To reach a power of discrimination of 1011  (comparable with STR analysis) around 30 
SNPs with minor and major allele frequency of 0.5 would need to be analysed. To implement 
such an SNP code identifier into routine practice, however, further evaluation of the test and 
decimation of the price are prerequisites.
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Abstract
A single G-to-T missense mutation in the gene for the JAK2 tyrosine kinase, leading to a 
V617F amino acid substitution, is commonly found in several myeloproliferative neoplasms. 
Reliable quantification of this mutant allele is of increasing clinical and therapeutic interest in 
predicting and diagnosing this group of neoplasms. Because JAK2V617F is somatically 
acquired and may be followed by loss of heterozygosity, the percentage of mutant versus 
wild-type DNA in blood can vary between 0% and almost 100%. Therefore, we developed 
a real-time PCR assay for detection and quantification of the low-to-high range of the 
JAK2V617F allele burden. To allow the assay to meet these criteria, amplification of the 
wild-type JAK2 was blocked with a peptide nucleic acid oligonucleotide. JAK2V617F patient 
DNA diluted in JAK2 wild-type DNA could be amplified linearly from 0.05% to 100%, with 
acceptable reproducibility of quantification. The sensitivity of the assay was 0.05% (n = 3 of 
3). In 9 of 100 healthy blood donors, a weak positive/background signal was observed in 
DNA isolated from blood, corresponding to approximately 0.01% JAK2V617F allele. In one 
healthy individual, we observed this signal in duplicate. The clinical relevance of this finding 
is not clear. By inhibiting amplification of the wild-type allele, we developed a sensitive and 
linear real-time PCR assay to detect and quantify JAK2V617F.
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Introduction
In 2005, the involvement of the JAK2V617F somatic point mutation in myeloproliferative 
neoplasms (MPNs) became clear. JAK2V617F is caused by a G-to-T transversion in the Janus 
kinase 2 (JAK2) gene resulting in a valine-to-phenylalanine amino acid substitution at codon 
617 [1– 4]. JAK2 is a nonreceptor tyrosine kinase involved in the JAK-STAT signaling pathway 
[5]. The autoinhibitory pseudokinase JH2 domain is thought to be by the mutation altered in 
such a way that the JAK-STAT signaling pathway is constitutively activated, resulting in growth 
factor–independent cell proliferation [6].
Since the discovery of JAK2V617F, other mutations in JAK2 and other genes, such as Exon 12, 
MPL, and TET2, have been described. These mutations occur in a relatively  small  percentage 
of  patients  with  MPN [7–10]. JAK2V617F, in contrast, is found in many patients: 65% to 
97% of polycythemia vera (PV) cases, 23% to 57% of essential thrombocythemia cases, and 
35% to 57% of chronic idiopathic myelofibrosis cases [11,12]. The diagnostic value of JAK2 
mutational analysis in MPN is now well established and endorsed in the classification of 
hematologic malignancies by the World Health Organization [13].
Patients with PV often carry a JAK2V617F homozygous burden, in contrast to those with 
essential thrombocythemia, in whom homozygosity is rare [14]. This finding was also 
recapitulated in a large multicenter study: PV (n = 323: 67.8% heterozygous and 32.2% 
homozygous) and essential thrombocythemia (n = 639: 40.2% wild-type, 57.6% 
heterozygous, and 2.2% homozygous) [15].  It is, therefore, more common for patients with 
PV to have a mutant allele burden >50%. Although the clinical value of the JAK2V617F allele 
burden is not yet fully understood, a correlation between disease phenotype and the 
proportion of mutant alleles has been postulated [15,16]. Splenomegaly, vascular events and 
pruritus in PV and splenomegaly, arterial thrombosis, and microvessel disease in essential 
thrombocythemia have been clinically correlated to mutant allele burdens [17,18]. Patients in 
the lowest quartile of mutant allele burden in idiopathic myelofibrosis had, overall, significantly 
shortened overall and leukemia-free survival compared with those with higher allele burdens 
and those negative for JAK2V617F [19]. In addition, the amount of mutant allele burden in 
correlation to therapy may be of increasing interest in future diagnostic and predictive tests [20].
With the discovery of JAK2V617F, the detection of this mutation became routine procedure 
in many laboratories. Since 2005, many assays to detect, and sometimes quantify, JAK2V617F 
have been described, evaluated, and compared [4,6,21–51]. Today, numerous techniques are 
used: PCR–restriction fragment length polymorphism (RFLP), direct sequencing, pyrosequencing, 
allele-specific PCR/amplification refractory mutation system, allelic discrimination, real-time PCR, 
high-resolution melting curve analysis, PCR, denaturing high-pressure liquid chromatography, 
PCR–matrix-assisted laser desorption/ ionization–time of flight (PCR-MALDI-TOF) mass 
spectrometry, and sequence-specific primer–single molecule fluorescence detection. The 
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techniques differ in a variety of characteristics,  such as sensitivity (ranging from 0.01% to 
20%, mutant allele diluted in wild-type allele), the potential for high-throughput diagnostics, 
and equipment required. An overview of currently available assays is presented in Table 1.
To increase the sensitivity of the JAK2V617F diagnostics, several techniques have been used 
in our laboratory during the past years. We started with an RFLP assay and subsequently used 
a semiquantitative real-time PCR and allele-specific minor groove–binding probes [41]. We 
then developed a quantitative real-time PCR using a locked nucleic acid (LNA) oligonucle-
otide to block amplification of the JAK2 wild-type allele. We report herein replacement of the 
LNA moiety by peptide nucleic acid (PNA) for better blocking.
Materials and Methods
JAK2V617F-Positive Blood Sample
JAK2V617F-positive blood containing 97% mutant allele, estimated by RFLP, the absence of 
a wild-type peak in the sequence chromatogram, the presence of minimal wild-type signal in 
real-time PCR, and a hematologic analysis showing 3% lymphoid cells and 97% myeloid cells 
together with a high white blood cell count (23.2 x 109/L) [41] was derived from a patient with PV 
and generated a mean ± SD CT value of 24.13 ± 0.02. A 100-fold dilution from DNA from this 
sample in JAK2 wild-type DNA was used as a 1% JAK2V617F-containing positive control.
A second positive blood sample, used for serial dilutions in this study, was obtained from a 
64-year-old man diagnosed as having possible PV, with a high number of erythrocytes [7.64 
x 1012/L (reference range, 4.4 to 5.8 x 1012/L)] and iron deficiency. JAK2V617F real-time PCR 
using the PNA oligonucleotide on genomic DNA derived from this sample generated a mean 
± SD CT value of 23.88 ± 0.07. Thus, the sample used in this study was considered to contain 
>97% JAK2V617F.
Cohort Healthy Donors
EDTA blood samples from 100 healthy blood donors -rendered anonymous- were used as a 
negative cohort. All the individuals were <30 years of age.
Genomic DNA Isolation from Blood
Genomic DNA was isolated from 200 µL of blood that had been anticoagulated with EDTA 
using the Qiagen blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. DNA was eluted in DNase and RNase-free water (Fisher Emergo B.V., Landsmeer, 
The Netherlands), quantified by photo spectrometer (Eppendorf BioPhotometer; Eppendorf, 
Hamburg, Germany), and diluted to 10 ng/µL in DNase- and RNase-free TE (10 mmol/L 
Tris-HCl, pH 8; 0.1 mmol/L EDTA).
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JAK2V617F Real-Time PCR Assay with PNA and LNA Blocking
Primers and probes were designed by Applied Biosystems (Foster City, CA) using TaqExpress 
software as previously described [41]. The wild-type probe was altered to function as a blocking 
oligonucleotide with PNA or LNA. Oligonucleotide sequences are listed in Table 2. The PCR (25 
µL) contained 20 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KCl, 3 mmol/L MgCl2 [prepared from 10x 
PCR buffer and 50 mmol/L MgCl2 solution delivered with Platinum Taq polymerase (Invitrogen, 
Breda, The Netherlands)], 0.75 U of Platinum Taq polymerase, 4% glycerol (molecular biology 
grade; CalBiochem, VWR International, Amsterdam, The Netherlands), 200 µmol/L of each 
deoxyribonucleotide triphosphate (Invitrogen), 0.5 µL of ROX reference dye (Invitrogen), 900 
nmol/L primers and 200 nmol/L probes (Applied Biosystems), 1 µmol/L PNA oligonucleotide 
(PanaGene, Daejeon, Korea; alternate source: Biosynthesis Inc., Lewisville, TX) or LNA oligonu-
cleotide (Sigma-Proligo, The Woodlands, TX), and 50 ng of target DNA. The ABI Prism 7500 
Fast sequence detection system (Applied Biosystems) was used for amplification and detection 
(10 minutes at 95°C, 45 cycles of 3 seconds at 95°C, and 30 seconds at 60°C and an infinite 
holding step at 25°C in Fast 7500 mode). The threshold was set at 0.008, and baseline was set 
from cycles 6 to 15 for both reporters. CT values were calculated using SDS version 1.3.1 software. 
A real-time PCR targeting the human albumin gene was used to test whether DNA extraction and 
dilution to 10 ng/µL were successful and to verify that the PCR was not inhibited. Amplification 
was performed as described previously herein with 900 nmol/L both primers and 200 nmol/L 
probe. Oligonucleotide sequences were described earlier and are denoted in Table 2 [53].
Table 2   Sequences of primers, detection probes, and PNA (Peptide Nucleic Acid) and LNA 
(Locked Nucleic Acid) blocking oligonucleotides to detect and quantify JAK2V617F 
and detect albumin by real-time PCR.
JAK2 V617F: primers and mutant probe [41] Sequences
Forward primer 5’-AAG CTT TCT CAC AAG CAT TTG GTT T-3’ 
Reverse primer 5’-AGA AAG GCA TTA GAA AGC CTG TAG TT-3’
Mutant probe 5’-FAM-TCC ACA GAA ACA TAC-MGB-BHQ-3’
LNA wild-type blocking probe 5’-ACA GAC ACA TA-3’
PNA wild-type blocking probe 5’-Acetyl-CTC CAC AGA CAC ATA C-3’
Albumin: primers and probe [53] Sequences
Forward primer 5’-TGA AAC ATA CGT TCC CAA AGA GTT T-3’  
Reverse primer 5’-CTC TCC TTC TCA GAA AGT GTG CAT AT-3’  
Probe 5’-FAM-TGC TGA AAC ATT CAC CTT CCA TGC 
AGA-TAMRA-3’  
BHQ, black hole quencher; MGB, minor groove binder.
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Sensitivity and Linearity Testing of PNA versus LNA Blocking
To compare PNA and LNA blocking oligonucleotides, a JAK2V617F real-time PCR was 
performed on twofold (v/v) serial dilutions of genomic DNA from the patient sample 
containing >97% JAK2V617F. JAK2V617F DNA (10 ng/ µL) was diluted in genomic DNA (10 
ng/µL) of a JAK2 wild-type individual. The lowest JAK2V617F concentration tested was 
0.006% v/v. All the dilutions were tested in triplicate.
Results
Sensitivity and Linearity Testing of PNA versus LNA Blocking
LNA nucleotides are generally used as blocking oligonucleotides [26,39,53]. Because our data 
using the LNA oligonucleotide showed suboptimal sensitivity of 0.2%, we introduced a PNA 
blocker approach. To determine the sensitivity and linearity of the real-time PCR test using 
the PNA oligonucleotide versus the LNA oligonucleotide, twofold (v/v) serial dilutions of 
genomic DNA from a patient with PV containing 0.006% to >97% JAK2V617F were tested. 
The assay combined with the PNA oligonucleotide linearly detected JAK2V617F with a for 
quantifi cation acceptable (mean CT value ± 1 CT) reproducibility ranging to be approximately 
97% to 0.05% (n = 3 of 3). This range was determined for the real-time PCR with the LNA 
oligonucleotide to be 97% to 0.2% (n = 3 of 3; Figure 1).
Figure 1  Standard curves  (using twofold  dilution  steps)  generated by JAK2V617F real-time PCR using 
PNA blocking (squares) and LNA blocking (triangles). Data are given as mean CT ± SD.
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Cohort Healthy Donors
One hundred healthy EDTA blood donors were tested in duplicate using the real-time PCR 
and the PNA blocking oligonucleotide. All individuals tested positive for the albumin 
housekeeping gene (CT mean ± SD, 23.16 ± 0.19; range, 22.60 to 23.88). All DNA isolations 
were considered successful with this value, and none of the samples showed PCR inhibition. 
Ninety-one patients (91%) were JAK2V617F negative. In nine patients (9%), a background 
signal corresponding to ±0.01% mutant allele was observed in one or both duplicates (eight 
patients and one patient, respectively). Two representative amplifi cation plots are depicted in 
Figure 2. The results are summarized in Table 3.
Figure 2  Amplifi cation plots of JAK2V617F real-time PCR of 25 (A) and 22 (B) healthy individuals in duplicate 
(JAK2V617F negative cohort) and one 1% JAK2V617F positive control. The amplifi cation plots shown 
are representative of the entire cohort. Gray horizontal line (at Delta Rn 0.8e-002) indicates threshold; 
black vertical line, cutoff CT value of 37.9.
Table 3   The samples were amplifi ed in duplicate (n = 2 x 100). Signals were considered 
background when CT ≥ 37.9.
n Description
Number of results 200 100 healthy individuals tested in duplicate
Negative results 190 Negative for JAK2V617F / positive for albumin
Background CT ≥ 37.9 10 Mean background signal ± 3SD (99.7% C.I.)
Eight patients single background signal; one patient in duplicate 
background signal
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Discussion
We developed a highly sensitive JAK2V617F detection and quantification method by inhibiting 
amplification of the JAK2 wild-type allele by means of a PNA wild-type blocking oligonucle-
otide. All CT values generated during sensitivity and linearity testing that were higher than the 
cutoff CT value of 37.9 [determined with the cohort of healthy donors = mean CT value ±3 SD 
(99.7% CI)] were excluded. Compared with LNA blocking, PNA blocking resulted in a more 
sensitive and linear assay using the dilution series of JAK2V617F DNA in JAK2 wild-type DNA: 
0.2% to ±97% JAK2V617F DNA versus 0.05% to ±97% JAK2V617F DNA (Figure 1). More 
efficient/stable blocking by the PNA oligonucleotide probably causes the difference in 
sensitivity and linearity of the real-time PCR using the PNA blocker versus the LNA blocker. 
Unlike DNA or DNA analogues such as LNA, PNAs do not contain any phosphate groups, 
resulting in a noncharged backbone. As a result, PNA-DNA complexes lack charge repulsion 
and are, therefore, more stable than are DNA-DNA and DNA-LNA complexes [54,55].
Although the clinical significance of a low JAK2V617F allelic  burden  in newly diagnosed 
patients  is not clear [38,40,52], highly sensitive mutant allele detection is currently used for 
minimal residual disease detection after allogeneic bone marrow transplantation [56]. In 
addition, quantification of JAK2V617F will help in monitoring new therapeutic strategies. A 
prerequisite for reliable quantification is the linearity of the assays from high to low allele 
burdens [57].
In the cohort of 100 healthy individuals (Table 3), 9% generated JAK2V617F background 
signals (Figure 2). A weak positive/background JAK2V617F signal was observed in duplicate 
in one healthy individual. First, these background signals could be due to a technical issue, 
such as incomplete blocking of wild-type amplification. Second, JAK2V617F could be present 
in these patients in an extremely small number of circulating cells. Although this phenomenon 
has been described for other JAK2V617F assays, its significance is not clear [38,40,52]. To 
prevent false positives in the clinical setting, a cutoff CT value was determined. The mean CT 
value (CT  values >40 are generally considered unreliable and were, therefore, excluded) ± 3 
SD of the negative cohort was determined, and signals with a generated value of CT ≥ 37.9 
(CI = 99.7%) were considered to be background. One patient generated duplicate JAK2V617F 
background signals (Table 3). Although both CT values were ≥ 37.9 and should be considered 
background, further analysis of this material may be of interest. Cloning and subsequent 
sequencing of these amplicons could be of value to determine whether the signals were 
nonspecific or that JAKV617F was, in fact, present. In addition, an assessment of the presence 
of erythropoietin-independent erythroid colonies might be useful in this and similar cases 
[58]. In addition, such a patient could undergo testing for the presence of the JAK2V617F 
predisposing haplotype [59–61]. In the routine diagnostic setting, a JAK2V617F allele burden 
of 0.1% to 1.0% is considered weak positive, and a remark stating that the clinical relevance 
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of this finding is unclear is added to the test report. In addition, we have requested a follow-up 
sample after 6 months.
Although sequencing is the gold standard for mutation screening, it is less suitable for the 
detection of JAK2V617F because the mutation can be present at low levels relative to the 
wild-type sequence. PCR-RFLP, pyrosequencing, sequence-specific primer–single molecule 
fluorescence detection, high-resolution melting curve analysis, and denaturing high-pressure 
liquid chromatography are all less sensitive than is the real-time PCR described herein 
(Table 1), which has a sensitivity of 0.05% and, thereby, is comparable with techniques such 
as allele-specific PCR/amplification refractory mutation system, allelic discrimination, and 
PCR-MALDI-TOF (Table 1) [4,21–51]. In addition, interpretation of PCR-RFLP results is 
complicated by the risk of incomplete digestion, resulting in JAK2V617F false positives (Table 1).
Besides the higher or equal sensitivity, the real-time PCR using the PNA oligonucleotide has 
some additional advantages compared with other assays: i) it is fast (<2 hours for DNA 
extraction and real-time PCR); ii) it eliminates the need of post-PCR processing, a key step in 
techniques such as allele-specific PCR/amplification refractory mutation system, sequencing, 
PCR-RFLP, PCR, and PCR-MALDI-TOF, reducing the risk of contamination; and iii) it has a 
reduced hands-on time of approximately 30 minutes.
In 2006, Sidon et al [39,40] described a similar real-time PCR as the assay described in this 
study using an LNA blocking oligonucleotide and claimed a sensitivity of their assay of 0.01% 
JAK2V617F diluted in wild-type allele. The sensitivity of this test, however, was determined 
using a HEL cell line, which is known to have more than two mutant alleles per cell, instead 
of patient DNA [29].
Prospective evaluation of the real-time PCR with PNA oligonucleotide in a diagnostic setting 
for 1 year now included the analysis of 293 patients suspected of having MPN. Fourteen 
patients (4.8%) showed a JAK2V617F allele burden >50%, 16 (5.5%) between 1% and 50%, 
and 2 (0.7%) between 0.1% and 1%. The results generated during the performance of 
routine JAK2 diagnostics indicate a robust and rapid test with excellent reproducibility: the 
overall CV with different batches of controls, reagents, and various real-time PCR cyclers was 
1.5% for the 1% control (n = 27) and 1.4% for the 50% control (n = 24). Reproducibility is 
essential for a reliable quantitative assay [57]; therefore, these observations further confirm 
that the developed assay is well suited for the application.
In summary, blocking of wild-type JAK2 with the PNA oligonucleotide resulted in a more 
sensitive real-time PCR assay to detect and quantify JAK2V617F with a longer range of 
linearity compared with the LNA oligonucleotide approach. Nine percent of healthy individuals 
in this negative cohort generated background JAK2V617F signals. Therefore, a cutoff CT value 
was introduced to prevent false-positive test results in a clinical setting.
90  |  Chapter 5
Acknowledgments
We thank Kathelijn Geraats-Peters for critical reading of the manuscript and Colin Ingham for 
valuable comments.
5
JAK2V617F quantification with PNA block  |  91
References
1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: 
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med 2005, 
352:1779-1790
2. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau1 F, Lacout C, Garçon L, Raslova H, Berger R, 
Bennaceur-Griscelli A, Villeval J, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal 
JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 
434:1144-1148
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, 
Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, 
Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, 
Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia 
vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 
7:387-397
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd 
EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in 
human myeloproliferative disorders. Lancet 2005, 365:1054-1061
5. Schindler C, Darnell JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. 
Annu Rev Biochem 1995, 64:621-651
6. Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical 
utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J 
Mol Diagn 2006, 8:397-411
7. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative 
neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, [Epub ahead of print]
8. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, 
Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR: JAK2 exon 12 mutations in polycythemia 
vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, 
Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL: MPLW515L 
is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 
3:e270
10. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager 
S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, 
Levine RL: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocy-
themia and myelofibrosis. Leukemia 2009, 23:905-911
11. Nelson ME, Steensma DP: JAK2 V617F in myeloid disorders: what do we know now, and where are 
we headed? Leuk Lymphoma 2006, 47:177–194
12. Tefferi A, Gilliland DG: The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: 
status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 
2005, 80:947–958
13. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, 
Hellström-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. 
Blood 2009, 11:937-951
14. Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F mutation 
occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 
108:2435-2437
15. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi 
G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, 
Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T: Clinical profile of homozygous JAK2 617V>F 
mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 
110:840-846
92  |  Chapter 5
16. Passamonti F, Rumi E: Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 
2009, 94:7-10
17. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, 
Rambaldi A, Guerini V, Bosi A, Barbui T; MPD Research Consortium: Prospective identification of 
high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 
21:1952-1959
18. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, 
Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC): 
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 
2008, 93:41-48
19. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland 
DG: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in 
polycythemia vera. Cancer 2006, 106:631-635
20. Tefferi A: Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on 
prognosis and therapeutic choices. Leuk Lymphoma 2010, 51:576-582
21. Cankovic M, Whiteley L, Hawley RC, Zarbo RJ, Chitale D: Clinical performance of JAK2 V617F 
mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and 
quantitation methods. Am J Clin Pathol 2009, 132:713-721
22. Frantz C, Sekora DM, Henley DC, Huang CK, Pan Q, Quigley NB, Gorman E, Hubbard RA, Mirza I: 
Comparative evaluation of three JAK2V617F mutation detection methods. Am J Clin Pathol 2007, 
128:865-874
23. Kannim S, Thongnoppakhun W, Auewarakul CU: Two-round allele specific-polymerase chain 
reaction: a simple and highly sensitive method for JAK2V617F mutation detection. Clin Chim Acta 
2009, 401:148-151
24. Kremer M, Horn T, Koch I, Dechow T, Gattenloehner S, Pfeiffer W, Quintanilla-Martínez L, Fend F: 
Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational 
load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 2008, 32:928-935
25. Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL: Detection of the JAK2 
V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006, 8:330-334
26. Shammaa D, Bazarbachi A, Halas H, Greige L, Mahfouz R: JAK2 V617F mutation detection: 
laboratory comparison of two kits using RFLP and qPCR. Genet Test Mol Biomarkers 2010, 14:13-15
27. James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JP, Giraudier S, Roy L, Saulnier P, Lacroix 
L, Maury S, Tulliez M, Vainchenker W, Ugo V, Casadevall N: Detection of JAK2 V617F as a first 
intention diagnostic test for erythrocytosis. Leukemia 2006, 20:350-353
28. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard 
C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, 
Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S: Concordance of assays designed 
for the quantification of JAK2V617F: a multicenter study. Haematologica 2009, 94:38-45
29. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian 
HM, Issa JP: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, 
Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 
106:3370-3373
30. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL: Amplification refractory mutation system, a 
highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F 
mutation in chronic myeloproliferative disorders. J Mol Diagn 2007, 9:272-276
31. Tan AY, Westerman DA, Dobrovic A: A simple, rapid, and sensitive method for the detection of the 
JAK2 V617F mutation. Am J Clin Pathol 2007, 127:977-981
32. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P: A quantitative assay for 
JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. 
Leukemia 2006, 20:1055-1060
33. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S: Development of a quantitative 
real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol 
Diagn 2007, 9:42-46
5
JAK2V617F quantification with PNA block  |  93
34. Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P: Frequent detection of 
the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative 
disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping 
assay: a retrospective study with pathologic correlations. Hum Pathol 2006, 37:1458-1464
35. Hammond E, Shaw K, Carnley B, P’ng S, James I, Herrmann R: Quantitative determination of JAK2 
V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with 
the different types of myeloproliferative disorders. J Mol Diagn 2007, 9:242-248
36. Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander AR, 
Fehse B: Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR 
after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321
37. Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL: Design and evaluation of a real-time 
PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical 
laboratory. J Mol Diagn 2010, 12:58-64
38. Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, Gallardo M, Gilsanz F, 
Martinez-Lopez J: Validity test study of JAK2 V617F and allele burden quantification in the diagnosis 
of myeloproliferative diseases. Ann Hematol 2008, 87:741-749
39. Sidon P, Heimann P, Lambert F, Dessars B, Robin V, El Housni H: Combined Locked Nucleic Acid and 
Molecular Beacon Technologies for Sensitive Detection of the JAK2V617F Somatic Single-Base 
Sequence Variant. Clin Chem 2006, 52:1436-1438
40. Sidon P, El Housni H, Dessars B, Heimann P: The JAK2V617F mutation is detectable at very low level 
in peripheral blood of healthy donors. Leukemia 2006, 20:1622
41. Poodt J, Fijnheer R, Walsh IB, Hermans MH: A sensitive and reliable semi-quantitative real-time PCR 
assay to detect JAK2 V617F in blood. Hematol Oncol 2006, 24:227-233
42. Er TK, Lin SF, Chang JG, Hsieh LL, Lin SK, Wang LH, Lin CW, Chang CS, Liu TC: Detection of the 
JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim 
Acta 2009, 408:39-44
43. Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC: Detection of the JAK2(V617F) mutation 
in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol 
Lab Med 2006, 130:997-1003
44. Sutton BC, Allen RA, Zhao ZJ, Dunn ST: Detection of the JAK2V617F mutation by asymmetric PCR 
and melt curve analysis. Cancer Biomark 2007, 3:315-324
45. Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata 
E, Takeuchi M, Murotani Y, Yokota A, Hirai M, Majima S, Taniwaki M, Maekawa T, Kimura S: Fully 
automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res 2008, 
32:1462-1467
46. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, and Prchal JT: 
Polycythemia vera is not initiated by JAK2V617F mutation. Experimental Hematology 2007, 
35:32–38
47. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri 
S, Malcovati L, Lazzarino M, Cazzola M: Relation between JAK2 (V617F) mutation status, 
granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myelo-
proliferative disorders. Blood 2006, 107:3676-3682
48. Sattler M, Walz C, Crowley BJ, Lengfelder E, Jänne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, 
Griffin JD: A sensitive high-throughput method to detect activating mutations of Jak2 in peripher-
al-blood samples. Blood 2006, 107:1237-1238
49. Fu JF, Shi JY, Zhao WL, Li G, Pan Q, Li JM, Hu J, Shen ZX, Jin J, Chen FY, Chen SJ: MassARRAY assay: 
a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloprolif-
erative disorders. Leukemia 2008, 22:660-663
50. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N, Loewenthal R, 
Nagler A, Cohen Y: A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in 
patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative 
disorders (MPD). Leuk Res 2008, 32:421-427
94  |  Chapter 5
51. Ohyashiki K, Hori K, Makino T, Ohyashiki JH: Automated JAK2V617F quantification using a 
magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. 
Cancer Genet Cytogenet 2007, 179:19-24
52. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ: JAK2(V617F): Prevalence in a large 
Chinese hospital population. Blood 2007, 109:339-342
53. Rijnders RJ, Christiaens GC, Bossers B, van der Smagt JJ, van der Schoot CE, de Haas M. Clinical 
applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 2004, 103:157-164
54. Denys B, El Housni H, Nollet F, Verhasselt B, Philippé J: A Real-Time Polymerase Chain Reaction 
Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked 
Nucleic Acid-Modified Oligonucleotide. J Mol Diagn 2010, [Epub ahead of print]
55. Karkare S, Bhatnagar K: Promising nucleic acid analogs and mimics: characteristic features and 
applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 2006, 71:575–586
56. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH: Use of the activating gene 
mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients 
with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplanta-
tion 2007, 15:1518-1520
57. Bernard PS, Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 2002, 
48:1178-1185
58. Prchal JF and Axelrad AA: Bone-marrow responses in polycythemia vera. N Engl J Med 1974, 
290:1382
59. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R: A 
common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 
41:450-454
60. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand 
F, Cross NC: JAK2 haplotype is a major risk factor for the development of myeloproliferative 
neoplasms. Nat Genet 2009, 41:446-449
61. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, 
Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL: A 
germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive 
myeloproliferative neoplasms. Nat Genet 2009, 41:455-459
5
JAK2V617F quantification with PNA block  |  95

6
Single nucleotide polymorphism 
(SNP)-based loss of heterozygosity (LOH) 
testing by real time PCR in patients suspect 
of myeloproliferative disease
Cornelis JJ Huijsmans, Jeroen Poodt, Jan Damen, 
Johannes C van der Linden, Paul HM Savelkoul, Johannes FM Pruijt, 
Mirrian Hilbink and Mirjam HA Hermans
PLoS ONE 2012, 7:e38362
Abstract
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded 
by an oncogene activating mutation, the mutant allele may be further potentiated if the 
wild-type allele is lost or inactivated. In myeloproliferative neoplasms (MPN) somatic 
acquisition of JAK2V617F may be followed by LOH resulting in loss of the wild-type allele. The 
occurrence of LOH in MPN and other proliferative diseases may lead to further potentiating 
of the mutant allele and thereby increased morbidity. A real time PCR based SNP profiling 
assay was developed and validated for LOH detection of the JAK2 region (JAK2LOH). Blood 
of a cohort of 12 JAK2V617F-positive patients (n = 6 25–50% and n = 6 >50% JAK2V617F) 
and a cohort of 81 patients suspected of MPN was stored with EDTA and subsequently used 
for validation. To generate  germline profiles, non-neoplastic formalin-fixed paraffin-embed-
ded tissue from each patient was analyzed. Results of the SNP assay were compared to those 
of an established Short Tandem Repeat (STR) assay. Both assays revealed JAK2LOH in 1/6 
patients with 25–50% JAK2V617F. In patients with >50% JAK2V617F, JAK2LOH was detected 
in 6/6 by the SNP assay and 5/6 patients by the STR assay. Of the 81 patients suspected of 
MPN, 18 patients carried JAK2V617F. Both the SNP and STR assay demonstrated the 
occurrence of JAK2LOH in 5 of them. In the 63 JAK2V617F-negative patients, no JAK2LOH 
was observed by SNP and STR analyses. The presented SNP assay reliably detects JAK2LOH 
and is a fast and easy to perform alternative for STR analyses. We therefore anticipate the 
SNP approach as a proof of principle for the development of LOH SNP-assays for other 
clinically relevant LOH loci.
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Introduction
Neoplastic disorders may have a variety of underlying molecular and cytogenetic defects. In 
2005, the involvement of the JAK2V617F somatic point mutation in myeloproliferative 
neoplasms (MPN) became apparent. JAK2V617F is caused by a G-to-T transversion in the 
Janus Kinase 2 (JAK2) gene resulting in a valine-to-phenylalanine (V-F) amino acid substitution 
at codon 617 [1,2,3,4]. JAK2 is a non-receptor tyrosine kinase involved in the JAK-STAT 
signalling pathway [5]. The JAK2V617F mutation apparently alters the activity of the 
autoinhibitory pseudokinase JH2 domain resulting in a constitutive activation of the JAK-STAT 
signalling pathway, leading to a growth factor independent cell proliferation [6]. The 
diagnostic value of JAK2 mutational analysis in MPN is now well established and has been 
endorsed in the classification of haematological malignancies by the World Health 
Organisation [7].
In addition to neoplasm-promoting mutations, chromosomal imbalance may lead to loss of 
heterozygosity (LOH) resulting in the deletion of tumor suppressor genes. Besides this, LOH 
may lead to acquired partial uniparental disomy, excluding the wild-type allele of a cancer-
critical gene by which the effect of the mutant oncogenic allele is further potentiated. The 
latter is commonly found in combination with the JAK2V617F mutation due to LOH of (part 
of) chromosome 9p [8]. A proposed mechanism which is suggested to give rise to (partial) 
LOH of chromosome 9p, and thereby JAK2V617F homozygosity, is the mitotic recombination 
between homologous regions of chromosome 9p in a heterozygous cell [3]. It is further 
speculated that the daughter cells homozygous for the JAK2V617F mutation gain additional 
proliferative advantage and outcompete the JAK2V617F heterozygous cells and homozygous 
wild-type JAK2 cells, thereby leading to an expansion of the JAK2V617F homozygous 
subclone [3].
Polycythemia Vera (PV) patients with JAK2V617F often carry a homozygous subclone in 
contrast to Essential Thrombocythemia (ET) in which homozygosity is rare. These homozygous 
subclones may predominate over time. It has been proposed that it may be more common 
for PV patients to have a mutant allele burden of >50% than for ET patients [9]. This was 
confirmed in a large multicentre study during which the JAK2V617F mutational status in 
patients with PV (n = 323) and ET (n = 639) was analysed. Of the PV patients, 67.8% was 
found to be JAK2V617F heterozygous and 32.2% JAK2V617F homozygous. Only 2.2% of ET 
patients were found to be JAK2V617F homozygous, whereas 40.2% was JAK2V617F-nega-
tive and 57.6% JAK2V617F heterozygous [10]. Although the clinical relevance of JAK2V617F 
allele burden is not yet fully understood; a correlation between disease phenotype and the 
proportion of mutant alleles has been postulated [11]. Splenomegaly, vascular events and 
pruritus in PV and splenomegaly, arterial thrombosis and microvessel disease in ET have been 
clinically correlated to mutant allele burdens [12,13]. In addition to the percentage of mutant 
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allele burden by itself, JAK2V617F homozygosity (through JAK2LOH) is thought to give rise to 
a more symptomatic myeloproliferative disease (MPD) resulting in several clinical manifestations 
such as lower platelet counts (PV), more frequent evolution into secondary myelofibrosis, 
higher risks of cardiovascular events, splenomegaly and higher leukocyte counts [10,14,15, 
16,17]. Besides this, JAK2V617F homozygosity more often necessitates the use of cytoreductive 
therapies [10,14]. With regard to ET, the large multicenter study showed also that ET patients 
harboring homozygous JAK2V617F mutation had a 3.9-fold higher risk of major cardiovascular 
events as compared to both their heterozygous and wild-type counterparts [10].
Quantitative real time PCR is an excellent tool for the quantification of JAK2V617F mutant 
allele burden and is therefore of clinical importance [18]. Also, determination of the LOH 
status of (part of) the JAK2 region (JAK2LOH) of chromosome 9p may be clinically relevant 
due to the possibility of pinpointing those patients carrying a JAK2V617F homozygous 
subclone, which is thought to give rise to a more symptomatic MPN. Several techniques to 
determine LOH status have been described, such as typing of STRs/microsatellite DNA analysis 
[19,20], SNP-based pyrosequencing [19] and Affymetrix SNP microarray [8]. Although these 
methods provide valuable information on the LOH status, they are often not accessible for 
routine molecular laboratories –due to the necessity of expensive (pyro)sequencing or array 
equipment- and often need post-PCR processing increasing contamination risk [8,19,20]. 
Therefore we developed a JAK2LOH test for routine use based on real time amplification of 
SNPs located in and adjacent to JAK2.
Materials and Methods
Ethics Statement
The presented study was performed retrospectively using archival patient samples which 
were rendered anonymous before use. The Board of Directors of the Jeroen Bosch Hospital 
and the JBZ Scientific Advisory Board approved this study. Additionally, the JBZ Scientific 
Advisory Board waived the need for informed consent from the participants due to the 
anonymous and retrospective nature of the study. No informed consent from the involved 
patients was therefore obtained.
JAK2V617F-positive Patient Cohort
To test our SNP assay for detection of JAK2LOH, 12 patients were selected based on 
JAK2V617F-positive mutational status. This status was determined with a quantitative 
JAK2V617F real time PCR based method using a PNA oligonucleotide for blocking the 
wild-type allele [18]. Patients 1 to 6 carried a JAK2V617F mutant allele burden of 25–50%, 
had a mean age of 73±8 years (mean ±1 standard deviation) and a male:female ratio of 2:1. 
Patients 7 to 12 with a mutant allele burden of >50%, rendering JAK2LOH very likely, had an 
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age of 77±5 years (mean ±1 SD) and a male:female ratio of 1:1. EDTA-blood samples used for 
JAK2V617F mutational status were used for LOH analysis. A non-neoplasmic archival 
formalin-fixed paraffin-embedded tissue (FFPE tissue) from each patient was included to 
establish the  germline profile.
Although not fully correct due to the heterogenous nature of blood tissue, results were stated 
as loss of heterozygosity or retention of heterozygosity (ROH) throughout this manuscript.
Patients Suspect of MPN Cohort
Eighty-one patients, suspected for myeloproliferative disease, were included in this study. 
Inclusion was based on EDTA-blood samples collected between December 2007 – December 
2009 for JAK2V617F analyses in combination with the availability of archived non-neoplasm 
related FFPE tissue. Mean age was 60±14 years (mean ±1 SD) with a 1:1.3 male to female 
ratio. In addition to these EDTA-blood samples used for LOH analysis, the same cohort of 
patients was used to analyze non-neoplasm related FFPE samples from a wide variety of 
tissues. These samples were originally taken for routine histological diagnostics and used in 
this study to determine  germline SNP and STR profiles.
Tissue Processing
Tissues for histological evaluation were fixed according to a routine procedure in 0.01 mol/L 
buffered (0.005 mol/L disodium hydrogen phosphate anhydrous and 0.005 mol/L sodium 
dihydrogen phosphate dihydrate, pH 7.0) 10% formalin, and processed for paraffin 
embedding using a Tissue-Tek VIP 5 (Sakura, Torrance, USA). The dehydration program 
consisted of 14 steps of 1 hour under continuous agitation, pressure, vacuum, and heating. 
At 40ºC, two 10% formalin treatments were followed by one 70% (v/v) ethanol treatment, 
two 96% ethanol treatments, three 100% ethanol treatments, and two 100% xylene 
treatments. Paraffin embedding was done at 60ºC in four 100% paraffin treatments.
Genomic DNA Extraction from FFPE tissues
Paraffin-embedded tissues were trimmed of paraffin excess and cut into 3 µm-thick sections. 
Approximately 1 to 1.5 cm2 of sectioned tissue (a single section or short ribbons depending 
on the surface per section) was put in 250 µL of digestion solution (digestion solution with 
proteinase K was prepared by adding 100 µL of proteinase K solution (20 mg/mL; Roche 
Diagnostics GmbH, Mannheim, Germany) and 10 µL of Tween 20 (Merck BV, Amsterdam, 
The Netherlands) to 2 mL of TE buffer (1 mmol/L EDTA, and 10 mmol/L Tris-HCl buffer, pH 
8.0)) and incubated overnight at 45ºC. Proteinase K was inactivated the next day by incubation at 
100ºC for 15–30 minutes. Afterwards, samples were centrifuged for 2 minutes at 14,000 rcf/G.
Genomic DNA was extracted from FFPE tissues using the EasyMAG NucliSens extraction 
system (BioMérieux Benelux BV, Zaltbommel, The Netherlands). Two hundred µL digested 
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sample, located beneath a paraffin cap, was added to 2 mL NucliSens lysis buffer, homogenized 
and incubated for 10 min. at room temperature. The mixture was then added to the EasyMAG 
vessel and 100 µL of diluted magnetic silica (50 µL silica + 50 µL ultrapure water) was 
subsequently added. The DNA was extracted on the EasyMAG machine (BioMérieux Benelux 
BV, Zaltbommel, The Netherlands) using the ‘‘Generic 2.0.1’’ program. Elution was performed 
in 200 µL NucliSens Extraction buffer 3.
Genomic DNA Extraction from EDTA-blood
Genomic DNA was extracted from blood using the DNA blood mini kit (Qiagen, Hilden, 
Germany). Two hundred µL EDTA-blood was added to 200 µL AL buffer, homogenized and 
incubated for 10 min. at room temperature. Two hundred µL of 96% ethanol (Merck KGaA, 
Darmstadt, Germany) was added. The mixture was transferred to a QIAamp column and 
centrifuged for 1 min. at 8,000 rcf/G. The column was put in a new collection tube, 500 µL 
AW1 buffer was added and centrifuged for 1 min. at 8,000 rcf/G. This procedure was repeated 
with 500 µL AW2 buffer and the column was centrifuged for 1 min. at 14,000 rcf/G. To remove 
all ethanol from the column it was put in a new collection tube and then subjected to a dry spin 
for 1 min. at 14,000 rcf/G. Elution was performed by adding 200 µL EL buffer, incubating for 5 
min. at room temperature followed by centrifugation for 1 min. at 8,000 rcf/G.
LOH Analysis by STR Detection
Microsatellite markers D9S1810 and D9S1681 spanned a 0.5 Mbp region of chromosome 9p, 
including the JAK2 gene (figure 1A) [1]. This 0.5 Mbp region –Mbp 4.8 to 5.3- is located 
within the minimal LOH region and downstream of the mitotic recombination breakpoint as 
described by Kralovics and coworkers [3].
The regions containing D9S1810 and D9S1681 were amplified. Fifteen µL of mix contained 
7.5 µL 2x Amplitaq Gold FAST (Applied Biosystems, Foster City CA, USA), 0.4 µM primers 
(D9S1810fw: 6FAM-TAT CAA GCA AAA CTT TTT ATT GTG ATC ACA, D9S1810rv: GTT TCT 
CTT CTC TGA CAG CAG AGC ATC C [210 bp] D9S1681fw: VIC-AGG CAG TTG CAC AGA 
TAG TTA TAT ACT and D9S1681rv: GTT TCT CAG ATT CAG CCA TGT TCC AG CAT [261 bp] 
(ABI); The underlined sequences indicate the pig tail that was used to promote adenylated 
products [3]) and 50 ng of isolated DNA.
DNA isolated from both EDTA-blood (tumor) and FFPE tissue (germline) from each patient 
were amplified in the same run using a Veriti FAST Thermal Cycler (Applied Biosystems, Foster 
City CA, USA) for 12 min. at 94ºC followed by 10 cycles of 15 sec. at 94ºC, 15 sec. at 60ºC, 
30 sec. at 72ºC, followed by 25 cycles of 15 sec. at 89ºC, 15 sec. at 60ºC, 30 sec. at 72ºC 
and a final elongation step of 10 min. at 72ºC.
Prior to capillary electrophoresis, PCR products were diluted in ultrapure water to obtain a 
fluorescence signal between 400 and 8000 Fluorescent Units. Capillary electrophoresis and 
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the Fluorescence Unit measurement of each PCR product was performed on a 3130 Genetic 
Analyzer (Applied Biosystems, Foster City CA, USA) in Hi-Di formamide together with a 
LIZ-600 size marker (Applied Biosystems, Foster City CA, USA). Allele ratios of tumor material 
were compared to allele ratios of germline DNA, using Genemapper Software Version 4.0 
(Applied Biosystems, Foster City CA, USA).
LOH Analysis by SNP Detection
Ten predesigned TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City CA, USA) 
were used according to the manufacturer’s instructions. Twenty-five µL of PCR, using the in 
house made JBZ 4x master mix contained, 20 mmol/L Tris-HCl, pH 8.4, 50 mmol/L KCl, 3 
mmol/L MgCl2 (prepared from 10x PCR buffer and 50 mmol/L MgCl2 solution delivered with 
Platinum Taq polymerase), 0.75 U of Platinum Taq polymerase (Invitrogen BV, Breda, The 
Netherlands), 4% glycerol (molecular biology grade; Calbiochem, VWR International BV, 
Amsterdam, The Netherlands), 200 µmol/L of each dNTP (Invitrogen BV), 0.5 µL of Rox 
reference dye (Invitrogen BV), 1.25 µL of predeveloped assay reagent from the Assays-on-
Demand SNP genotyping products (Applied Biosystems, Foster City CA, USA) containing two 
primers and two MGB TaqMan probes (5’ VIC for allele 1, 5’ FAM for allele 2 and a 3’ black 
hole quencher for both alleles), and 11.25 µL of target DNA. Real time PCR was performed in 
three different ABI Prism 7500 FAST SDS (ABI) machines for 1 minute at 95ºC, followed by 45 
cycles of 3 seconds at 95ºC and 30 seconds at 60ºC.
Statistical Analysis SNP LOH Detection
To determine and visualize the distribution of delta Rn VIC/ FAM ratios (ratio allele 1/allele 2), 
box-and-whisker plots were generated for each SNP based of the EDTA-blood samples from 
the heterozygous patients –based on the germline profile generated using the corresponding 
FFPE tissues– from the patient cohort that were negative for the JAK2V617F mutation (63/81). 
The box extends from the 25th  to 75th  percentile of observations, representing the 
interquartile range (IQR). The bars/whiskers define the +1.5 IQR and -1.5 IQR and indicate the 
cut off value for normal ratio distribution. Therefore, ratios plotted within 1.5–3x IQR are 
outliers and were considered equivocal with regard to JAK2LOH status. Ratios plotted ≥3x 
IQR are extremes and were considered to be representative for JAK2LOH. All ratios with an 
IQR of <1.5 follow normal distribution and were interpreted as JAK2ROH.
Leukocyte, Thrombocyte and Erythrocyte Counts
Leukocyte, thrombocyte and erythrocyte counts were routinely determined directly after 
sampling by the SE9500/XE2100 (Goffin Meyvis, Etten-Leur, The Netherlands) analyzers.
The cell counts were firstly judged for fit to the normal distribution by using stem-and-leaf 
plots and quantile-quantile plots. As our data did not follow a normal distribution, Mann- 
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Whitney U tests were performed for comparison of the cell counts between the JAK2ROH 
and JAK2LOH group.
Results
STR and SNP Selection 
STRs D9S1810 and D9S1681 span the 0.5 Mbp minimal 9pLOH region, incorporating the 
JAK2 gene (fi gure 1A), and have been used before by Kralovics and coworkers to investigate 
9pLOH [3].
Ten SNPs were selected in silico using SNP browser software Version 4.0 (ABI). Selection was 
based on allele frequencies of around 0.5 and location within or near the JAK2 gene covering 
Figure 1  Distribution of Short Tandem Repeat (STR) and Single Nucleotide Polymorphism 
(SNP) markers on the JAK2 region, along part of chromosome 9p. A. SNP (rs#) and STR (D9S#) 
marker loci within a 0.5 Mbp spanning genomic region harboring the JAK2 gene (JAK2 region). RCL1 = 
RNA terminal phosphate cyclase-like 1 gene, JAK2 = Janus Kinase 2 gene, INSL4/6 = insulin-like 4 and 6 
genes and RLN2 = relaxin 2 gene. The arrow indicates the approximate position of JAK2V617F. B. STR 
and SNP results of JAK2 region of 16 patients (pt). PV = polycythemia vera, NC = non-classifi ed myelo-
proliferative neoplasm. The boxes represent all heterozygous markers. Black boxes = LOH observed for 
this marker, white boxes = retention of heterozygosity observed for this marker and striped boxes = 
equivocal for this marker, homozygous markers are not shown.
A
B
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the 0.5 Mbp 9p region in between D9S1810 and D9S1681 (figure 1A and table 1). For real 
time PCR based amplification and SNP detection, TaqMan® SNP Genotyping Assays from 
Applied Biosystems were used. During technical validation, one (SNP rs7862852) of the ten 
SNP assays showed cross reactivity of the FAM MGB probe with allele 1 (VIC) and poor 
amplification of allele 2 (FAM) in the presence of allele 1. Therefore, allele calling could not 
be performed and TaqMan® SNP Genotyping Assay for rs7862852 was excluded from LOH 
analyses. The other 9 SNP assays generated reliable allele calls and were therefore suitable for 
inclusion in the JAK2LOH panel (figure 1A and table 1).
Patient Cohorts
Two patient cohorts were used in this study: a cohort of 12 JAK2V617F-positive patients and 
a cohort of 81 patients suspect of MPN.
FAM/VIC ratios were plotted per SNP in a scatterplot. Figure 2A shows the scatterplot of SNP 
rs3780378 for paired paraffin and blood samples of all patients in both cohorts. The data 
obtained for SNP rs3780378 are representative for the entire SNP panel. Four clusters –
homozygous VIC, homozygous FAM, heterozygous FAM/VIC ABI7500FAST machine 1 and 2 
and heterozygous FAM/VIC ABI7500FAST machine 3- were observed. FAM/VIC ratios plotted 
outside these clusters were considered to represent LOH or to be equivocal as was statistically 
Table 1   Panel of selected Single Nucleotide Polymorphisms (SNPs).
SNP-ID (hCV) SNP-ID (rs) Base (9p) SNP Minor allele frequency
CEU CHB JPT YRI
29340651 7869592 4,866,301 T/C 0.46 0.40 0.35 0.47
2008226 10974837 4,885,391 A/G 0.48 0.44 0.49 0.46
657006 7853852 4,879,126 C/G 0.46 0.49 0.47 0.49
34291956* 7862852 4,962,398 C/T 0.45 0.46 0.35 0.33
2008287 7849191 4,978,761 C/T 0.50 0.48 0.41 0.19
29340600 7857730 5,074,049 T/G 0.47 0.42 0.45 0.11
27480690 3780378 5,102,288 T/C 0.47 0.46 0.50 0.45
16225021 2381195 5,135,887 T/C 0.49 NA NA NA
28001006 2224572 5,278,707 A/T 0.37 0.43 0.49 0.44
31941380 10815188 5,344,681 T/C 0.40 0.41 0.48 0.30
SNP-ID (hCV) = Celera SNP ID. SNP-ID (rs) = reference SNP ID number. Base (9p) = the nucleotide position on 
chromosome 9(p). The particular nucleotide variation is referenced in “SNP”-column. Minor allele frequencies are 
indicated for different populations: CEU, CEPH (Centre d’Etude du Polymorphisme Humain) from Utah; CHB, Chinese 
from Beijing; JPT, Japanse from Tokyo and YRI, Yoruba from Ibadan Nigeria. *SNP rs7862852 is excluded from the 
panel of recommended SNPs. NA = not applicable.
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determined using box-and-whisker plots (fi gure 2B). In addition, a FAM/VIC ratio of a blood 
sample from a heterozygous patient present in a homozygous cluster was considered to 
represent LOH.
Statistical Analysis SNP LOH Detection
Box-and-whisker plots were generated, based on the VIC/FAM ratios from EDTA-blood 
samples of all heterozygous patients from the patient cohort suspect of MPN that were 
negative for the JAK2V617F mutation (63/81), for all SNP assays (data not shown). Data from 
the JAK2V617F-positive cohort samples that were selected based on their mutant allele 
burdens of 25–50% and >50% JAK2V617F and therefore more likely to contain JAK2LOH 
were not included. Inclusion of JAK2V617F-positives would lead to a larger variety in VIC/
FAM ratios and therefore a biased IQR. This would infl uence outlier (equivocal) and extreme 
(JAK2LOH) calling. VIC/FAM ratios generated with the JAK2V617F-positive patients were 
called (JAK2ROH, equivocal or JAK2LOH) using the measured IQRs of the JAK2V617F-nega-
tive patients from the patient cohort.
Figure 2  Visualization of FAM/VIC ratios generated by representative SNP rs3780378 A. Scatterplot 
of SNP rs3780378 analyses of paired EDTA-blood and formalin-fi xed paraffi n-embedded (FFPE) tissues 
of 93 patients (12 patients from JAK2V617F-positive cohort and 81 sample pairs from the MPN suspect 
patient cohort). X-axis: Delta Rn VIC (T = Thymine), Y-axis: Delta Rn FAM (C = Cytosine). White squares 
(bl-M1&2) = EDTA-blood samples amplifi ed using ABI7500FAST machines 1 and 2, grey squares (bl-M3) = 
EDTA-blood samples amplifi ed using ABI7500FAST machine 3, white triangles (par-M1&2) = FFPE tissue 
samples amplifi ed using ABI7500FAST machines 1 and 2 and grey triangles (par-M3) = FFPE tissue 
samples amplifi ed using ABI7500FAST machine 3. B. Representative box-and-whisker plot generated 
using the SNP rs3780378 VIC/FAM ratios of the EDTA-blood samples of all heterozygous patients from 
the patient cohort analyzed with ABI7500FAST machines 1 and 2. Stars represent extremes (>3x IQR = 
JAK2LOH).
A B
106  |  Chapter 6
One representative box-and-whisker plot generated using SNP rs3780378 is shown in figure 
2B. Based on these calculations, patient 15, 39, 44 and 61 were found to be extremes 
(JAK2LOH) as additionally presented in figure 1B.
JAK2V617F-positive Patient Cohort
The cohort of 12 JAK2V617F-positive patients was composed with samples containing 
mutant allele burdens of 25–50% (patients 1–6) and burdens above 50% (patients 7–12). 
The results of STR vs. SNP LOH analyses are summarized in cross table 2. Patients 1, 2 and 4 
showed STR and SNP results consistent with ROH of the JAK2 region. Patients 5, 7, 9, 10, 11 
and 12 showed JAK2LOH in both assays. In patient 3 discrepant results were found in STR vs. 
SNP testing (ROH/LOH). The STR assay results were indicative of JAK2ROH, whilst the SNP 
profile revealed different results among the various SNPs. SNPs rs7857730 and rs3780378 
revealed the presence of one of the two germ line alleles, while the 3 other informative SNPs 
were found to be heterozygous. Overall results for patient 6 were ROH/ROH. However, SNP 
rs7869592 result was found to be equivocal, while the 4 other SNPs showed ROH and the 
remaining 4 SNPs were non-informative (table 2). LOH of the JAK2 region was additionally 
shown in patient 8 using the SNP assay while STR results were non-informative (figure 1B and 
table 3). In patient 4, SNP rs7869592 was heterozygous but was found to be equivocal, STR 
results were indicative for ROH.
Patients Suspect of MPN Cohort
Eighteen patients harbored the JAK2V617F mutation, whereas 63 patients did not. The 
JAK2LOH/ROH results for both groups, as generated by SNP and STR analysis, are summarized 
in cross table 4. Equivocal and non-informative results are summarized in table 3.
Table 2   Cross table of JAK2 region loss of heterozygosity results of the JAK2V617F-positive 
patient cohort, generated by the Short Tandem Repeat (STR) assay and the Single 
Nucleotide Polymorphism (SNP) based assay. 
SNP JAK2LOH assay
STR JAK2LOH assay JAK2LOH JAK2ROH Total
JAK2LOH 6A 0 6
JAK2ROH 1B 3C 4
Total 7 3 10
A = patient (pt) 5, 7, 9, 10, 11 and 12, B = pt 3*, C = pt 1, 2 and 6**.
*LOH observed for a small region of the JAK2 gene, in proximity of the JAK2V617F codon.
**rs7869592 equivocal, other 4 SNPs indicative of ROH.
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of heterozygosity on the JAK2 region.
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Within this cohort, 64 patients were found to generate ROH results in both assays (ROH/
ROH). Patients 15, 39, 41, 44 and 61– all JAK2V617F-positive- yielded results indicative of 
JAK2LOH in both assays (figure 1B). Patient 68 displayed JAK2LOH in the SNP assay, whilst 
the STR assay was non-informative due to homozygosity for both markers. Patient 38 yielded 
equivocal results using SNP rs7869592, while SNP rs10815188 and STR D9S1810 results were 
indicative of ROH. Patients 13, 20, 22, 24, 25, 59 and 69 were found to be non-informative 
with the STR assay, while SNP analysis showed JAK2ROH. SNP profiles of patients 32, 55 and 
93 were considered non-informative due to an incomplete SNP profile (4, 7 and 5 out of 10 
Table 3   Cross table of equivocal and non-informative results, generated by the Short 
Tandem Repeat (STR) assay and the Single Nucleotide Polymorphism (SNP) based 
assay. 
SNP JAK2LOH assay
STR JAK2LOH assay JAK2LOH JAK2ROH Non- 
informative
Equivocal Total
JAK2LOH NA NA 0 0 0
JAK2ROH NA NA 3E 2F 5
Non-informative 2G 7H 0 0 9
Equivocal 0 0 0 0 0
Total 2 7 3 2 14
E = pt 32, 55 and 93, F = pt 4 and 38, G = pt 8 and 68, H = pt 13, 20, 22, 24, 25, 59 and 69. 
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of heterozygosity on the JAK2 region. 
Results were indicated as non-informative due to homozygous STR/SNP profiles in the formalin-fixed paraffin- embedded 
tissues. NA = not applicable.
Table 4   Cross table of JAK2 region loss of heterozygosity results of the patients suspect 
of MPN cohort, generated by the Short Tandem Repeat (STR) assay and the Single 
Nucleotide Polymorphism (SNP) based assay. 
SNP JAK2LOH assay
STR JAK2LOH assay JAK2LOH JAK2ROH Total
JAK2LOH 5D 0 5
JAK2ROH 0 64 64
Total 5 64 69
D = patients 15, 39, 41, 44 and 61.
JAK2LOH = loss of heterozygosity on the JAK2 region, JAK2ROH = retention of heterozygosity on the JAK2 region. 
MPN = myeloproliferative neoplasm.
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SNPs, respectively) of the reference FFPE sample (due to low DNA loads) in combination with 
being homozygous for all interpretable SNPs. These patients showed JAK2ROH in the STR 
assay (table 3).
Leukocyte, Thrombocyte and Erythrocyte Counts
Mean cell counts (±1 SD), due to the retrospective nature of this study available for 24 
JAK2V617F-positive patients, for the JAK2LOH (n = 12 [including patient 3]) vs. the JAK2ROH 
(n = 12) group were: 18.7±14.9x109 vs. 10.6±4.1x109 leukocytes/L, 460±266x109 vs. 
688±390x109 thrombocytes/L and 6.00±1.38x1012 vs. 4.58±1.05x1012 erythrocytes/L.
Leukocyte and erythrocyte counts were significantly higher (p-value = 0.045 and 0.007) in 
the JAK2LOH group than in the JAK2ROH group. Thrombocyte counts did not differ 
significantly between the two groups (p-value = 0.068).
Discussion
We have developed a SNP based assay, which is easy to perform and reliably detects JAK2LOH. 
Ten SNPs located on 9p within the JAK2 region were selected in silico based on incidence 
around 0.5 in Caucasian (CEU, CEPH (Centre d’Etude du Polymorphisme Humain) from Utah), 
Chinese (CHB, Chinese from Beijing), Japanese (JPT, Japanese from Tokyo) and African (YRI, 
Yoruba from Ibadan Nigeria) populations. Technical validation of the accompanying SNP 
assays revealed that nine SNP assays fulfilled the criteria for inclusion -clear distinction of 
homo-/ heterozygous clusters, allele frequency in investigated population around 0.5 (data 
not shown) and sufficient sensitivity- in the JAK2LOH/ROH panel. SNP rs7862852 was 
excluded from the recommended panel of SNP markers due to poor performance.
A second technical issue with regard to the SNP assay was encountered when three different 
ABI7500FAST systems were employed. Two distinct groups of homozygotes were observed 
for machine 1&2 vs. machine 3 (figure 2). For each ABI7500FAST system all dyes employed 
(including FAM and VIC) are calibrated individually once every three months in our diagnostic 
setting. Variations introduced during such a calibration are inevitable as well as those caused 
by differences in light intensity generated by the integrated lamp which is replaced after 
2,000 burning hours. These technical issues may induce inter-machine variability. To prevent 
misinterpretation of JAK2LOH/ROH status, we recommend analyzing EDTA-blood samples 
and corresponding FFPE tissue on one ABI7500FAST as a control within the same run.
When interpreting the results with regard to JAK2LOH and ROH status, it should be taken 
into account that blood is a heterogeneous tissue. The demonstrated technique will therefore 
only detect JAK2LOH in those patients where the homozygous subclone is abundant enough. 
The assess the range in which homozygous subclones are abundant enough to be detected 
by the SNP assay, a serial dilution of DNA of a healthy homozygous patient and DNA of a 
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healthy heterozygous patient (for SNP rs7849191) was made and tested. The 5%, 10% and 
≥20% (20, 30, 40 and 50%) dilutions yielded results that were interpreted using the generated 
cut off values as ‘‘ROH’’, equivocal with regard to ‘‘LOH status’’ and indicative of ‘‘LOH’’, 
respectively (results not shown). Indicating a sensitivity of at least 20% homozygous cells in 
a heterozygous background using representative SNP rs7849191.
With regard to the interpretation of the STR results, difficulties were encountered when 
analyzing the data automatically. When allelic ratios were called by the Genemapper Software 
Version 4.0 (ABI), LOH/ROH calls were found to be doubtful in cases where DNA loads were 
aberrant -low loads observed in several FFPE tissues and high loads in some blood samples-. 
The software did not take into account that signals >8,000 or with very low fluorescent units 
negatively influenced allelic ratios, resulting in false LOH calls. Therefore, an additional manual 
analysis of all STR results was performed to determine STR JAK2 status. To assure that manual 
interpretation was objective, an LOH index was calculated. This index was calculated by 
determining the intensity of the PCR products, which was used to calculate the intensity ratio 
between the peaks of both alleles in the tumor sample. Dividing this ratio by the same ratio 
found in the normal tissue yielded the LOH index. When this LOH index was below 0.75, this 
was interpreted as LOH, whereas an LOH index of >0.75 was interpreted as ROH.
Considering the STR assay to be the golden standard, the SNP assay’s sensitivity and negative 
predictive value were 100% for both the JAK2V617F-positive patient cohort and the patients 
suspect of MPN cohort. Positive predictive values of the SNP assay were 85.7% and 100% 
and the specificity was 80% and 100% in the respective cohorts. Patient 3 showed no signs 
of JAK2LOH using the STR assay. Analyses of SNPs close to both STR loci also showed ROH. 
However, two SNPs in between the two STR loci in relative close proximity to JAK2V617F 
(rs7857730 and rs3780378 10–15 Kb and 35–50 Kb downstream, resp.) were not indicative 
of ROH. Rs7857730 and rs3780378 clearly showed JAK2LOH. It is likely that a small deletion, 
point mutation or a small recombination event around rs7857730 and rs3780378 accounts 
for these observations.
Of the 81 patients in the patient cohort suspect of MPN, JAK2LOH was found in 6 patients 
(7%), i.e. one-third (6/18) of the JAK2V617F-positive patients. Amongst the JAK2V617F-neg-
ative patients, no cases of JAK2LOH were found.
That JAK2LOH was found in 2/5 patients from the JAK2V617F-positive cohort with a JAK2V617F 
mutant allele burden below 50% is in line with the findings of Scott and coworkers, describing 
that a large number of PV patients harbor homozygous subclones, which may predominate 
over time [9]. Moreover, it indicates that next to JAK2V617F quantification the determination of 
JAK2LOH status provides additional information and could be of value.
In patient 4, rs7869592 was the only informative SNP and was found to be equivocal. Patient 
38 –positive for JAK2V617F- yielded an equivocal result for SNP rs7869592, SNP rs10815188 
and D9S1681 were representative of JAK2ROH. All other markers were non-informative due 
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to homozygosity. The overall result was therefore concluded to be equivocal for patients 4 
and 38 (figure 1B, table 3). Patient 44 yielded results indicative of JAK2LOH for D9S1810 and 
8/9 SNPs, whereas D9S1681 and rs10815188 yielded results indicative of JAK2ROH (figure 
1B). The mechanism behind this observation is unclear. A possible explanation could be an 
inversion of the D9S1681/rs2224572 locus that might have arisen during the process of 
recombination. In patient 61, the result from marker D9S1681 was indicative of JAK2LOH, 
whereas D9S1810 yielded a JAK2ROH result. Results from 6/9 SNPs were indicative of 
JAK2LOH, the result from one SNP was equivocal (figure 1B). We presume that this aberrant 
observation is due to mutation of the concerning JAK2 region.
In both patient cohorts the STR assay resulted in a total of 9 non-informative homozygous 
profiles, of which patient 8 and 68 were found in the SNP assay to harbor cells with JAK2LOH. 
Analysis of the cohorts using the SNP assay resulted in 3 non-informative homozygous 
profiles, of which the STR results were representative of JAK2ROH. Thus the SNP assay has a 
higher success rate than the STR assay in this population. Caution is however advised when 
handling samples with low DNA loads. Additionally, the SNP assay provides more detailed 
information with regard to ROH/LOH status of the JAK2 gene and surrounding loci.
In total, in 14 patients the SNP assay results were indicative of JAK2LOH (including patient 3, 
where a small part of the JAK2 region was affected; figure 1B and table 2) with an overall 
mean age of 74±7 years and a male:female ratio of 1.00:0.75. The 30 JAK2V617F-positive 
patients consisted of 8 PV patients, 7 ET patients, 1 IMF patient and 14 patients with a 
non-classified MPN. The occurrence of JAK2LOH amongst the different disease phenotypes 
was: PV 100% (n = 8), ET 0% (n = 7), IMF 0% (n = 1) and non-classified MPN 42.9% (n = 14). 
Similar distributions were previously found showing that JAK2LOH is a common event in PV 
and the contrary, is very rare in ET and IMF [9,10,11,12,13,14,15,16,17]. The fact that within the 
group of JAK2V617F-positive patients, leukocyte and erythrocyte counts were significantly 
higher in patients with JAK2LOH in comparison to patients with JAK2ROH may indicate a 
more symptomatic disease in the first group. This is in line with previous findings where the 
higher mutant allele burden was found to be correlated to lower platelet counts, higher 
incidence of splenomegaly and larger spleen size, cytoreductive therapy needed in a greater 
number of patients and higher white blood cell counts in PV and ET. A higher incidence of 
thrombotic events is also observed in PV and ET, particularly with mutant allele burdens 
above 50%. Significantly higher chances of fibrotic transformation have been observed in 
both PV and ET [10,14,15,16,17]. Additionally, MPN in patients 10 and 44 with JAK2LOH 
evolved into leukemia; patient 10 suffered from AML and patient 44 suffered from B-CLL in 
combination with AML and subsequently deceased. No leukemic transformation was 
observed in the JAK2ROH group.
Because the SNP assay relies on real time PCR, the technique is fast, easy to perform and 
requires less hands-on time in comparison to STR analysis –1.5 hours vs. 3 hours-. In addition, 
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the SNP assay does not require the use of expensive sequencing equipment, is therefore more 
easily accessible for smaller routine molecular diagnostic laboratories. No post-PCR processing 
is necessary, diminishing contamination risks. Besides the current application of JAK2LOH 
testing, the demonstrated SNP technique may prove useful as a diagnostic strategy for 
determination of LOH status in other neoplastic entities such as 18q LOH in colorectal cancer 
[21,22,23]. In addition to the in this study described use of archival FFPE tissues to generate 
germline SNP profiles, real time PCR based SNP profiling was described to be suitable in 
combination with buccal swabs [24], providing more-easy-to-obtain reference material.
In conclusion, we have developed a novel and easily accessible SNP based assay to reliably 
determine JAK2LOH status.
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Abstract
Breast cancer is a heterogeneous disease with various histological features and molecular 
markers. These are utilized for the prediction of clinical outcome and therapeutic decision 
making. In addition to well established markers such as HER2 overexpression and estrogen 
and progesterone receptor (ER and PR) status, chromosomal instability is evolving as an 
important hallmark of cancers. The HER2/TOP2A locus is of great importance in breast 
cancer. The copy number variability at this locus has been proposed to be a marker for the 
degree of chromosomal instability. We therefore developed a Single Nucleotide Polymorphism 
(SNP) assay to evaluate allelic imbalance at the HER2/TOP2A locus in three different entities 
of primary breast tumors.
Eleven SNPs were carefully selected and detected by real time PCR using DNA extracted from 
paired (histologically normal and tumor) paraffin-embedded tissues. Primary breast tumors 
of 44 patients were included, 15 tumors with HER2 overexpression, 16 triple negative tumors, 
defined by the absence of HER2 overexpression and a negative ER and PR status and 13 ER 
and PR positive tumors without HER2 overexpression. As controls, histologically normal 
breast tissues from 10 patients with no breast tumor were included. 
Allelic imbalance was observed in 13/15 (87%) HER2 positive tumors, the remaining 2 being 
inconclusive. Of the 16 triple negative tumors, 12 (75%) displayed instability, 3 (19%) displayed 
no instability, and 1 was inconclusive. Of the 13 hormone receptor positive tumors, 5 (38%) 
displayed allelic imbalance, while 8 did not.
We conclude that the SNP assay is suitable for rapid testing of allelic (im)balance at the HER2/
TOP2A locus using paraffin-embedded tissues. Based on allelic imbalance at this locus, both 
triple negative and ER and PR positive breast tumors can be subcategorized. The clinical 
relevance of the allelic (im)balance status at the HER2/TOP2A locus in breast cancer is subject 
of future study. 
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Introduction
Breast cancer is a heterogeneous disease that can display a diverse variety of biological 
features. Several proteins are well known to be expressed excessively in these tumors. Based 
on the excessive presence of such proteins, breast cancer can be divided in several different 
biological entities. This breast cancer categorization is utilized for the prediction of clinical 
outcome and therapy selection [1].
Well known examples of overexpressed proteins that play a critical role in breast cancer 
diagnostics and choice of therapy, are the estrogen and progesterone receptors (ER and PR). 
Available targeted therapies in these breast cancer cases are e.g. Tamoxifen and aromatase 
inhibitors [2-4]. 
In addition to the overexpression of ER and PR, aberrations of the chromosome 17q12-q22 
genomic region play an important role in breast cancer. This locus incorporates the HER2 
gene as well as the juxtaposed TOP2A gene, which is located 700 kb telomeric of HER2 [5-7]. 
The HER2 oncogene encodes the human epidermal growth factor receptor 2 protein, a 185 
kDa transmembrane tyrosine kinase receptor also known as erbB-2 and neu [5,6]. Upon 
ligand binding the other types of HER receptors will dimerize with HER2. Such dimerization 
triggers an integrate network of HER signal transduction involving a variety of signaling 
pathways [8-10]. When the HER2 oncogene is amplified, HER2 overexpression occurs resulting 
in overstimulation of HER mediated signal transduction [8]. HER2 is found to be amplified in 
25-30% of breast cancers [11]. Patients with HER2 amplified breast tumors resulting in 
overexpression of HER2, benefit from treatment with the monoclonal antibody Trastuzamab 
(Herceptin). Trastuzamab is thought to abolish the HER2 mediated signaling of the HER signal 
transduction network [12, 13]. In addition, analysis of several studies has shown an association 
of improved adjuvant anthracycline (AC)-based chemotherapy response rates in HER2 
amplified breast tumors [14]. However, there is no clear AC induced HER2 inhibiting 
mechanism, it is therefore suggested that TOP2A coamplification is the biological rationale 
behind these observations [15]. The TOP2A gene encodes topoisomerase II alpha, a 170 kDa 
enzyme that catalyzes the topological DNA changes needed during the multistep process of 
cell division [16]. Coamplification of TOP2A occurs along with HER2 amplification in 
approximately 30-45% of the HER2 amplified cases [15, 17, 18]. Patients with TOP2A 
amplified breast tumors seem to benefit from adjuvant AC-based chemotherapy. ACs are 
chemotherapeutic agents that are known to have, among other mechanisms of action, 
TOP2A inhibiting properties. TOP2A catalytic activity is inhibited by ACs via stabilization of 
the intermediate complex where TOP2A tyrosine residues are covalently linked to the 5’ 
phosphoryl ends of the cut DNA strands during the topological changes which they catalyze. 
Trapping the complex in this state prevents DNA resealing and further cell cycle progress, 
which ultimately induces programmed cell death [16, 19, 20]. In patients that are treated with 
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AC-based chemotherapy, breast tumors with TOP2A amplification show a trend towards a better 
disease free survival than tumors lacking this amplification. In addition, TOP2A amplification 
is an independent predictor of a significantly higher pathological complete response rate in 
these patients [18]. On the contrary, TOP2A deletion, occurring in 15-40% of HER2 amplified 
cases, has been associated with AC resistance [15, 17, 18]. Tumors lacking ER and PR over-
expression as well as HER2 amplification are defined as “triple negative” breast tumors. Triple 
negative tumors are associated with poor clinical outcome and lack of (currently) available 
targeted therapy [21, 22].
The above mentioned biological characteristics are well established biomarkers utilized to 
categorize breast cancer types for diagnostic and treatment related purposes. More recently, 
high resolution array based systems, targeting Single Nucleotide Polymorphisms (SNPs) or 
utilizing Comparative Genomic Hybridization, have been employed to subcategorize these 
breast tumor types and revealed distinct profiles of gene-expression or genetic alterations 
[23-28]. Hormone receptor positive tumors without HER2 overexpression showed minor and 
less frequent chromosomal instability in comparison to HER2 overexpressed and triple negative 
tumors that showed more extensive and more frequent chromosomal instability [23-29]. 
Copy number alterations across the genomic region incorporating the HER2/TOP2A locus 
have been proposed to be a marker for the degree of chromosomal instability in breast 
cancer [30, 31]. Early breast cancer patients with a tumor containing extensive chromosomal 
instability, that were treated with AC-based therapy, were shown to have a decreased risk of 
death and a trend towards a decreased risk of relapse. Similarly treated patients with a tumor of 
low chromosomal instability showed no apparent benefit [30, 31]. Determining such instability 
in a diagnostic setting may therefore be of clinical relevance as an adjuvant molecular marker. 
Single Nucleotide Polymorphisms (SNP) are easily detected by real time PCR, a technique that 
is widely available in many laboratories that routinely employ molecular diagnostics. By 
analyzing a panel of heterozygous SNPs, copy number alterations and thereby allelic 
imbalance of the involved locus can be determined. It therefore may provide an accessible 
method to assess allelic imbalance at the HER2/TOP2A locus. 
Materials and methods
Study population and clinical specimens
The study was carried out retrospectively with the approval of the Board of Directors and the 
Scientific Advisory Board of the Jeroen Bosch Hospital. All patient samples were rendered 
anonymous before use in this study.
120  |  Chapter 7
Control group 
Ten histologically normal formalin-fixed paraffin-embedded (FFPE) breast -tissues from 10 
different patients (CT1-10) with no breast tumor were included as controls (table 1). Age of 
included patients was 32.8±12.0 years (mean age ± 1 standard deviation (STD)).
Breast tumor patient group 
Breast tumors (FFPE tissue) with known HER2 immunohistochemistry (IHC) and silver in situ 
hybridization (SISH) status from 44 patients were included in this study (table 2): 15 tissues 
with HER2 amplification (IHC 3+, patients HER2+1-15; aged 52.9±14.2 years (mean age ± 1 
STD)) 16 triple negatives (patients TN1-16; aged 53.4±12.9 years (mean age ± 1 STD)) and 13 
ER/PR positive and HER2 non-amplified (ERPR+) breast tumors (patients ERPR+1-13; aged 
55.5±9.3 years (mean age ± 1 STD)). To establish the germline SNP profile, a histologically 
normal archival FFPE tissue (breast tissue or lymph node tissue in case no breast tissue was 
available; table 2) from each patient was analyzed. 
Tissue Processing
Tissues were fixed and processed as previously described [32]. Three-µM-thick sections were 
cut from each FFPE tissue and mounted on glass slides in sevenfold. One was used for 
Hematoxylin & Eosin (HE) staining, two to four (depending on tissue size, with a total of 
approximately 2 cm2) for genomic DNA extraction, one for SISH and one for IHC. The latter 
two were only performed for the tumor samples. 
Table 1   Patient data and SNP test results from the control group. 
Patient data and SNP results. The top right represents the HER2/TOP2A locus and the schematic positions of the 
employed SNP markers. The arrows indicate the location of the HER2 and TOP2A genes. The boxes represent all 
informative SNPs that were considered not affected (dashed)/affected (grey) by allelic instability or equivocal (dashed 
crosswise and grey). Homozygous SNPs are not informative, and are therefore shown as a horizontal line.
7
Allelic imbalance at the HER2/TOP2A locus  |  121
HER2 immunohistochemistry
To establish the HER2 expression status, IHC was performed on all 44 tumor samples using the 
Ventana anti-Her2/neu(4B5) (Roche Diagnostics GmbH, Mannheim, Germany) in combination 
with the VENTANA system (Roche Diagnostics GmbH) according to the manufacturers 
Table 2   Patient data, tumor characteristics and IHC, SISH and SNP test results from breast 
tumor group. 
Patient data, tumor characteristics and IHC, SISH and SNP test results. L and B represent the use of lymph node 
or breast histologically normal tissue. IHC = immunohistochemistry, SISH = silver in situ hybridization, HER2+ = HER2 
overexpression observed based on IHC, TN = triple negative, ERPR+ = estrogen receptor and progesterone receptor 
positive. Chr17 status = chromosome 17 status with M (monosomy), D (disomy), T (trisomy) and P (polysomy) as 
possible outcomes supplemented with the number of chromosomes 17 observed per nucleus. Pred. = predominantly 
and TC % = tumor cell percentage. Failed = SISH repeatedly failed. The top right represents the HER2/TOP2A locus 
and the schematic positions of the employed SNP markers. The arrows indicate the location of the HER2 and TOP2A 
genes. The boxes represent all informative SNPs that were considered not affected (dashed)/affected (grey) by allelic 
instability or equivocal (dashed crosswise and grey). Homozygous SNPs are not informative, and are therefore shown 
as a horizontal line.
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protocol. IHC 0 and 1+ were considered to represent normal expression, 2+ was considered 
borderline with regard to expression and 3+ was considered to represent overexpression. 
HER2 silver in situ hybridization
To determine the HER2 amplification status and to assess chromosome 17 copy number 
status, SISH was performed on all 44 tumor samples using the INFORM HER2 Dual colour 
SISH DNA probe cocktail (Roche Diagnostics GmbH) in combination with the VENTANA 
system (Roche Diagnostics GmbH) according to the manufacturers protocol. Twenty nuclei 
were counted independently by 2 individuals. The mean from these 2 nuclei counts was 
calculated. Interpretation was as follows: a ratio (HER2 probe/centromere probe) of <1.8 
represented no amplification; a ratio of 1.8-2.2 was equivocal and a ratio of >2.2 represented 
amplification. 
Genomic DNA extraction from FFPE tissues
From each FFPE tissue, tumor as well as (reference) histologically normal tissue, a HE-slide was 
made. The tumor tissue containing HE slides were used to determine the area with the 
highest tumor cell percentage (TC%). The HE slides containing the histologically normal tissue 
were used to determine the location of the highest nuclei density. Subsequently, these were 
used as a reference for tumor and histologically normal cell macrodissection, respectively. The 
respective cells were scraped off the corresponding blank slides. The scrapings were used for 
digestion and subsequent EasyMAG NucliSens (BioMérieux Benelux BV, Zaltbommel, The 
Netherlands) DNA extraction as described previously [32].
SNP selection
From the TaqMan® SNP Genotyping Assays from Applied Biosystems, 11 suitable SNPs were 
chosen using SNP browser software Version 4.0 (Applied Biosystems, table 3). SNP 1-6 were 
located up- and downstream of the HER2 gene within the  HER2 smallest region of 
amplification [33]. The remaining 5 SNPs (7-11) were located up- and downstream of the 
TOP2A gene. The selected SNPs displayed an allele frequency of approximately 0.5 in 
Caucasian (CEU, CEPH (Centre d’Etude du Polymorphisme Humain) from Utah), Chinese 
(CHB, Chinese from Beijing), Japanese (JPT, Japanese from Tokyo) and African (YRI, Yoruba 
from Ibadan Nigeria) populations. The latter to maximize the chance for heterozygosity, 
independent of the patients’ ethnicity, for only those SNPs are informative. 
Allelic instability testing by SNP detection
For real time PCR based amplification and detection of the selected SNPs, corresponding 
predesigned TaqMan® SNP Genotyping Assays were purchased (Applied Biosystems, Foster 
City CA, USA; table 3) containing two primers and two MGB TaqMan probes (5’ VIC for allele 1, 
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5’ FAM for allele 2 and a 3’ black hole quencher for both alleles). The SNP assays were used 
according to the manufacturer's instructions. Real time PCR based SNP detection was 
performed as previously described [32], in an ABI Prism 7500 FAST SDS (Applied Biosystems) 
machine for 1 minute at 95°C, followed by 45 cycles of 3 seconds at 95°C and 30 seconds at 
60°C. To maximize pipetting accuracy and thereby minimize its influence on the data 
generated, all initial PCR setups were performed using the Hamilton StarLet instrument 
(Hamilton Robotics, Bonaduz, Switzerland).
Subsequent analysis was based on the generated fluorescence emission intensity of the VIC 
and FAM reporter dyes divided by the fluorescence emission intensity of the passive reference 
ROX dye (delta Rn value). When both alleles were present, a delta Rn VIC/FAM ratio could be 
established (allele 1/allele 2). This ratio was considered to be informative with regard to the 
relative number of alleles present and therefore a reflection of the allelic (im)balance status. 
Only the SNPs that were heterozygous for a given patient were informative. A schematic 
representation of this experimental scheme is presented in figure 1.
For each informative SNP the VIC/FAM ratios were plotted in a scatterplot. To minimize the 
influence of DNA concentration on VIC/FAM ratio and therefore data interpretation, the 
Table 3   Panel of selected Single Nucleotide Polymorphisms (SNPs). 
SNP nr dbSNP-ID (rs) SNP-ID (hCV) Base (17q) SNP Minor allele frequency
CEU CHB JPT YRI
1 7214151 30187206 34,761,298 C/T 0.38 0.04 0.45 0.46
2 7503195 437172 34,976,041 A/G 0.38 0.04 0.45 0.45
3 876493 7452397 35,078,071 G/A 0.36 0.23 0.43 0.43
4 4795408 30547514 35,361,153 A/G 0.47 0.43 0.47 0.39
5 4794822 31651885 35,410,238 T/C 0.42 0.38 0.39 0.39
6 868150 471861 35,466,885 A/G 0.42 0.34 0.44 0.45
7 2015561 7479296 35,846,755 G/A 0.46 0.44 0.42 0.00
8 4890114 27932396 35,857,075 T/C 0.46 0.44 0.42 0.00
9 8065040 11876205 36,073,767 A/G 0.37 0.43 0.43 0.36
10 10491123 29903401 36,086,722 A/G 0.37 0.44 0.44 0.47
11 7502428 29885409 36,133,740 C/T 0.47 0.44 0.43 0.41
SNP-ID (rs) = reference SNP ID number. SNP-ID (hCV) = Celera SNP ID. Base (17q) = the nucleotide position on 
chromosome 17(q). The HER2 gene is positioned at base 35,097,919-35,138,441, the TOP2A gene at 35,798,321-
35,827,695 (SNP browser software Version 4.0, Applied Biosystems). SNP 1-6 were located up- and downstream of 
the HER2 gene within the  HER2 smallest region of amplification [33]. The remaining 5 SNPs (7-11) were located up- 
and downstream of the TOP2A gene. The particular nucleotide variation is referenced in “SNP”-column. Minor allele 
frequencies are indicated for different populations: CEU, CEPH (Centre d’Etude du Polymorphisme Humain) from 
Utah; CHB, Chinese from Beijing; JPT, Japanse from Tokyo and YRI, Yoruba from Ibadan Nigeria.
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Figure 1  Schematic representation of allelic instability testing by real time PCR based SNP 
detection. A. Possible genotypes, from top to bottom: homozygous allele 1 and homozygous allele 2 
(both non-informative), heterozygous normal and heterozygous imbalance (a 3:1 ratio of allele 1 vs. 2 
and vice versa as a conceptual example). The probe corresponding to allele 1 is labeled with a 5’ VIC 
reporter, the allele 2 probe is labeled with a 5’ FAM reporter. Both probes contain a 3’ black hole 
quencher (BHQ). A = Adenine, T = Thymine, G = Guanine and C = Cytosine. B. The corresponding real 
time PCR component plots of above genotypes of representative SNP 8. X-axis: number of cycles, Y-axis: 
fl uorescence. The arrows indicate the approximate delta Rn of the respective VIC or FAM reporters. C. 
Resulting scatterplot of SNP 8 of encountered genotypes. Dotted ovals indicate hypothetical homo- and 
heterozygous clusters. X-axis: delta Rn VIC, Y-axis: delta Rn FAM.
A B
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delta Rn FAM was corrected. The correction was performed by adapting the delta Rn FAM 
values of the histologically normal samples per SNP according to the crossing point of the trend 
line with the y-axis. This resulted in the translocation of the trend lines of the histologically 
normal tissues so that they all passed through the origin. All delta Rn FAM data of the tumor 
samples were subsequently corrected accordingly.
Statistical analysis allelic instability testing
To gain insight into the distribution of delta Rn VIC/FAM ratios (ratio allele 1/allele 2), the 25th 
and 75th percentiles of the ratios generated by all histologically normal tissues (from the 
control group as well as the group of breast tumor patients) were calculated for each SNP 
assay using Microsoft Offi ce Excel 2007 (Microsoft, Redmond WA, USA). The distance 
between these percentiles represents the interquartile range (IQR), which was used to 
establish cut-off values for the normal ratio distribution per SNP. The +1.5 IQR and -1.5 IQR 
were taken as cut-off value for normal ratio distribution for 10/11 SNPs (all SNPs except SNP 3). 
All ratios with an IQR of <1.5 follow normal distribution and were interpreted as genetically 
stable with regard to the HER2/TOP2A locus. Ratios plotted within 1.5-3 x IQR were considered 
equivocal with regard to HER2/TOP2A allelic instability status. Ratios plotted ≥3x IQR were 
considered to be representative for HER2/TOP2A allelic instability. Due to the large IQR 
generated using SNP 3 (varying from 2.3 to 15.1 times as large as found with the other SNPs), 
the cut-off values for that particular SNP were defi ned as follows: normal = -1 to +1 IQR; 
equivocal = 1-2 IQR and ≥2 IQR = indicative of allelic instability.
When a sample generated an equivocal result for any of the employed SNPs, the analysis of 
that particular sample was repeated in duplicate (with non-diluted DNA and with 5-fold 
Figure 1  Continued.
C
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diluted DNA in Tris Low EDTA buffer) using the respective SNP. When 2/3 results corresponded, 
the sample was called accordingly (e.g. equivocal/equivocal/normal was called equivocal). 
When results were conflicting, the sample was called equivocal (e.g. equivocal/allelic 
instability/normal).
Results
Two patient groups were used in this study: a control group of 10 histologically normal 
tissues from patients (CT1-10) with no breast tumors and a group of 44 breast tumor patients 
with different entities of primary breast cancer (HER2+1-15, TN1-16 and ERPR+1-13) of which 
both tumor and normal tissues were available. 
SNP selection
Technical validation of the selected SNP assays was performed using the 10 histologically 
normal breast tissues from the control group. All SNP assays had a sufficient sensitivity, 
yielding cycle-threshold values of <35 (threshold 0.007), a cut-off above which results are 
routinely considered less reliable in our laboratory. In addition, little or no cross-reaction of 
the SNP assays’ allele 1 corresponding probes (VIC reporter) with allele 2, and of the allele 2 
corresponding probes (FAM) with allele 1 was observed. This resulted in clear clustering of 
homozygous allele 1, homozygous allele 2 and heterozygous patients. The panel of 11 SNP 
markers (table 3) was therefore used to analyze the clinical specimens (table 1 and 2).
SNP analysis of patient materials
To minimize the influence of DNA concentration on VIC/FAM ratio and therefore data 
interpretation, a correction on all delta Rn FAM data was performed as described in the 
Materials and Methods section. Figure 2 shows the corrected scatterplot of representative 
SNP 8 for histologically normal tissues from the control group and paired histologically normal 
and tumor samples of all patients in the breast tumor group. Ratios of each sample pair 
(histologically normal and tumor tissues) were connected. 
Subsequently, the delta Rn VIC/FAM ratios of all informative SNPs of the histologically normal 
tissues from both groups (10 tissues from the control groups and 44 tissues from the breast 
tumor group) were used to gain insight in normal data distribution. Combining the data of 
the histologically normal tissues from these groups was justified due to the mutual similarity 
of delta Rn VIC/FAM ratio distribution amongst both groups. To determine the HER2/TOP2A 
allelic (im)balance, fluorescent ratios of the panel of 11 informative SNP’s were analyzed using 
the cut-off values based on the interquartile range of data distribution amongst the 
histologically normal samples.
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Histologically normal tissues 
As expected, all informative SNP results (total of 54 SNPs of 10 patients) of the breast tissues 
from the control group fell within the normal IQR range (-1.5 to 1.5 IQR for SNP 1, 2 and 4-11 
and -1 to 1 IQR for SNP 3). Overall results are depicted in table 1, fi gure 2 represents the 
corrected scatterplot of representative SNP 8.
The 44 histologically normal samples of the breast tumor patient group generated SNP results 
that fell within the normal IQR range and are therefore in agreement with the normal range 
observed in the control group. Only 1 out of the total of 208 informative SNPs yielded an 
equivocal result (patient TN2, SNP 11, triplicate analysis yielded 2 equivocal results and 1 
result was found to indicate allelic instability). 
Figure 2  Visualization of VIC/FAM ratios that were generated using representative SNP 8 
after FAM correction. Scatterplot of SNP 8 analyses of histologically normal tissues from the control 
group and paired histologically normal and tumor tissues from the group of breast tumor patients. 
Connected symbols indicate normal and tumor tissue of a single patient. X-axis: delta Rn VIC (T = 
Thymine), Y-axis: corrected delta Rn FAM (C = Cytosine).
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Breast tumor tissues 
Results of IHC and SISH are depicted in table 2. The SNP assays were used to investigate in more 
detail the genomic composition of the HER2/TOP2A locus. The results are summarized in table 2. 
HER2+ group
Within the group of patients with tumors overexpressing HER2, the SNP data of patients 
HER2+ 2-5 and 7-15 were consistently indicative of an instable HER2/TOP2A locus. IHC scores 
were 3+, SISH ratios were 2.0-15.2 and TC% ranged from 40 to 80%. SNP 1 in patient HER2+ 
8 generated an equivocal result. SNP results from patient HER2+ 1 and 6 showed inconsistent 
results between informative SNPs. All informative SNPs were therefore subsequently repeated 
in duplicate for these patients yielding identical results. SNP results from patient HER2+ 1 
showed allelic balance of SNPs 8 and 9, whereas results from SNPs 1 and 10 were found to 
indicate allelic instability. IHC yielded a 3+ score, whilst the SISH ratio was 1.1. The sample 
had a TC% of 30%. SNP results from patient HER2+ 6 were also inconsistent. SNPs 1, 2 and 
8 were indicative of allelic stability, while results from SNPs 4, 7 and 11 showed allelic 
instability. IHC, SISH ratio and TC% in this patient were 3+, 4.1 and 80%, respectively. 
Triple negative group
In the triple negative group, patients TN1-4, 6, 9, 10 and 12-16 showed SNP results consistent 
with instability of the HER2/TOP2A locus. IHC scores, SISH ratios and TC% varied from 0-2+, 
0.7-1.9 and 25-90%, respectively. Several SNPs generated equivocal results in patients TN1 
(SNP 3 3x equivocal), 3 (SNP 4 3x equivocal), 8 (SNP 1 2x equivocal, 1x normal and SNP 2 3x 
equivocal), 10 (SNP 3 2x equivocal, 1x allelic instability) and 13 (SNP 1 and 3 both 3x equivocal). 
Patients TN5, 7 and 11 revealed no signs of HER2/TOP2A allelic imbalance, IHC scores were 
0-1+, SISH yielded ratios of 1.1-1.6 and the samples contained 30-95% tumor cells. In patient 
TN8, the 2 SNPs that were informative (SNPs 1 and 2) yielded equivocal results. IHC score, 
SISH ratio and TC% for this patient were 1+, 0.9 and 70%, respectively.
Estrogen and progesterone positive group
From the ERPR+ group, patients ERPR+1-3, 6 and 7 yielded SNP results indicative of HER2/
TOP2A locus instability. IHC scores, SISH ratios and TC% varied from 0-1+, 0.5-1.1 and 
30-70%, respectively. Equivocal results were generated in patients ERPR+3 (SNP 3 3x 
equivocal) and 7 (SNP 3 1x equivocal, 1x allelic instability and 1x normal). The ratio of SNP 3 
was found to be equivocal (equivocal, allelic instability and normal) in patient ERPR+7. The 
breast tumor tissues from patients ERPR+4, 5 and 8-13 showed a stable HER2/TOP2A locus, 
IHC scores were 0-1+, SISH ratios ranged from 1.0-1.5 and a TC% was 50-70%. Patient 
ERPR+8 and 11 generated an equivocal result utilizing SNP 8 (2x equivocal, 1x allelic instability) 
and 4 (3x equivocal), respectively. 
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Discussion
We have shown that the presented SNP based real time PCR assay is easy to perform and can 
be employed to reveal allelic instability of the HER2/TOP2A locus in breast tissues. The assay 
yielded results that fell within the normal range of data distribution in the control tissues. SNP 
results were consistent (all informative SNPs stable or instable) within most (42/44) tumor 
samples and were indicative of abundant allelic imbalance in HER2 amplified and TN tissues. 
In all patients (15/15) where HER2 overexpression was observed by IHC, SNP results were 
found to be indicative of HER2/TOP2A allelic instability. In 2 patients conflicting results 
between informative SNPs were found. In one sample (patient HER2+ 1), SNP 1 (instable in 
2/3 observations and 1 equivocal) and SNP 10 results showed allelic instability while no allelic 
instability was observed for SNP 8 and 9. SISH analysis of this sample revealed no genomic 
amplification of the HER2 locus. This possibly implies a false positive IHC result or HER2 
overexpession not related to gene amplification, which has been reported in 3-8% of breast 
tumors [34-36]. However, the SNP assay did show the presence of a genetic aberration of 
part of the locus under investigation. Additionally, in patient HER2+ 6, allelic instability was 
observed for 3 non-contiguous SNPs out of 6 informative SNPs. The other 3 non-contiguous 
SNPs showed results indicative of a stable HER2/TOP2A locus. These observations may be the 
result of a combination of relatively small genetic aberrations each affecting part of the locus. 
In the TN group, 75% of the tumor samples (12/16) showed results indicative of allelic 
instability of the HER2/TOP2A locus. This is in line with previous findings where the complex 
genomic profiles, with numerous gains and losses, of these tumors were classified as 
“sawtooth patterns” [23-28]. Nineteen percent of the TN patients (3/16) yielded results that 
were representative of a stable HER2/TOP2A locus. In one sample (patient TN8) the only 2 
informative SNPs were found to be equivocal, making the overall result with regard to the 
stability of the HER2/TOP2A locus equivocal. 
Within the ERPR+ group, 38% of the tumor samples (5/13) yielded results representative of 
allelic instability of the HER2/TOP2A locus, whilst 62% (8/13) did not. Patient ERPR+ 7 showed 
discordant results in SNP 3, which was therefore concluded to be equivocal. Although the 
biological and/or technical rationale behind this observation remains unclear, we believe that 
it is justified to conclude that this sample harbors HER2/TOP2A allelic instability due the data 
of the remaining 5 informative SNPs. Beside the HER2 normal tissue, patient ERPR+11 also 
harbored HER2 amplified tumor tissue, which was most likely caused by the presence of a 
second tumor or tumor heterogeneity. The tissue included in this study, which had a stable 
HER2/TOP2A locus, was not HER2 amplified and was ERPR positive. This patient was therefore 
included in the ERPR+ group. 
High chromosome instability, detected using FISH, in breast tumors is of prognostic value 
with regard to clinical outcome and may be useful in predicting response to AC-based therapy 
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[31], since topoisomerase is targeted by AC. It is of particular interest whether these 
observations are also true for the allelically imbalanced groups found amongst the TN and the 
ERPR+ patient groups using the presented SNP based assay. Although the number of samples 
in our study is limited, the portion of tumor samples that contain HER2/TOP2A allelic instability 
in the TN and ERPR+ group (75% and 38%, respectively) roughly corresponded to the 
AC-based chemotherapy response rates found within these groups (85% and 47%, 
respectively) [37]. A future study analyzing patients with available 5 year clinical follow-up 
data is needed to support this observation. 
Overall, 8 out of 10 tissues where part of the tumor cells harbored polysomy of chromosome 
17, which was detected by the chromosome 17 centromeric probe included in the SISH assay, 
showed SNP results indicative of allelic instability. The SNP observations however may be the 
cumulative effect of several genetic aberrations including the polysomia. Reflection of 
monosomy and trisomy of chromosome 17 in the SNP results was less evident. In all tumors 
where aneuploidy chromosome 17 was observed, heterogeneity was observed with regard 
to chromosome 17 status as well. 
SNP 3 cut-off values were adapted due to its large normal ratio distribution. Employing 
identically calculated cut-off values for SNP 3 would lead to the unjustified normal/equivocal 
calling of samples that clearly demonstrate a deviant VIC/FAM delta Rn ratio based on the 
generated scatterplot (data not shown). 
The single anomaly concerning SNP 11 that was found aberrant in a histologically normal 
sample from the breast tumor group may be caused by a small deletion, point mutation(s) or 
a small recombination event around the involved SNP. Although sequencing of this SNP locus 
of this particular patient is of interest, it is beyond the scope of this study.
Although the SNP test performed well, some drawbacks may be encountered. When 
analyzing a heterogeneous tumor tissue, unjustified (im)balance calling may occur. The 
resolution per SNP is relatively low, which may lead to an inconclusive result when (a large 
part of) the employed SNPs are homozygous and therefore non-informative. However, this 
issue is easily overcome by increasing the number of SNPs to be analysed. Additionally, the 
SNP test is well suited for the detection of copy number variations, but is not able to distinguish 
between various underlying mechanisms (e.g. gains vs. losses). SNP assays have a limited 
sensitivity, around 20% “mutant” DNA extracted from whole blood is detectable in a 
“wildtype” background [32]. For FFPE tissues, this sensitivity might be even somewhat lower. 
Therefore, to prevent false negativity with regard to allelic instability, the minimum tumor cell 
percentage was set at 25%. This implies that allelic imbalance in minor tumor cell populations 
may have stayed unnoticed.
To minimize the effect of pipetting inaccuracy and to prevent pipetting errors, manual liquid 
handling was reduced to a minimum by performing all initial PCR setups using a Hamilton 
StarLet robot. Any inaccuracies or errors with regard to pipetting could negatively influence 
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the determination of the natural ratio distribution of the histologically normal tissues and 
ultimately the allelic stability vs. instability calling.
In summary, the presented SNP methodology is easy to perform when compared to other 
copy number variation detection techniques such as array based systems targeting SNPs and 
Comparative Genomic Hybridization and corresponds well to positive SISH results. The real 
time PCR based SNP test may have an added value in the TN as well as the ERPR+ patient 
group. Within these groups, 75% of the TN and 38% of the ERPR+ tumors showed allelic 
instability with the SNP based assay. To determine such a possible added value of the 
presented SNP test a large-scale study should be performed. Ample size TN and ERPR+ 
patient groups with 5 year clinical follow-up data should be included to assess whether the 
determination of allelic instability of the HER2/TOP2A locus as a marker has clinical relevance 
and is of any significance for therapeutic decision making. 
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8.1 SUMMARY AND GENERAL DISCUSSION
Since the discovery of Nuclein by Friedrich Miescher during the winter of 1868/1869 [1], later 
named DNA [2, 3], great scientific progress has been made in the fields of biotechnology and 
genetics. The development of DNA sequencing and the polymerase chain reaction (PCR) 
accelerated developments leading to a new era in science and medicine [4, 5]. Using these 
techniques scientists were able to study specific DNA regions of interest, leading to the 
identification of variations in oncogenes and tumor suppressor genes (TSGs). Upon completion 
of the Human Genome Project (HGP), data on the complete human genome, including 
genomic diversity, became available [6-8]. The most common sequence variations found 
were Single Nucleotide Polymorphisms (SNPs), occurring approximately once every 100-1000 
base pairs [9, 10] and are defined as a difference of a single base occurring at a particular 
genomic location [11]. Additionally, the term SNP is often used limited to single base variations 
with a frequency of occurrence of at least 1% in a particular population and to those that are 
non-disease conferring. Variations that do not meet these criteria are considered to be 
mutations rather than polymorphisms. Both restrictions however pose a dilemma. Firstly, a 
SNP in one population should be considered a mutation in the other due to population 
dependent occurrence of >1% vs. <1%. Secondly, a disease causing mutation of a single 
nucleotide in one individual could hypothetically be non-disease conferring in another and 
therefore should be considered a SNP. To overcome these issues the term SNP is used 
throughout this thesis as a single base variation on a certain genomic position regardless of 
occurrence and disease causing potential, that persists in a population. 
Each individual has a unique set of these SNPs, ones SNP genotype can therefore be 
considered as a genetic fingerprint. SNPs occur less frequent in coding regions when 
compared to non-coding regions. Obviously, when located in a coding region a SNP may 
have a direct effect on the encoded protein [11-13]. SNPs in non-coding regions however, 
may still have a functional effect due to altered expression of the protein involved [14-16]. 
Because of the large amount of SNPs throughout the entire human genome and their possible 
effect on encoded proteins and gene expression, variations in SNPs do attribute largely to 
human phenotypic diversity. Because of their presence throughout the genome and frequent 
occurrence, SNPs are hypothesized to be highly useful markers with regard to tissue 
identification and loss of heterozygosity (LOH) and allelic instability testing of cancer critical 
stretches of DNA.
8.1.1. Technological advances
Due to several technological advances during the last decade(s) the use of routine molecular 
techniques has increased greatly. Currently, (real time) PCR is often the technique of choice 
of many routine molecular laboratories for a diverse range of diagnostic applications. At 
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present, routine tests include for example the detection of bacteria and viruses [17-23], neo-
plasm-associated mutations [24-26] and up- and down-regulation of mRNA’s [27]. The (real 
time) PCR technique is therefore widespread and many laboratories are skilled users. However, 
more “specialized” molecular techniques are currently used for various purposes such as 
tissue identification with regard to sample mix-ups, LOH testing of clinically relevant genomic 
loci in neoplasms and allelic imbalance of cancer critical genes. Real time PCR is an excellent 
and relatively easy tool to detect SNPs and it may therefore be particularly useful when 
detecting SNPs with regard to these applications. 
CHAPTER 2 | OPTIMIZING DNA EXTRACTION
In several studies described in this thesis, extraction of DNA from formalin-fixed paraffin-
embedded (FFPE) tissues is an important primary process on which the reliability of the 
downstream analysis partly depends. DNA extraction from FFPE tissues suffers from difficulties 
due to formalin-fixation induced cross-links between tissue proteins and DNA, which may 
result in blocking of amplification. Secondly, DNA may be fragmented due to aging of the 
specimen or the pH of the fixative [28].
In chapter 2, a comparative analysis of four DNA extraction methods is described for 
extraction of DNA from FFPE tissues. The methods tested were heat-treatment, QIAamp, 
EasyMAG and Gentra. All methods were tested with and without proteïnase K digestion as 
a pretreatment. The resulting DNA extracts were tested regarding i) the cumulative effect of 
extraction efficiency and PCR inhibition by monitoring amplification of an internal control 
DNA virus, ii) the performance in SNP analysis by real time PCR and iii) performance in a 
conventional multiplex PCR amplifying 200, 400 and 600 bp human DNA fragments. Gentra 
DNA extraction was found not suitable for purifying DNA from FFPE samples in general. This 
was possibly due to the method’s inability to remove protein-DNA cross-links and insufficient 
lysis, both resulting in the loss of DNA during washing steps. Proteïnase K digestion was 
found to be indispensable for optimal DNA purification from FFPE tissues, as was previously 
described [29, 30]. Although the heat-treatment, QIAamp and EasyMAG methods were all 
successful in extracting DNA, the latter two methods performed best for real time SNP 
detection. Amplification of the 400 and 600 bp amplicons was found to be most successful 
using QIAamp extracts followed by the use of extracts from heat-treatment and EasyMAG. 
Hands-on-time was lowest using heat-treatment followed by EasyMAG and QIAamp (when 
extracting 24 samples: approximately 60 min. for QIAamp versus 5 min. for heat-treatment 
and 25 min. for EasyMAG). 
We concluded that the extraction methodology strongly influences the downstream 
molecular analyses, which is in line with previous findings [28, 31-35]. Therefore, the choice 
of which extraction is best to be employed should be based on the envisioned downstream 
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molecular analyses. For the experiments described in this thesis, when extracting DNA from 
FFPE tissues in combination with real time PCR based detection of SNPs, the EasyMAG 
extraction method was found most suitable.
CHAPTER 3 AND 4 | CONFIRMING THE IDENTITY OF HUMAN TISSUES 
Although specimen identification is a carefully controlled factor during pre-laboratory 
handling in clinical laboratories, mislabeling does occur. Unfortunately, the patients involved 
may suffer from severe consequences due to these sample mix-ups. Therefore issues of 
potential sample mix-up need to be addressed. When focusing on surgical pathology and its 
main sample type, FFPE tissue, error rates are reported ranging from 0.08 to 1.2% [36-41]. A 
second widely used patient material for diagnostic and treatment related purposes is serum. 
The percentage of mislabeling when handling serum is estimated to be around 0.1% [42-45]. 
These error rates further emphasize the need for thorough identification of clinical samples 
to address suspected mix-ups. Numerous techniques for the detection of specimen mix-ups 
have been described. Most rely on characterization of DNA repeats [46-48], human leukocyte 
antigen system (HLA) [49-54], or other polymorphic genetic loci [50]. In addition, commercial 
identification kits are available [55-57]. However, implementation of these methods is 
hampered by several issues such as the need for expensive sequencing equipment, 
contamination risk caused by post-PCR processing, poor DNA quality (FFPE tissues) and low 
DNA quantity (serum). To overcome these issues, a SNP profiling assay suitable for identity 
confirmation of FFPE tissues and serum samples was developed and described in chapter 3 
and 4. The assays applicability was demonstrated by means of several cases of potential 
mix-ups.
To maximize the chance that an individual could be distinguished based on their SNP profile 
while analyzing a limited number of SNPs, a symmetrical distribution of alleles (minor and 
major allele frequencies of approximately 0.5) was chosen. A panel of 17 SNP assays, targeting 
SNPs distributed over 16 different chromosomes, was selected. Three SNPs were excluded 
from the final recommended panel of SNPs due to a significantly (chi-square test; P value of 
<0.05) differing allele frequency within the population tested. Four SNPs (2 of which were 
also excluded due to deviant allele frequencies) were excluded based on an in silico 
investigation of all 17 SNPs on whether the SNP loci were located in frequent LOH regions. 
Finally, 2 SNPs were excluded based on their technical limitations. Employing a final panel of 
10 SNPs with an approximate MAF of 0.5 and assuming their genotype frequencies to be in 
the Hardy-Weinberg equilibrium [58, 59], the chance for 2 randomly chosen individuals to 
have the same SNP profile is 1 in 18,000. All described cases of potential sample mix-up (total 
n=7; FFPE tissues n=6; serum samples n=1) were resolved and our findings were confirmed 
by additional histological and serological testing, respectively.
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The currently available assays have an extraordinary high average probability of identity of up 
to 5 x 1012. Evidently, such high average probabilities of identity are needed in court. For use 
in cases of potential mix-ups however, the accuracy of our test (1 in 18,000 average probability 
of identity) appeared sufficient in all cases handled so far. If a higher accuracy is necessary, 
the average probability of identity generated by our SNP profiling assay could easily be 
enlarged by increasing the number of SNP assays included. When analyzing 20 or even 30 
SNPs with approximate allele frequencies of 0.5, the discriminatory power of our test would 
rise to 3.3 x 108 and 6 x 1012, respectively. SNP profiling has the advantage that very small 
stretches of DNA (around 80 bp) are amplified in contrast to other techniques requiring up to 
360 bp. Furthermore, SNP profiling can be performed on any standard real time PCR cycler 
and does not need expensive sequencing equipment. Other significant advantages of our 
real time PCR based procedure are its quick turnaround time and the lack of post-amplifica-
tion handling, strongly reducing the risk of amplicon contamination.
CHAPTER 5 | DETERMINING JAK2V617F MUTATIONAL STATUS 
The Janus Kinase 2 (JAK2) gene encodes the JAK2 tyrosine kinase [60]. JAK2 plays a major 
role in mediating cytokine-signaling and therefore has a large impact on haematopoiesis [61]. 
A G-to-T missense mutation in JAK2 results in a valine-to-phenylalanine (V-F) amino acid 
substitution at codon 617 (JAK2V617F) and subsequently constitutive activation of the 
JAK-STAT pathway [60, 62-66]. JAK2V617F is commonly found in myeloproliferative diseases 
(MPD), such as polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic 
myelofibrosis (IMF) [62-65]. In addition to mutation detection, a correlation between 
JAK2V617F mutant allele burden and severity of disease has been postulated [67-76].
To assess the JAK2V617F mutational status in patients suspect of MPD a real time PCR suited 
for sensitive detection and quantification of this mutant allele amongst wild-type DNA was 
developed and described in chapter 5. 
To maximize the sensitivity of our real time PCR, amplification of the wild-type allele was 
blocked. Two different blockers were tested, one was a locked nucleic acid (LNA) oligonucle-
otide the other a peptide nucleic acid (PNA) oligonucleotide. Sensitivity and linearity of both 
blocking strategies were compared by determining the limit of detection using twofold (v/v) 
serial dilutions (0.006% to >97% JAK2V617F DNA diluted in wild-type DNA) of genomic 
DNA from a patient with PV in genomic DNA of a JAK2V617F negative donor. The assay 
combined with the PNA oligonucleotide linearly detected JAK2V617F with a for quantification 
acceptable (mean Ct-value ± 1 Ct) reproducibility ranging from approximately 0.05% to 97%. 
This range was determined for the real time PCR with the LNA oligonucleotide to be 0.2% to 
97%. The developed real time PCR assay in combination with the PNA oligonucleotide has 
an equal sensitivity to techniques such as allele-specific PCR/amplification refractory mutation 
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system, allelic discrimination, and PCR-MALDI-TOF. A similar real time PCR employing an LNA 
blocking oligonucleotide described in 2006, yielded a sensitivity of 0.01% [77, 78]. However, 
it’s sensitivity was determined using a HEL cell line, which is known to carry more than two 
mutant alleles per cell, instead of patient DNA [79]. When analyzing a cohort of 100 healthy 
individuals (blood donors) of <30 years of age utilizing the real time PCR in combination with 
the PNA oligonucleotide a background signal was observed in 9% of the healthy donors. In 
one healthy donor a weak positive/background signal was observed in duplicate. Firstly, 
these background signals could be caused by technical limitations of the assay. Secondly, 
JAK2V617F could in fact be present in these patients in an extremely small amount of 
circulating cells. Although similar observations have been made with other JAK2V617F assays, 
its clinical significance remains unclear [78, 80, 81]. To prevent false positives in a clinical 
setting a cut-off Ct-value of ≥37.9 (based on the mean Ct-value of the negative cohort ± 
3*SD) was determined. 
The presented assay has been employed for diagnostic use for over a year. The generated 
results indicate a robust and rapid test with excellent reproducibility: the overall CV with 
different batches of controls, reagents, and various real time PCR cyclers was 1.5% for the 
1% JAK2V617F control (n = 27) and 1.4% for the 50% JAK2V617F control (n = 24). Because 
reproducibility is essential for a reliable quantitative assay [82] these observations confirm 
that the developed assay is well suited for the intended application.
CHAPTER 6 | LOSS OF HETEROZYGOSITY OF THE JAK2 GENOMIC REGION 
Loss of heterozygosity (LOH) is a genetic incident where heterozygosity at a chromosomal 
locus within an organism’s germline DNA is lost in a somatically altered (cancer) cell. LOH can 
therefore contribute to the accumulation of genetic alterations during carcinogenesis [83-85]. 
LOH may occur through several major mechanisms such as partial and whole chromosome 
loss [83, 86]. Another LOH causing mechanism is mitotic recombination leading to acquired 
uniparental disomy (aUPD) [62, 87]. When aUPD is preceded by an oncogene activating 
mutation, such as JAK2V617F, resulting in homozygosity of the mutant allele, the effect of 
the mutation may be further potentiated [62]. JAK2V617F mutant allele burdens in general 
and mutant allele burdens of >50% in PV and ET are correlated with severity of disease 
[67-72, 74-76]. In the case of aUPD, conventional cytogenetic analyses techniques are not 
able to detect such an abnormality [88]. Currently, STR typing and SNP oligonucleotide 
genomic microarrays are used to assess LOH status [88]. Both techniques however are less 
accessible to routine molecular diagnostic laboratories, hampering the implementation of 
these clinically relevant diagnostic tools.
A real time PCR based SNP assay was developed to detect LOH of the JAK2 region and is 
described in chapter 6. The LOH test consisted of a panel of 10 real time SNP PCRs. Obviously, 
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when testing for LOH only heterozygous SNPs are informative. To maximize the chance that 
an observed SNP profile was informative only SNPs with an approximate MAF of 0.5 were 
included in the SNP panel. To determine which SNPs were informative, the germline SNP 
profile was determined for all included patients using archived, non-neoplasm related FFPE 
tissues.
The JAK2V617F detection and quantification assay described in chapter 5 was used to select a 
group of 12 blood samples containing the JAK2V617F mutation. Six of these harbored a mutant 
allele burden of 25-50% and the remaining 6 above 50%. This panel was used to test our 
JAK2LOH SNP assay. Subsequently, 81 patients suspect of a myeloproliferative neoplasm (MPN) 
were tested with the JAK2LOH assay and the JAK2V617F mutational status was determined. All 
93 samples were simultaneously tested with regard to JAK2LOH status using an STR assay as 
previously used by Kralovics and coworkers in 2005 [62]. In the JAK2V617F-positive patient 
cohort 2 of the 5 patients with a mutant allele burden of 25-50% harbored JAK2LOH. This 
indicates that in addition to JAK2V617F detection and quantification, determining the JAK2LOH 
status is of value as well. These findings are in line with those of Scott and colleagues, describing 
that a large number of PV patients harbor homozygous subclones, which may predominate 
over time [89]. As expected all 6 patients with a mutant allele burden larger than 50% were 
found to have JAK2LOH. In the patients suspect of MPN cohort a total of 6 patients were found 
to have JAK2LOH. In none of the JAK2V617F-negative patients JAK2LOH was detected. 
Considering the STR assay to be the gold standard, our SNP assay had a sensitivity and negative 
predictive value of 100% for both the JAK2V617F-positive patient cohort and the patients 
suspect of MPN cohort. Positive predictive values of the SNP assay were 85.7% and 100% and 
the specificity was 80% and 100% in the respective cohorts. The SNP assay was found to have 
a higher success rate than the STR assay (3 vs. 9 non-informative profiles) in this population. 
Additionally, the SNP assay was found to provide more detailed information with regard to 
ROH/LOH status of the JAK2 gene and surrounding loci.
CHAPTER 7 | ALLELIC IMBALANCE AT THE HER2/TOP2A LOCUS 
Breast cancer is a heterogeneous disease displaying a diverse variety of biological features. 
The estrogen and progesterone receptors (ER, PR) are proteins well known to be expressed 
excessively by these tumors [90-92]. Categorizing breast cancers based on the level of 
expression of these proteins is utilized for the prediction of clinical outcome and therapy 
selection [93]. Available treatments in ER and PR positive breast cancer cases are e.g. 
Tamoxifen and aromatase inhibitors [90-92]. 
The HER2 oncogene encodes the human epidermal growth factor receptor 2 protein [94, 95]. 
HER2 plays a pivotal role in the integrate network of HER signal transduction involving a 
multitude of pathways [96-98]. HER2 amplification, found in approximately 25-30% of 
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breast cancers, results in HER2 overexpression and subsequent overstimulation of the 
pathways involved [96, 99]. Patients with HER2 amplified breast tumors benefit from 
treatment with Trastuzamab (Herceptin), a monoclonal antibody that is thought to block 
HER2 mediated HER signal transduction [100, 101]. The juxtaposed TOP2A gene encoding 
toposiomerase II alpha coamplifies in 30-45% of HER2 amplified cases [102-104]. TOP2A is 
an enzyme that catalyzes the topological DNA changes needed during cell division [105]. 
TOP2A amplification is a favorable characteristic in patients treated with anthracycline (AC)-
containing adjuvant chemotherapy [102-104]. The opposite is true for TOP2A deletion, which 
is found in 15-40% of HER2 amplified cases [102-104]. ACs are chemotherapeutic agents 
known to exert TOP2A inhibiting properties. It is these properties that are suggested to be 
the biological rationale behind the added benefit from adjuvant AC therapy in tumors with 
TOP2A amplification [105-107]. In fact, the association of improved AC response rates in 
HER2 amplified tumors is now suggested to be attributed to TOP2A coamplification [104]. 
Tumors lacking ER, PR and HER2 overexpression are defined as “triple negative” (TN) breast 
tumors. TN tumors are associated with poor clinical outcome and lack of (currently) available 
targeted therapy [108, 109]. In addition to these well established biological characteristics, 
distinct gene-expression profiles and genetic alterations may yield added information suitable 
to subcategorize these breast cancer types [110-116]. Copy number alteration of the genomic 
region incorporating the HER2/TOP2A locus is suggested to be a marker for the degree of 
chromosomal instability in breast cancer [117, 118]. The higher degree of chromosomal 
instability has been associated with better response to adjuvant AC-based chemotherapy [114]. 
To be able to employ such HER2/TOP2A allelic instability as a possible adjuvant molecular 
marker in a diagnostic setting, a real time PCR based SNP assay was developed and described 
in chapter 6. Eleven SNPs on the HER2/TOP2A locus were selected. The SNPs were chosen 
based on their location within the smallest region of HER2 amplification (SNP 1-6) [119] and 
up- and downstream of TOP2A (SNP 7-11). Additionally, SNPs were chosen with a MAF of 0.5 
amongst different ethnic groups to maximize the informative value of the assay independent 
of patients’ ethnicity. The germline SNP profile of each patient was determined by analyzing 
a histologically normal breast or lymph node FFPE tissue.  
Fourty-four patients with 3 different entities of primary breast cancer were included: 1) a 
HER2 overexpressed (HER2+) group (n=15), 2) a triple negative (TN) group (n=16) and 3) a ER 
and PR positive (ERPR+) group (n=13). As a control group, histologically normal FFPE tissues 
of 10 patients with no breast tumor were included. As expected, all informative SNP results 
from the breast tissues in the control group fell within the range of normal data distribution. 
In the histologically normal samples from the 44 breast tumor patients, only 1 of 208 
informative SNPs was found to be equivocal, indicating well established cut-off values for 
statistical allelic (im)balance calling. Amongst the HER2+ group, all patients (15/15) showed 
SNP results indicative of allelic imbalance. In 2 patients, a portion of SNP results were 
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indicative of allelic imbalance, while the remaining SNPs were normal. These observations 
were possibly caused by several small mutations each affecting part of the locus involved. Of 
the 16 triple negative tumors, 12 (75%) displayed instability. This is in line with previous 
findings where the complex genomic profiles, with numerous gains and losses, of these 
tumors were classified as “sawtooth patterns” [110-115]. Three (19%) samples from the TN 
group displayed no instability, and 1 was inconclusive. Of the 13 hormone receptor positive 
tumors, 5 (38%) displayed allelic imbalance, while 8 (62%) did not. Although the number of 
samples in our study is limited, the portion of tumor samples that contain HER2/TOP2A allelic 
instability in the TN and ERPR+ group (75% and 38%, respectively) roughly corresponded to 
the AC-containing adjuvant chemotherapy response rates found within these groups (85% 
and 47%, respectively) [120]. To establish whether the presented SNP test provides added 
diagnostic value, a clinical study should be performed in which ample size TN and ERPR+ 
patient groups are included with 5 year clinical follow-up data. Such a study could provide 
information with regard to allelic instability at the HER2/TOP2A locus as a marker for the 
prediction on clinical outcome and its possible use for therapeutic decision making. 
8.2  VENTURING BEYOND THE SCOPE OF THIS THESIS: 
BACTERIAL SNP GENOTYPING
In addition to the focus on various human diagnostic applications of real time PCR based SNP 
profiling, we investigated its employability in bacterial genotyping. 
During a 4-year period, from 2007 to 2010, The Netherlands was confronted with the largest 
Coxiella burnetii –the causative agent of Q-fever [121, 122] - epidemic ever, with approximately 
3,500 notified human cases at the end of 2009 [123]. Since epidemiological data concerning 
this outbreak were lacking and no direct typing method was available at that time we set out 
to explore the possibilities of C. burnetii SNP genotyping. A panel of 10 discriminatory SNPs 
was firstly used to genotype an international panel of 28 reference strains, which were 
previously typed by Multi Locus Sequence Typing (MLST) [124, 125] and 5 commercial strains. 
Secondly, 40 outbreak related samples (14 of human origin and 26 of animal origin) were SNP 
genotyped. Thirdly, the developed SNP genotyping assay was employed to determine 
whether the mandatory vaccination of dairy goats with the formalin inactivated Coxevac® C. 
burnetii vaccine could result in excretion of C. burnetii (DNA) in the milk. Such false positive 
bulk milk results could lead to an unjustified culling of animals. Six adult dairy producing 
goats were subcutaneously inoculated twice with Coxevac® and 2 were not inoculated as 
negative controls. 
The international panel revealed a total of 9 SNP genotypes, representing 14 MLVA types. 
The outbreak panel consisted of a broad spectrum of human and animal sample types on 
which SNP genotyping could directly be successfully employed. We were able to identify 5 
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distinct genotypes: 3 in human samples and 4 in samples derived from livestock. This implies 
that environmental circumstances (such as the high density of farms and people in the same 
area, dry periods during spring) rather than one highly virulent C. burnetii strain favored the 
Dutch Q fever spread. In the six vaccinated goats, C. burnetii DNA became detectable in milk 
samples from a few hours after the first vaccination until day 10. The 2 control goats remained 
negative throughout the experiment. SNP profiling showed an identical profile to that of the 
Coxevac® vaccine, which was not observed in any other outbreak related sample. This strongly 
indicates the vaccine being the source of the C. burnetii DNA in milk. Our observation had 
implications for the policy of the Dutch Ministry of Agriculture, Nature and Food Quality to 
combat the spread of the ongoing Q fever epidemic in the Netherlands. The strategy of 
simultaneous vaccination of dairy goats and bulk tank milk testing to identify contaminated 
farms was reconsidered and a 2-week interval between vaccination and bulk tank milk testing 
was imposed.
Our findings were published in Applied and Environmental Microbiology [126] and Vaccine 
[127] in 2011.
8.3 CONCLUDING REMARKS
As demonstrated by the studies described in this thesis, real time PCR based SNP profiling 
currently has a broad range of diagnostic applications. In combination with the relative ease 
of implementation of the technique in any molecular laboratory makes real time SNP profiling 
an attractive diagnostic tool. We therefore hypothesize that the presented assays form a 
starting point for the development of other clinically relevant diagnostic tests with regard to 
loss and/or gain of cancer critical stretches of DNA and possibly even interlaboratory bacterial 
genotyping. Additionally, broad implementation and use of the SNP assay to confirm the 
identity of all human clinical samples in a hospital setting would result in an improved securing 
of downstream evaluations and critical decisions concerning the patients involved. To realize 
this concept, the number of targeted SNPs should be increased to reach sufficient 
discriminatory strength. The costs could be reduced drastically by performing the 
corresponding real time PCRs in small reaction volumes (<5 µl) using 384- or even 1536-well 
platforms.
Ultimately, whole genome sequencing could make many currently employed molecular 
diagnostic assays redundant in the future, including real time PCR based SNP profiling. 
However, the corresponding equipment and techniques needed are very expensive and not 
accessible for most molecular laboratories. Additionally, analysis of the extremely large 
amounts of generated data is still difficult to handle and interpret. Real time PCR may 
therefore be the most probable technique of choice in most molecular laboratories, currently 
and in the near future. 
8
Summary and general discussion  |  147
REFERENCES
1. Dahm R: Discovering DNA: Friedrich Miescher and the early years of nucleic acid research. 
Hum Genet 2008, 122(6):565-581.
2. Levene PA: The structure of yeast nucleic acid: IV. Ammonia hydrolysis. J Biol Chem 1919, 
40:415-424.
3. Watson JD, Crick FH: Molecular structure of nucleic acids; a structure for deoxyribose 
nucleic acid. Nature 1953, 171(4356):737-738.
4. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc 
Natl Acad Sci U S A 1977, 74(12):5463-5467.
5. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H: Specific enzymatic amplification of DNA 
in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986, 51 Pt 
1:263-273.
6. Collins FS, Brooks LD, Chakravarti A: A DNA polymorphism discovery resource for research 
on human genetic variation. Genome Res 1998, 8(12):1229-1231.
7. Collins FS, Morgan M, Patrinos A: The Human Genome Project: lessons from large-scale 
biology. Science 2003, 300(5617):286-290.
8. A haplotype map of the human genome. Nature 2005, 437(7063):1299-1320.
9. Zhang W, Duan S, Dolan ME: HapMap filter 1.0: a tool to preprocess the HapMap genotypic 
data for association studies. Bioinformation 2008, 2(8):322-324.
10. Casey D: Scientists Hunt SNPs to Uncover Variation, Disease In: Human Genome News. 
Washington, DC: Human Genome Program, U.S. Department of Energy; 1999.
11. Brookes AJ: The essence of SNPs. Gene 1999, 234(2):177-186.
12. Komar A: Single Nucleotide Polymorphisms, Methods in Molecular Biology 587, chapter 
Hunt R Silent (Synonymous) SNPs: Should We Care About Them? In.; 2009.
13. Duncan BK, Miller JH: Mutagenic deamination of cytosine residues in DNA. Nature 1980, 
287(5782):560-561.
14. ElSharawy A, Manaster C, Teuber M, Rosenstiel P, Kwiatkowski R, Huse K, Platzer M, Becker A, 
Nurnberg P, Schreiber S et al: SNPSplicer: systematic analysis of SNP-dependent splicing in 
genotyped cDNAs. Hum Mutat 2006, 27(11):1129-1134.
15. Kim S, Misra A: SNP genotyping: technologies and biomedical applications. Annu Rev 
Biomed Eng 2007, 9:289-320.
16. Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications for 
cancer research. Nat Rev Cancer 2010, 10(6):389-402.
17. Shibata DK, Arnheim N, Martin WJ: Detection of human papilloma virus in paraffin-embed-
ded tissue using the polymerase chain reaction. J Exp Med 1988, 167(1):225-230.
18. Cao M, Xiao X, Egbert B, Darragh TM, Yen TS: Rapid detection of cutaneous herpes simplex 
virus infection with the polymerase chain reaction. J Invest Dermatol 1989, 92(3):391-392.
19. Brandsma JL, Lewis AJ, Abramson A, Manos MM: Detection and typing of papillomavirus 
DNA in formaldehyde-fixed paraffin-embedded tissue. Arch Otolaryngol Head Neck Surg 
1990, 116(7):844-848.
20. Unger ER, Vernon SD, Lee DR, Miller DL, Reeves WC: Detection of human papillomavirus in 
archival tissues. Comparison of in situ hybridization and polymerase chain reaction. J 
Histochem Cytochem 1998, 46(4):535-540.
21. Biedermann K, Dandachi N, Trattner M, Vogl G, Doppelmayr H, More E, Staudach A, Dietze O, 
Hauser-Kronberger C: Comparison of real-time PCR signal-amplified in situ hybridization 
and conventional PCR for detection and quantification of human papillomavirus in 
archival cervical cancer tissue. J Clin Microbiol 2004, 42(8):3758-3765.
22. Johansen IS, Thomsen VO, Forsgren A, Hansen BF, Lundgren B: Detection of Mycobacterium 
tuberculosis complex in formalin-fixed, paraffin-embedded tissue specimens with 
necrotizing granulomatous inflammation by strand displacement amplification. J Mol 
Diagn 2004, 6(3):231-236.
148  |  Chapter 8
23. Beqaj SH, Flesher R, Walker GR, Smith SA: Use of the real-time PCR assay in conjunction with 
MagNA Pure for the detection of mycobacterial DNA from fixed specimens. Diagn Mol 
Pathol 2007, 16(3):169-173.
24. Burmer GC, Rabinovitch PS, Loeb LA: Analysis of c-Ki-ras mutations in human colon 
carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res 
1989, 49(8):2141-2146.
25. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, 
Bourne HR et al: Two G protein oncogenes in human endocrine tumors. Science 1990, 
249(4969):655-659.
26. Kramer D, Thunnissen FB, Gallegos-Ruiz MI, Smit EF, Postmus PE, Meijer CJ, Snijders PJ, Heideman 
DA: A fast, sensitive and accurate high resolution melting (HRM) technology-based assay 
to screen for common K-ras mutations. Cell Oncol 2009, 31(3):161-167.
27. Iverson AA, Gillett C, Cane P, Santini CD, Vess TM, Kam-Morgan L, Wang A, Eisenberg M, Rowland 
CM, Hessling JJ et al: A single-tube quantitative assay for mRNA levels of hormonal and 
growth factor receptors in breast cancer specimens. J Mol Diagn 2009, 11(2):117-130.
28. Gilbert MT, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, Van Marck E, Worobey M: The 
isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are 
useful when? PLoS One 2007, 2(6):e537.
29. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F: Analysis of changes in DNA sequence copy 
number by comparative genomic hybridization in archival paraffin-embedded tumor 
samples. Am J Pathol 1994, 145(6):1301-1308.
30. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR: Microwave-based DNA 
extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 1995, 
18(5):768-770, 772-763.
31. Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF: Evaluation of extraction methods 
from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin 
Pathol 2001, 54(5):401-403.
32. Wu L, Patten N, Yamashiro CT, Chui B: Extraction and amplification of DNA from formalin-
fixed, paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 2002, 10(3):269-274.
33. Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF: Comparison of methods for DNA 
extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 2003, 
27(5):397-404.
34. Rivero ER, Neves AC, Silva-Valenzuela MG, Sousa SO, Nunes FD: Simple salting-out method for 
DNA extraction from formalin-fixed, paraffin-embedded tissues. Pathol Res Pract 2006, 
202(7):523-529.
35. Dedhia P, Tarale S, Dhongde G, Khadapkar R, Das B: Evaluation of DNA extraction methods 
and real time PCR optimization on formalin-fixed paraffin-embedded tissues. Asian Pac J 
Cancer Prev 2007, 8(1):55-59.
36. Ramsay AD, Gallagher PJ: Local audit of surgical pathology. 18 month’s experience of peer 
review-based quality assessment in an English teaching hospital. Am J Surg Pathol 1992, 
16(5):476-482.
37. Safrin RE, Bark CJ: Surgical pathology sign-out. Routine review of every case by a second 
pathologist. Am J Surg Pathol 1993, 17(11):1190-1192.
38. Lind AC, Bewtra C, Healy JC, Sims KL: Prospective peer review in surgical pathology. Am J Clin 
Pathol 1995, 104(5):560-566.
39. Wakely SL, Baxendine-Jones JA, Gallagher PJ, Mullee M, Pickering R: Aberrant diagnoses by 
individual surgical pathologists. Am J Surg Pathol 1998, 22(1):77-82.
40. Renshaw AA, Cartagena N, Granter SR, Gould EW: Agreement and error rates using blinded 
review to evaluate surgical pathology of biopsy material. Am J Clin Pathol 2003, 119(6):797-
800.
41. Renshaw AA, Young ML, Jiroutek MR: How many cases need to be reviewed to compare 
performance in surgical pathology? Am J Clin Pathol 2003, 119(3):388-391.
8
Summary and general discussion  |  149
42. Galloway M, Woods R, Whitehead S, Baird G, Stainsby D: An audit of error rates in a UK district 
hospital transfusion laboratory. Transfus Med 1999, 9(3):199-203.
43. Dzik WH, Murphy MF, Andreu G, Heddle N, Hogman C, Kekomaki R, Murphy S, Shimizu M, 
Smit-Sibinga CT: An international study of the performance of sample collection from 
patients. Vox Sang 2003, 85(1):40-47.
44. Houtz T, Chiafari FA, Wenk RE: Controlling specimen misidentification in parentage analysis. 
Transfusion 2004, 44(8):1258-1259.
45. Murphy MF, Stearn BE, Dzik WH: Current performance of patient sample collection in the 
UK. Transfus Med 2004, 14(2):113-121.
46. Romero RL, Juston AC, Ballantyne J, Henry BE: The applicability of formalin-fixed and formalin 
fixed paraffin embedded tissues in forensic DNA analysis. J Forensic Sci 1997, 42(4):708-714.
47. Moretti TR, Baumstark AL, Defenbaugh DA, Keys KM, Smerick JB, Budowle B: Validation of short 
tandem repeats (STRs) for forensic usage: performance testing of fluorescent multiplex 
STR systems and analysis of authentic and simulated forensic samples. J Forensic Sci 2001, 
46(3):647-660.
48. Koyama H, Iwasa M, Tsuchimochi T, Maeno Y, Isobe I, Matsumoto T, Nagao M: Utility of Y-STR 
haplotype and mtDNA sequence in personal identification of human remains. Am J 
Forensic Med Pathol 2002, 23(2):181-185.
49. Shibata D, Namiki T, Higuchi R: Identification of a mislabeled fixed specimen by DNA 
analysis. Am J Surg Pathol 1990, 14(11):1076-1078.
50. Shibata D, Kurosu M, Noguchi TT: Fixed human tissues: a resource for the identification of 
individuals. J Forensic Sci 1991, 36(4):1204-1212.
51. Bateman AC, Sage DA, Al-Talib RK, Theaker JM, Jones DB, Howell WM: Investigation of 
specimen mislabelling in paraffin-embedded tissue using a rapid, allele-specific, 
PCR-based HLA class II typing method. Histopathology 1996, 28(2):169-174.
52. Bateman AC, Hemmatpour SK, Theaker JM, Howell WM: Genetic analysis of hydatidiform 
moles in paraffin wax embedded tissue using rapid, sequence specific PCR-based HLA 
class II typing. J Clin Pathol 1997, 50(4):288-293.
53. Tsongalis GJ, Berman MM: Application of forensic identity testing in a clinical setting. 
Specimen identification. Diagn Mol Pathol 1997, 6(2):111-114.
54. Giroti R, Kashyap VK: Detection of the source of mislabeled biopsy tissue paraffin block 
and histopathological section on glass slide. Diagn Mol Pathol 1998, 7(6):331-334.
55. Walsh PS, Fildes N, Louie AS, Higuchi R: Report of the blind trial of the Cetus Amplitype HLA 
DQ alpha forensic deoxyribonucleic acid (DNA) amplification and typing kit. J Forensic Sci 
1991, 36(5):1551-1556.
56. Baird ML: Use of the AmpliType PM + HLA DQA1 PCR amplification and typing kits for 
identity testing. Methods Mol Biol 1998, 98:261-277.
57. Tsongalis GJ, Wu AH, Silver H, Ricci A, Jr.: Applications of forensic identity testing in the 
clinical laboratory. Am J Clin Pathol 1999, 112(1 Suppl 1):S93-103.
58. Hardy GH: Mendelian Proportions in a Mixed Population. Science 1908, 28(706):49-50.
59. Weinberg W: Über den nachweis der verebung beim menschen. Nat Wüttemberg 1908, 
64:368-382.
60. Schindler C, Darnell JE, Jr.: Transcriptional responses to polypeptide ligands: the JAK-STAT 
pathway. Annu Rev Biochem 1995, 64:621-651.
61. Jatiani SS, Baker SJ, Silverman LR, Reddy EP: Jak/STAT pathways in cytokine signaling and 
myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010, 
1(10):979-993.
62. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: 
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 
352(17):1779-1790.
63. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, 
Bennaceur-Griscelli A et al: A unique clonal JAK2 mutation leading to constitutive signalling 
causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
150  |  Chapter 8
64. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, 
Moore S et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, 
essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 
7(4):387-397.
65. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd 
EM, Curtin N et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloprolif-
erative disorders. Lancet 2005, 365(9464):1054-1061.
66. Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their 
clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on 
Molecular Pathology. J Mol Diagn 2006, 8(4):397-411; quiz 526.
67. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi 
G, Guerini V, Fabris F et al: Clinical profile of homozygous JAK2 617V>F mutation in patients 
with polycythemia vera or essential thrombocythemia. Blood 2007, 110(3):840-846.
68. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T: 
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction 
with treatment, standard risk factors, and Jak2 mutation status. Blood 2007, 109(6):2310-
2313.
69. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, Cross NC: JAK2(V617F) allele 
burden in polycythemia vera correlates with grade of myelofibrosis, but is not 
substantially affected by therapy. Leuk Res 2011, 35(2):177-182.
70. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, 
Rambaldi A, Guerini V et al: Prospective identification of high-risk polycythemia vera 
patients based on JAK2(V617F) allele burden. Leukemia 2007, 21(9):1952-1959.
71. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, 
Delaini F, Rambaldi A, Barbui T: JAK2V617F allele burden and thrombosis: a direct comparison 
in essential thrombocythemia and polycythemia vera. Exp Hematol 2009, 37(9):1016-1021.
72. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland 
DG: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in 
polycythemia vera. Cancer 2006, 106(3):631-635.
73. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, 
Lo-Coco F, Delaini F et al: Characteristics and clinical correlates of MPL 515W>L/K mutation 
in essential thrombocythemia. Blood 2008, 112(3):844-847.
74. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S 
et al: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 
(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation 
and vascular complications. Leukemia 2010, 24(9):1574-1579.
75. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, 
Ponziani V, Delaini F et al: Identification of patients with poorer survival in primary 
myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114(8):1477-
1483.
76. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A: Low 
JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele 
burden or unmutated status, is associated with inferior overall and leukemia-free 
survival. Leukemia 2008, 22(4):756-761.
77. Sidon P, Heimann P, Lambert F, Dessars B, Robin V, El Housni H: Combined locked nucleic acid 
and molecular beacon technologies for sensitive detection of the JAK2V617F somatic 
single-base sequence variant. Clin Chem 2006, 52(7):1436-1438.
78. Sidon P, El Housni H, Dessars B, Heimann P: The JAK2V617F mutation is detectable at very low 
level in peripheral blood of healthy donors. Leukemia 2006, 20(9):1622.
79. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian 
HM, Issa JP: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, 
Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 
106(10):3370-3373.
8
Summary and general discussion  |  151
80. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ: JAK2(V617F): Prevalence in a large 
Chinese hospital population. Blood 2007, 109(1):339-342.
81. Rapado I, Albizua E, Ayala R, Hernandez JA, Garcia-Alonso L, Grande S, Gallardo M, Gilsanz F, 
Martinez-Lopez J: Validity test study of JAK2 V617F and allele burden quantification in the 
diagnosis of myeloproliferative diseases. Ann Hematol 2008, 87(9):741-749.
82. Bernard PS, Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 2002, 
48(8):1178-1185.
83. Knudson AG, Jr.: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci 
U S A 1971, 68(4):820-823.
84. Ponder B: Cancer. Gene losses in human tumours. Nature 1988, 335(6189):400-402.
85. Rodriguez E, Sreekantaiah C, Chaganti RS: Genetic changes in epithelial solid neoplasia. 
Cancer Res 1994, 54(13):3398-3406.
86. Ogiwara H, Kohno T, Nakanishi H, Nagayama K, Sato M, Yokota J: Unbalanced translocation, a 
major chromosome alteration causing loss of heterozygosity in human lung cancer. 
Oncogene 2008, 27(35):4788-4797.
87. Bonaglia MC, Giorda R, Beri S, Bigoni S, Sensi A, Baroncini A, Capucci A, De Agostini C, Gwilliam 
R, Deloukas P et al: Mosaic 22q13 deletions: evidence for concurrent mosaic segmental 
isodisomy and gene conversion. Eur J Hum Genet 2009, 17(4):426-433.
88. Tuna M, Knuutila S, Mills GB: Uniparental disomy in cancer. Trends Mol Med 2009, 15(3):120-128.
89. Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F mutation 
occur in most patients with polycythemia vera, but not essential thrombocythemia. 
Blood 2006, 108(7):2435-2437.
90. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi 
R, Luini A et al: Chemotherapy is more effective in patients with breast cancer not 
expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 
2004, 10(19):6622-6628.
91. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR: Oestrogen receptor status, pathological 
complete response and prognosis in patients receiving neoadjuvant chemotherapy for 
early breast cancer. Br J Cancer 2004, 91(12):2012-2017.
92. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 
15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
93. Subramaniam DS, Isaacs C: Utilizing prognostic and predictive factors in breast cancer. Curr 
Treat Options Oncol 2005, 6(2):147-159.
94. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, 
Schlessinger J, Francke U et al: Tyrosine kinase receptor with extensive homology to EGF 
receptor shares chromosomal location with neu oncogene. Science 1985, 230(4730):1132-1139.
95. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: 
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor 
receptor. Nature 1986, 319(6050):230-234.
96. Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the 
ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000, 77:25-79.
97. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal 
diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 
410(1):83-86.
98. Tzahar E, Yarden Y: The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from 
orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998, 1377(1):M25-37.
99. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, Cummings M, Farshid G, Field A, Morey A 
et al: Predicting the HER2 status of breast cancer from basic histopathology data: an 
analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003, 
12(2):92-98.
100. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, 
Wolter J, Pegram M et al: Use of chemotherapy plus a monoclonal antibody against HER2 
for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
152  |  Chapter 8
101. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, 
Novotny WF, Burchmore M et al: Efficacy and safety of trastuzumab as a single agent in 
first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 
20(3):719-726.
102. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and 
deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect 
sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000, 
156(3):839-847.
103. Konecny GE, Pauletti G, Untch M, Wang HJ, Mobus V, Kuhn W, Thomssen C, Harbeck N, Wang L, 
Apple S et al: Association between HER2, TOP2A, and response to anthracycline-based 
preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 
2010, 120(2):481-489.
104. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, 
Pienkowski T, Martin M et al: Alteration of topoisomerase II-alpha gene in human breast 
cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin 
Oncol 2011, 29(7):859-867.
105. Watt PM, Hickson ID: Structure and function of type II DNA topoisomerases. Biochem J 
1994, 303 ( Pt 3):681-695.
106. Binaschi M, Farinosi R, Borgnetto ME, Capranico G: In vivo site specificity and human 
isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res 2000, 
60(14):3770-3776.
107. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F: 
Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001, 
1(2):113-130.
108. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, 
Luts J, Monleon D et al: Triple-negative breast cancer: present challenges and new 
perspectives. Mol Oncol 2010, 4(3):209-229.
109. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. Histopathology 2008, 
52(1):108-118.
110. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, 
Borresen-Dale AL, Pollack JR: Distinct patterns of DNA copy number alteration are associated 
with different clinicopathological features and gene-expression subtypes of breast 
cancer. Genes Chromosomes Cancer 2006, 45(11):1033-1040.
111. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, 
Ryder T et al: Genomic and transcriptional aberrations linked to breast cancer pathophysi-
ologies. Cancer Cell 2006, 10(6):529-541.
112. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain 
AN et al: Breast tumor copy number aberration phenotypes and genomic instability. BMC 
Cancer 2006, 6:96.
113. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor 
V et al: Novel patterns of genome rearrangement and their association with survival in 
breast cancer. Genome Res 2006, 16(12):1465-1479.
114. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, 
Glogovac J, Li CI et al: Array comparative genomic hybridization analysis of genomic 
alterations in breast cancer subtypes. Cancer Res 2004, 64(23):8541-8549.
115. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, 
Meyerson M et al: Loss of heterozygosity and its correlation with expression profiles in 
subclasses of invasive breast cancers. Cancer Res 2004, 64(1):64-71.
116. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, Oga A, Nagashima Y, Sasaki 
K: Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture 
of tumors with different genotype. BMC Res Notes 2012, 5:376.
117. Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD: Amplification 
of HER2 is a marker for global genomic instability. BMC Cancer 2008, 8:297.
8
Summary and general discussion  |  153
118. Munro AF, Twelves C, Thomas JS, Cameron DA, Bartlett JM: Chromosome instability and 
benefit from adjuvant anthracyclines in breast cancer. Br J Cancer 2012, 107(1):71-74.
119. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, 
Tamber N, Fenwick K et al: Genomic analysis of the HER2/TOP2A amplicon in breast cancer 
and breast cancer cell lines. Lab Invest 2008, 88(5):491-503.
120. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou 
CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer 
subtypes. Clin Cancer Res 2007, 13(8):2329-2334.
121. Benenson AS, Tigertt WD: Studies on Q fever in man. Trans Assoc Am Physicians 1956, 
69:98-104.
122. Kazar J: Coxiella burnetii infection. Ann N Y Acad Sci 2005, 1063:105-114.
123. van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, ter Schegget R, 
Hackert V, van Duynhoven Y: Q fever in the Netherlands: an update on the epidemiology 
and control measures. Euro Surveill 2010, 15(12).
124. Arricau-Bouvery N, Hauck Y, Bejaoui A, Frangoulidis D, Bodier CC, Souriau A, Meyer H, Neubauer 
H, Rodolakis A, Vergnaud G: Molecular characterization of Coxiella burnetii isolates by 
infrequent restriction site-PCR and MLVA typing. BMC Microbiol 2006, 6:38.
125. Tilburg JJ, Melchers WJ, Pettersson AM, Rossen JW, Hermans MH, van Hannen EJ, Nabuurs-Frans-
sen MH, de Vries MC, Horrevorts AM, Klaassen CH: Interlaboratory evaluation of different 
extraction and real-time PCR methods for detection of Coxiella burnetii DNA in serum. J 
Clin Microbiol 2010, 48(11):3923-3927.
126. Huijsmans CJ, Schellekens JJ, Wever PC, Toman R, Savelkoul PH, Janse I, Hermans MH: Single-
nucleotide-polymorphism genotyping of Coxiella burnetii during a Q fever outbreak in 
The Netherlands. Appl Environ Microbiol 2011, 77(6):2051-2057.
127. Hermans MH, Huijsmans CR, Schellekens JJ, Savelkoul PH, Wever PC: Coxiella burnetii DNA in 
goat milk after vaccination with Coxevac((R)). Vaccine 2011, 29(15):2653-2656.
154  |  Chapter 8
8Summary and general discussion  |  155

9
Nederlandse samenvatting en discussie
158  |  Chapter 9
Variaties in het humane genoom: geschikte markers voor weefsel 
identificatie en het testen van allelische instabiliteit
9.1 Samenvatting en algemene discussie
Sinds de ontdekking van “Nuclein” in de winter van 1868/1869 door Friedrich Miescher, wat 
later DNA werd genoemd, is er een enorme wetenschappelijke vooruitgang geboekt op het 
gebied van biotechnologie en genetica. De daaropvolgende ontwikkeling van DNA 
sequencing en de polymerase chain reaction (PCR) hebben deze vooruitgang versneld wat 
heeft geleidt tot een nieuw tijdperk in de wetenschap en geneeskunde. Met behulp van deze 
technieken werden wetenschappers in staat gesteld specifieke delen van het DNA te 
bestuderen. Hierdoor werden variaties in oncogenen en tumor suppressor genen (TSG) ge-
identificeerd. De sequenties van verschillende humane genomen en de onderlinge 
overeenkomsten en verschillen werden door de voltooiing van het Humane Genoom Project 
(HGP) onthuld. De meest frequent gevonden variaties, ongeveer eens in de 100-1.000 
baseparen, waren Single Nucleotide Polymorphisms (SNPs). Deze worden gedefinieerd als 
variaties van één enkele nucleotide op een bepaalde positie van het genoom. Daarnaast 
wordt de term SNP regelmatig gebruikt met de restricties dat deze variatie bij ten minste 1% 
van de individuen binnen een bepaalde populatie voorkomt en dat deze niet ziekmakend is. 
Indien een variatie niet aan deze criteria voldoet, wordt deze beschouwd als een mutatie in 
plaats van een polymorphisme. Beide beperkingen zorgen echter voor een dilemma. Ten 
eerste zou een SNP in de ene populatie een mutatie zijn in de andere, aangezien het 
voorkomen van de SNP tussen verschillende populaties kan variëren (van bv. >1% tot <1%). 
Ten tweede kan een mutatie van een enkele nucleotide theoretisch gezien in het ene individu 
leiden tot ziekte terwijl deze in het andere individu geen ziekmakend effect heeft. In het 
laatste geval zou de enkele nucleotide variatie geen mutatie zijn, maar een SNP. Om dergelijke 
onduidelijkheden te voorkomen is de term SNP in dit proefschrift gebruikt als een enkele 
base variatie op een specifieke positie in het genoom die overgeërfd wordt binnen een 
populatie, ongeacht de frequentie van het voorkomen en de eventuele potentie om ziekte te 
veroorzaken.
Ieder individu heeft een unieke combinatie van deze SNPs. Een dergelijk SNP genotype kan 
dan ook als genetische vingerafdruk beschouwd worden. SNPs komen minder frequent voor 
in coderende gebieden van het genoom in vergelijking tot gebieden die niet coderend zijn. 
Wanneer een SNP zich in een coderende regio bevindt dan kan de SNP een direct effect 
hebben op het betreffende eiwit. Een SNP in een niet coderende regio kan door het 
teweegbrengen van veranderingen in de eiwit expressie echter ook een functioneel effect 
hebben. De enorme hoeveelheid SNPs verspreid over het genoom en het mogelijke effect 
van deze enkele nucleotide variaties op de gecodeerde eiwitten en de expressie daarvan zijn 
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grotendeels verantwoordelijk voor de fenotypische diversiteit. Doordat SNPs zeer frequent en 
verspreid over het gehele genoom voorkomen, zijn deze enkele nucleotide variaties in 
potentie een zeer waardevolle (en bijna onuitputtelijke) bron van biomarkers voor o.a. weefsel 
identificatie en het testen van instabiliteit van tumor gerelateerde allelen.
9.1.1. Technologische vooruitgang
Verschillende technologische ontwikkelingen gedurende de afgelopen decennia hebben er 
voor gezorgd dat het routinematig gebruik van moleculaire methodes enorm is toegenomen. 
Momenteel is o.a. de (real time) PCR techniek breed geïmplementeerd voor de detectie van 
micro-organismen, aan kanker gerelateerde mutaties en afwijkende gen expressie op mRNA 
niveau. De (real time) PCR techniek is daardoor gemakkelijk toegankelijk voor diagnostische 
laboratoria en kent vele ervaren gebruikers. Daarnaast worden momenteel meer gespeciali-
seerde technieken gebruikt voor de eerder benoemde toepassingen van weefsel identificatie 
en het testen van instabiliteit van tumor gerelateerde allelen. Voor deze toepassingen is real time 
PCR mogelijk een goed alternatief, aangezien deze techniek gemakkelijk te implementeren is 
en uitermate geschikt is voor de detectie van SNPs.
Hoofdstuk 2 | Optimalisatie van DNA extractie
Gedurende verschillende studies beschreven in dit proefschrift werd gebruikt gemaakt van 
formaline gefixeerde weefsels die ingebed waren in paraffine (FFPE weefsel) . De kwaliteit 
van de DNA isolatie uit deze FFPE weefsels was van grote invloed op de analyses die op het 
DNA werden uitgevoerd. Het isoleren van DNA uit deze weefsels is echter lastig. Ten eerste 
resulteert de formaline fixatie in de vorming van crosslinks die de amplificatie van het DNA 
kunnen blokkeren. Ten tweede kan fragmentatie van het DNA plaatsvinden door de 
zuurgraad van het fixatief en veroudering van het betreffende patiëntenmonster. In hoofdstuk 
2 wordt een studie beschreven waarin een vergelijking van DNA extractie methoden 
plaatsvond voor gebruik in combinatie met de FFPE weefsels. De geteste methodes waren: 
verhitting, QIAamp, EasyMAG en Gentra. Deze 4 methodes werden getest met en zonder 
proteïnase K digestie als voorbehandeling. De DNA extracten werden vervolgens getest op i) 
het cumulatieve effect van extractie efficiëntie en aanwezigheid van remming van de PCR 
middels de detectie van een interne controle (DNA virus), ii) geschiktheid voor gebruik in real 
time SNP PCR en iii) geschiktheid voor gebruik in een conventionele multiplex PCR welke 
amplicons genereerde van 200, 400 en 600 bp. Gentra DNA extractie werd ongeschikt 
bevonden voor het zuiveren van DNA uit FFPE weefsels. De voorbehandeling middels 
proteïnase K digestie werd noodzakelijk bevonden voor een zo optimaal mogelijke DNA 
isolatie uit FFPE weefsels. Wanneer het geëxtraheerde DNA gebruikt werd voor real time SNP 
PCR bleken de QIAamp en EasMAG methodes het meest geschikt. De amplificatie van de 
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400 en 600 bp producten was het meest succesvol na QIAamp extractie gevolgd door de 
EasyMAG methode. 
We concludeerden dat DNA extractie methode een grote invloed had op de daaropvolgende 
analyse, wat overeenkomt met eerdere bevindingen. Het is daarom belangrijk om de DNA 
isolatie methode af te stemmen op de beoogde analyse die gebruikt gaat worden. Voor de 
experimenten beschreven in dit proefschrift zal voor het extraheren van DNA uit FFPE weefsels 
ten behoeve van real time SNP PCR gebruik gemaakt worden van de EasyMAG methode.
Hoofdstuk 3 en 4 | Identificatie van humane weefsels
In klinische laboratoria heeft het voorkomen van verwisselingen van patiënten materialen 
hoge prioriteit. In de praktijk vinden dergelijke verwisselingen echter plaats, wat kan leiden 
tot ernstige gevolgen voor de betrokken patiënten. Het is daarom belangrijk potentiële 
verwisselingen op te lossen door identificatie van de betrokken weefsels. Het in de literatuur 
gerapporteerde verwisseling percentage van FFPE weefsels en serum ligt rond respectievelijk 
0.08-1.2% en 0.1%. Dit benadrukt het belang van stringente monsteridentificatie en het 
oplossen van potentiële verwisselingen. 
Er bestaan momenteel verschillende technieken, veelal gebaseerd op de karakterisatie van korte, 
repeterende DNA sequenties, het humane leukocyten antigeen systeem (HLA) en andere 
polymorfe regionen van het genoom, om humaan materiaal te identificeren. Implementatie van 
deze technieken is echter lastig vanwege het gebruik van kostbare apparatuur, het contaminatie-
risico in verband met post-PCR handelingen, slechte DNA kwaliteit (FFPE weefsel) en lage 
hoeveelheden DNA (serum). Om de implementatie problemen van deze technieken te omzeilen 
werd een real time PCR gebaseerde test voor het opmaken van SNP profielen ontwikkeld en 
beschreven in hoofdstuk 3 en 4. De toepasbaarheid van deze test werd gedemonstreerd middels 
het oplossen van een aantal mogelijke verwisselingen uit de praktijk.
Er werd een panel van 17 SNPs verdeeld over 16 verschillende chromosomen en met allel 
frequenties van ≈ 0,5 samengesteld. Zeven van deze 17 SNPs werden uiteindelijk geëxcludeerd 
op basis van i) een afwijkende allel frequentie binnen de geteste populatie (chi-square test; P 
waarde <0,05, n=3), ii) op basis van een in silico onderzoek naar de LOH (loss of heterozygosity; 
verlies van heterozygotie) frequentie van de DNA regio waarin de SNP zich bevindt (n=4, 
waarvan 2 reeds geëxcludeerd op basis van afwijkende allel frequentie) en iii) op basis van 
technische tekortkomingen (n=2). Bij het gebruik van een dergelijk panel kan gesteld worden 
dat de kans dat 2 willekeurig gekozen individuen hetzelfde SNP profiel hebben 1 op 18.000 
is. Hoewel deze kans bij de huidige (commercieel beschikbare) technieken veel kleiner is, 
bleek de SNP test geschikt om de beschreven casussen van mogelijke monsterverwisselingen 
(totaal n=7; FFPE weefsels n=6; serum monsters n=1) op te lossen. Onze bevindingen werden 
bevestigd door aanvullend histologisch of serologisch onderzoek.
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Een voordeel van de beschreven SNP test is dat er zeer kleine stukjes DNA van ongeveer 80 
bp geamplificeerd worden, terwijl bij andere beschikbare technieken een amplicon grootte 
van wel 360 bp benodigd is. Daarnaast kan de gepresenteerde SNP test verricht worden 
middels iedere standaard real time PCR cycler, in plaats van dure sequencing apparatuur. 
Andere significante voordelen van de SNP test zijn de snelle doorlooptijd en het gebrek aan 
post-PCR handelingen waardoor de kans op amplicon contaminatie erg klein is.
Hoofdstuk 5 | Bepalen van de JAK2V617F mutatie status
Het Janus Kinase 2 (JAK2) gen codeert voor het JAK2 tyrosine kinase. JAK2 speelt een 
belangrijke rol in de door cytokines gemedieerde signaaltransductie en heeft daardoor een 
grote invloed op de hematopoiese. De activerende JAK2V617F mutatie resulteert in 
onafgebroken activatie van de JAK-STAT signaaltransductie en wordt frequent gevonden in 
myeloproliferatieve ziekten (MPZ) zoals polycythemie vera (PV), essentiële thrombocythemie 
(ET) en chronische idiopathische myeolofibrose (IMF). Naast de detectie van de JAK2V617F 
mutatie, is ook de hoeveelheid die van dit mutant allel aanwezig is mogelijk van klinisch belang.
Hoofdstuk 5 beschrijft de ontwikkeling van een real time PCR voor de detectie en 
kwantificering van JAK2V617F in patiënten met een mogelijke MPZ. Om de gevoeligheid van 
de beschreven real time PCR te maximaliseren werd amplificatie van het wildtype allel 
geblokkeerd door gebruik van een locked nucleic acid (LNA) probe in vergelijking tot een 
peptide nucleic acid (PNA) probe. De gevoeligheid en lineariteit werden vervolgens bepaald 
middels een verdunningsreeks (0,006% tot 97% JAK2V617F DNA verdunt in wildtype DNA). 
Zowel de gevoeligheid als de lineariteit van de test in combinatie met het gebruik van de PNA 
probe (0,05-97%) lagen hoger in vergelijking tot het gebruik van de LNA probe (0,2-97%). 
De ontwikkelde real time PCR in combinatie met het gebruik van de PNA probe liet daarmee 
een gevoeligheid zien vergelijkbaar met die van verschillende reeds beschreven testen.
In 9 van de 100 geteste bloedmonsters van gezonde donoren (<30 jaar) werden JAK2V617F 
achtergrondsignalen gezien. Eén van deze donoren liet in duplo een dergelijk achtergrond-
signaal zien. Deze observatie kan veroorzaakt zijn door een technisch artefact of mogelijk 
was het JAK2V617F allel daadwerkelijk aanwezig bij deze patiënten. Deze bevindingen komen 
overeen met die in de literatuur, al blijft de klinische relevantie van dit fenomeen onduidelijk. 
Om te voorkomen dat de test in een diagnostische setting resulteert in vals positieven werd 
er een Ct-waarde van 37,9 aangehouden als grens.
Hoofdstuk 6 | LOH van het JAK2 locus
LOH is een genetisch incident waarbij heterozygotie van een bepaald locus verloren gaat. 
LOH kan daarmee bijdragen aan het vergaren van de mutaties die benodigd zijn voor het 
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ontstaan van kanker. In combinatie met JAK2V617F kan LOH resulteren in homozygotie van 
dit mutant allel waardoor het effect ervan mogelijk versterkt wordt. Het detecteren van LOH 
van het JAK2 locus is daarom mogelijk klinisch relevant. In hoofdstuk 6 wordt de ontwikkeling 
van een JAK2 LOH test met behulp van real time PCR gebaseerde SNP detectie beschreven. 
Daarnaast werd de SNP gebaseerde JAK2 LOH test vergeleken met een in de literatuur 
beschreven STR (short tandem repeat) gebaseerde test. Twee patiënten groepen werden 
geïncludeerd: een groep bestaande uit 12 bekend JAK2V617F positieve patiënten (waarvan 6 
met 25-50% mutant allel en 6 >50% mutant allel) en een groep van 81 patiënten met een 
mogelijke MPZ. In de 6 patiënten met 20-25% mutant allel en in de 6 patiënten met >50% 
mutant allel werd op basis van de SNP test JAK2 LOH vastgesteld in respectievelijk 2 en 6 
patiënten. In de groep patiënten met mogelijke MPZ werd bij 6 van hen JAK2 LOH vastgesteld. 
Bij het beschouwen van de STR test als gouden standaard, had de SNP test een gevoeligheid 
en negatief voorspellende waarde van 100% in beide patiënten groepen. De positief 
voorspellende waarde van de SNP test in de groep met bekend JAK2V617F positieven en in 
de groep met mogelijke MPZ patiënten waren respectievelijk 85,7% en 100%. De specificiteit 
van de SNP test was 80% en 100% in deze groepen. De SNP test bleek een hoger slagings-
percentage te hebben dan de STR test (3 versus 9 niet informatieve profielen). Daarnaast 
genereerde de SNP test meer gedetailleerde informatie met betrekking tot het JAK2 locus. 
Hoofdstuk 7 | Allelische instabiliteit van het HER2/TOP2A locus
Borstkanker is een heterogene aandoening die een verscheidenheid aan biologische aspecten 
kent. Op basis van o.a. een verhoogde expressie van eiwitten zoals de oestrogeen, progesteron 
en humane epidermale groeifactor receptoren (ER, PR en HER2), wordt borstkanker verdeeld 
in verschillende categorieën. Deze categorisatie wordt gebruikt om een voorspelling te doen 
van het klinisch verloop van de ziekte en om bijpassende therapieën te selecteren. 
Borsttumoren negatief voor zowel ER, PR als HER2 worden “triple negative” (TN) genoemd. 
Deze TN tumoren worden geassocieerd met een slechte prognose en een gebrek aan gerichte 
therapie.
Amplificatie van het HER2 gen leidt tot overexpressie van het HER2 eiwit. Dit eiwit speelt een 
belangrijke rol in de HER signaaltransductie. HER2 amplificatie komt ongeveer in 25-30% van 
de borstkanker gevallen voor. Daarnaast vindt in 30-45% van de HER2 geamplificeerde 
gevallen coamplificatie plaats van het naastgelegen topoisomerase II alpha (TOP2A) gen. 
TOP2A is belangrijk bij de topologische veranderingen van het DNA benodigd gedurende de 
DNA replicatie. TOP2A deletie vindt plaats in ongeveer 15-40% van de HER2 geamplificeerde 
borsttumoren. Patiënten met een dergelijke TOP2A amplificatie lijken meer baat te hebben 
bij behandeling met anthracycline (AC), terwijl deletie van TOP2A juist een negatieve 
uitwerking op de effectiviteit van deze behandeling lijkt te hebben. 
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Instabiliteit van het HER2/TOP2A allel wordt geassocieerd met een verhoogde chromosomale 
instabiliteit wat mogelijk een verhoogde effectiviteit van AC therapie tot gevolg heeft. In 
hoofdstuk 7 wordt de ontwikkeling van een op real time PCR gebaseerde SNP test om deze 
allelische instabiliteit vast te kunnen stellen beschreven. Er werden 44 patiënten met 3 
verschillende borstkanker typen geïncludeerd: borstkanker met HER2 overexpressie (n=15), 
TN borstkanker (n=16) en ER en PR positieve borstkanker (n=13). Daarnaast werd in deze 
studie een negatieve controle groep van 10 patiënten zonder borstkanker opgenomen. Alle 
borsttumoren met HER2 overexpressie lieten allelische instabiliteit van het HER2/TOP2A locus 
zien. Daarnaast was dit bij 12/16 (75%) van de TN borsttumoren en bij 5/13 (38%) ER en PR 
positieve borsttumoren het geval. Alhoewel het aantal onderzochte borsttumoren in deze 
studie gering was, kwamen de percentages allelische instabiliteit in de TN groep en de ER en 
PR positieve groep van respectievelijk 75% en 38% ruwweg overeen met de AC responsper-
centages van 85% en 47% in deze groepen. Een (5-jaars) klinische vervolgstudie is echter 
benodigd om vast te stellen of allelische instabiliteit van het HER2/TOP2A locus daadwerkelijk 
klinisch relevant is.
9.2  Toepassing buiten de scope van dit proefschrift: bacteriële 
SNP genotypering
Naast de focus op diverse humane toepassingen, werd de inzetbaarheid van real time PCR 
gebaseerde SNP detectie op het gebied van bacteriële genotypering onderzocht.
Gedurende een periode van 4 jaar (2007-2010) werd Nederland geconfronteerd met de 
grootste Q-koorts (Coxiella burnetii) epidemie ooit. Op het moment van deze uitbraak was er 
geen epidemiologische data beschikbaar, noch bestond een directe typeringsmethode.
Als eerste werd een panel van 10 onderscheidende SNPs gebruikt om een internationale 
verzameling van 28 referentie stammen met beschikbare Multi Locus Sequence Typing 
(MLST) data en 5 commerciële stammen te genotyperen. Ten tweede werden 40 monsters 
gerelateerd aan de uitbraak (14 van humane en 26 van dierlijke oorsprong) getypeerd middels 
het SNP panel. Als derde werd de SNP genotypering gebruikt om vast te stellen of de 
verplichte vaccinatie van melkgeiten ertoe kon leiden dat C. burnetii DNA afkomstig van het 
vaccin in de bulkmelk van deze geiten terecht zou kunnen komen. Dit zou namelijk kunnen 
leiden tot het onterecht ruimen van de betrokken dieren.
De verzameling referentie stammen waarin zich 14 verschillende MLST types bevonden 
bevatte 9 SNP genotypen. Onder de uitbraak gerelateerde monsters werden 5 verschillende 
SNP genotypen geïdentificeerd (3 in de humane monsters en 4 in de dierlijke monsters). Dit 
suggereert dat de Nederlandse uitbraak waarschijnlijk niet te wijten is aan 1 hypervirulent C. 
burnetii type, maar dat omgevingsfactoren (zoals een hoge bevolkingsdichtheid in combinatie 
met de aanwezigheid van veel geitenboerderijen en droge perioden gedurende de lente) de 
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uitbraak bespoedigd hebben. In de bulkmelkmonsters werd vastgesteld dat het aanwezige C. 
burnetii DNA zeer waarschijnlijk afkomstig was van het toegediende vaccin. Dit had tot 
gevolg dat het Nederlandse Ministerie van landbouw, Natuur en Voedselkwaliteit het vacci-
natiebeleid herzag en een 2 weken durende periode tussen vaccinatie en het testen van de 
bulkmelk introduceerde.
9.3 Slotbeschouwing
Zoals gedemonstreerd middels de studies beschreven in dit proefschrift, heeft real time 
gebaseerde SNP detectie momenteel een breed spectrum aan klinisch relevante toepassingen. 
De techniek kan daarnaast gemakkelijk geïmplementeerd worden in ieder moleculair 
diagnostisch laboratorium. Dit maakt real time gebaseerde SNP detectie een aantrekkelijk 
diagnostisch middel. We voorzien daarom dat de beschreven testen een startpunt zijn voor 
de ontwikkeling van andere, diagnostisch relevante analyses op het gebied van de oncologie 
en bacteriële SNP genotypering. Daarnaast zou de SNP identificatie van alle humane weefsels 
in behandeling binnen een klinisch laboratorium bewerkstelligd kunnen worden door een 
brede implementatie van de daarvoor ontwikkelde SNP test. Dit zou resulteren in een 
verbeterde monsteridentificatie en het aantal verwisselingen kunnen reduceren. Om dit te 
realiseren zal het aantal te detecteren SNPs uitgebreid moeten worden zodat het 
onderscheidend vermogen van de test toereikend is. Daarnaast zullen de kosten drastisch 
gereduceerd moeten worden door de real time PCR volumina sterk te verlagen en gebruik te 
maken van apparatuur met 384- of zelfs 1536-wells formaat.
Uiteindelijk zal (next generation) sequencing van het gehele genoom de toegevoegde waarde 
van andere moleculaire technieken zoals real time SNP PCR mogelijk teniet doen. Momenteel 
is de benodigde apparatuur hiervoor echter nog zeer kostbaar en niet toegankelijk voor de 
meeste moleculair diagnostische laboratoria. Daarnaast is de analyse van de enorme 
hoeveelheid gegenereerde data een grote uitdaging. Als diagnostisch middel zal real time 
PCR in de nabije toekomst daarom waarschijnlijk de meest voor de hand liggende keuze 
blijven voor moleculair diagnostische laboratoria.
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Dankwoord
De totstandkoming van dit proefschrift is gerealiseerd door de gezamenlijk inspanning van 
velen. Hierbij wil ik van de gelegenheid gebruik maken allen van hen via deze weg te 
bedanken. Ik voel mij bijzonder vereerd dat ik mijn promotieonderzoek heb mogen verrichten 
bij het laboratorium voor Moleculaire Diagnostiek van het Jeroen Bosch Ziekenhuis in 
samenwerking met de afdeling Medische Microbiologie en Infectiepreventie van het VU 
Universitair medisch centrum. Daarnaast verdient een aantal mensen een persoonlijke noot.
Allereerst wil ik mijn promotor en copromotor bedanken. Prof. dr. P.H.M. Savelkoul, beste 
Paul, zonder u had dit proefschrift niet bestaan. Uw wetenschappelijk inzicht gekoppeld aan 
een enorme kennis op o.a. het gebied van moleculaire biologie zijn van grote invloed geweest 
op dit proefschrift. Dr. M.H.A. Hermans, beste Mirjam, jij hebt me de afgelopen jaren de kans 
gegeven en geïnspireerd om mezelf te ontwikkelen van stagiair, tot unithoofd Moleculaire 
Diagnostiek en uiteindelijk tot het voltooien van dit proefschrift. Je kritische blik heeft mij 
geholpen om mijn werk in het algemeen, maar ook dat met betrekking tot dit promotieon-
derzoek naar een hoger niveau te tillen. Ik ben je daar heel erg dankbaar voor en ik kijk er 
naar uit onze huidige samenwerking voort te zetten. 
Ten tweede wil ik graag de leden van de leescommissie: prof. dr. R.H. Brakenhoff, prof. dr. 
E.J.M. Speel, dr. S. Ouburg, prof. dr. E. Schuuring en prof. dr. S. Morré, bedanken voor het 
kritisch beoordelen van dit proefschrift en voor deelname aan de oppositie.
Alle co-auteurs met wie ik de afgelopen jaren met veel plezier heb samengewerkt wil ik 
graag bedanken voor de fijne samenwerking en de input die zij hebben geleverd. In het 
bijzonder wil ik Jeroen Poodt en Jan Damen bedanken die mij de afgelopen jaren op praktisch 
en inhoudelijk gebied op vele momenten hebben ondersteund. Jeroen, jouw kennis van 
moleculaire technieken en apparatuur zijn absoluut onmisbaar geweest. Jan, hetzelfde geldt 
voor jou wat betreft de algehele pathologie. Ik heb veel van jullie mogen leren en heb 
daarnaast met nog meer plezier met jullie samengewerkt. We hebben wat afgelachen! 
Uiteraard wil ik jou Jeroen, succes wensen met het navolgen van je droom; je eigen bedrijf 
gespecialiseerd in het oplossen van laboratorium gerelateerde automatiseringvraagstukken. 
Ook al steek ik er vaak de draak mee, ik ben er van overtuigd dat je het tot een succes zult 
brengen. Dr. A.J.C. van den Brule, beste Adriaan, je bent in een later stadium betrokken 
geraakt bij mijn promotieonderzoek, maar je hebt zeker bij het laatste gedeelte een hele 
belangrijke rol gespeeld. Daarvoor ben ik je ontzettend dankbaar. Ik kijk er naar uit om in de 
toekomst op het gebied van de moleculaire diagnostiek (in de pathologie) nog veel van je te 
mogen leren en met je samen te werken. Dr. M. Hilbink, beste Mirrian, jouw kennis van de 
statistiek heeft mij enorm geholpen. Bedankt voor jouw bereidheid om (vaak op korte 
termijn) met mij te discussiëren over allerlei statistische vraagstukken. Dr. P.C. Wever, beste 
Peter, een jaar of 4 á 5 geleden hebben we een gesprek gehad over de mogelijkheid voor mij 
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om promotieonderzoek te doen. Ook al heeft het onderzoek uiteindelijk een andere focus 
gekregen, wil ik je toch bedanken voor jouw input op “Q-koorts” gebied. Jouw ongekende 
drive en enthousiasme hebben mij geïnspireerd en ik heb genoten van het “veldonderzoek” 
tijdens onze bezoeken aan de verschillende boerderijen. 
Het RVE management van de RVE Medische Microbiologie en Infectiepreventie en de RVE 
Pathologie, Theo van Well, dr. Sander Leenders en dr. Hans van der Linden, wil ik bedanken 
voor de mogelijkheid om in combinatie met mijn unithoofdschap te kunnen promoveren. 
Beste Theo, Sander en Hans, zonder deze commitment vanuit het management was mijn 
promotieonderzoek niet mogelijk geweest. Hans, naast jouw ondersteuning vanuit het 
management wil ik je ook bedanken voor je inhoudelijke input.
Daarnaast wil ik alle collega’s van de Moleculaire Diagnostiek bedanken voor hun steun 
en interesse. De dagelijkse vraag “is je boekje nou onderhand eens af” zal ik overigens niet 
missen. In het bijzonder wil ik Bas Beerens, Jeroen Schellekens, Inge Hurkmans en Linda van 
de Werken bedanken voor de praktische ondersteuning. Anne Loonen, ik wil jou als 
medepromovenda graag bedanken voor de gezelligheid, het bespreken van de stand van 
zaken omtrent onze onderzoeken en ons periodieke “klaag half uurtje”. Het was fijn om 
dergelijke frustraties met een “lotgenoot” te kunnen delen. Geweldig dat het er voor ons 
beiden bijna op zit, ik kijk uit naar jouw promotie.
Op een meer persoonlijk vlak verdient ook zeker een aantal mensen een persoonlijke noot. 
Als eerste mijn lieve vrouw Sanne, je hebt wat afgezien met me en hebt me door dik en dun 
gesteund! Zonder jou was dit proefschrift er niet gekomen. Onze prachtige dochter Lynn, 
bedankt dat je nog even hebt gewacht met geboren worden totdat ik het concept van dit 
proefschrift had afgerond, wat een timing! Je hebt me daarnaast de energie gegeven voor 
de spreekwoordelijke laatste loodjes. Mijn ouders Jac en Bep, bedankt voor alle steun. Niet 
alleen gedurende de afgelopen jaren tijdens mijn promotieonderzoek, maar ook zeker voor 
alle jaren daarvoor. Ik mag me gelukkig prijzen met ouders als jullie! Alexander en Suzanne, 
ook jullie wil ik bedanken voor de steun van de afgelopen jaren. Mijn schoonouders Roxane 
de Beaumont en Rob van der Meij wil ik bedanken voor hun steun en interesse in mijn werk 
in het algemeen en specifiek in dit promotieonderzoek. Last but not least, wil ik mijn 
vriendengroep, in het bijzonder Joost, Annemieke, Davy, Inge, Dakmar, Jolanda, Ellen en 
Stefan, bedanken voor de steun en de broodnodige afleiding en steun van de afgelopen 
jaren. Ik hoop dat we in de toekomst nog veel lol mogen beleven (waar ik weer wat meer tijd 
voor heb!).
Als laatste wil ik ook alle mensen die ik niet persoonlijk heb genoemd graag bedanken voor 
de getoonde interesse en steun.
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